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An adverse drug reaction (ADR) is defined as “an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, which 
predicts hazard for future administration and warrants prevention or specific treatment, 
or alteration of the dosage regimen, or withdrawal of the product” 1. ADRs are a serious 
problem for public health and an obstruction to drug development and clinical use 
after marketing. For instance, almost half a million adverse drug events were reported 
worldwide in 1999 2 and according to a study in the UK, ADRs are responsible for 1 in 15 
hospital admissions, of which the mortality rate was 2.3% 3. Additionally, from almost 550 
drugs that were approved for the US market between 1975 and 1999, 10% of those acquired 
black box warnings and almost 3% were subsequently withdrawn from the marketas a 
result of ADR 4. In addition to the suffering of the patients from this ADR, withdrawal of a 
drug means a massive financial loss to the pharmaceutical company that already spent up 
to a few billion dollars developing it.
Of all organs the liver is involved most frequently in ADRs as itis highly exposed to 
orally-ingested drugs and contains a high concentration of drug-metabolizing enzymes 
that may produce toxic metabolites. Drug-induced liver injury (DILI) has surpassed viral 
hepatitis as the leading cause (~50% of cases) of acute liver failure cases in the USand can 
lead to liver transplantation or death 5, 6. The predominant clinical presentations of DILI 
resemble acute hepatitis or cholestatic liver disease, typically accompanied by markedly 
elevated serum transaminases, jaundice, systemic symptoms and in the more severe cases, 
coagulopathy and encephalopathy indicative of acute liver failure 7. DILI has also been the 
top reason for withdrawing drugs from the market 4, 8. 
The manifestation of DILI can be in the form of acute or cholestatic liver injury. 
Acute liver injury can involve two different modes of cell death; traumatic (necrosis) or 
programmed (apoptosis) cell death. The relative importance of these two modes of cell 
death is still arguable in DILI. When the injury is not massive, apoptosis might be less 
damaging than necrosis, which is more likely to promote inflammation and consequent 
collateral damage 9. The ATP level can determine whether injury leads to apoptosis or 
necrosis. Conditions in which a mild damage to mitochondria occurs but ATP level is still 
sustained above a critical threshold, will favor apoptosis. Meanwhile, a more severe hit to 
mitochondria might favor necrosis 10. Moreover, cholestatic liver injury refers to liver injury 
in the presence of bile flow impairment and is characterized by increased hepatocellular 
levels of toxic bile acids 11. 
DILI, which has not been detected in preclinical studies, can be observed in clinical trials 
when it occurs at an incidence of up to one in several hundreds or thousands patients. 
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However, when the incidence is below one in ten thousands of patients DILI can be 
observed only after a drug is on the market, as this incidence is too low to be detected 
during clinical trials 12. Therefore, DILI is commonly classified into intrinsic (type A) vs. 
idiosyncratic (type B) hepatotoxicity. Intrinsic DILI is regarded predictable (relatively 
higher incidence and dose-dependent), while idiosyncratic DILI is usually unpredictable 
(very low incidence and no obvious dose-dependency). One common misconception is 
that a drug can be clearly classified as either intrinsic or idiosyncratic hepatotoxin, as 
some drugs are known to cause both.One example is isoniazid that is associated with mild 
intrinsic DILI as well as severe idiosyncratic DILI13.  The difference between these two 
types will be described in detail in the following sections. 
2. Intrinsic DILI
Intrinsic DILI is usually unrelated to the pharmacology of the drug, exhibits dose and time 
dependency and can often be detected during pre-clinical (at least as species differences 
are minimal) or clinical trials. Paracetamol or acetaminophen (APAP) is considered as a 
classic intrinsic hepatotoxin that may cause severe liver toxicity above therapeutical doses. 
Approximately 80% of drug-associated cases of liver failure is caused by APAP, be it 
intentional or accidental overdose 5, but other well-known examples are methotrexate14, 
isoniazid15, and voriconazole16, 17. APAP overdose also causes severe hepatotoxicity in 
experimental animals,but the dose that exerts the toxicity highly depends on the species. 
Experiments in primary mouse, rat, and human hepatocytes indicated that mouse is the 
most sensitive species, while human is the least sensitive species to APAP toxicity18. Since 
APAP is the most widely-studied drug in the field of toxicology, there is a myriad of data 
about the mechanisms of APAP-induced liver injury that might be beneficial in explaining 
the mechanisms of intrinsic DILI in general.
APAP is commonly used as a painkiller (analgesic) and/or to reduce fever (antipyretic). 
APAP is generally safe to use at a dose below 4 g per day. It is believed that APAP by 
itself is not cytotoxic to the liver19; however APAP is metabolized extensively by the liver 
via three main pathways, namely glucuronidation, sulfation and oxidation20. The first two 
pathways lead to formation of non-toxic conjugates (APAP-glucuronide and APAP-sulfate) 
and are quantitatively the most important, but the oxidative, CYP-dependent pathway 
(mainly involving CYP 2E1 and 3A4) is the primary culprit as far as hepatotoxicity is 
concerned21. This pathway produces a toxic reactive metabolite known as N-acetyl-p-benzo-
quinoneimine (NAPQI), which at a low level, can normally be detoxified by conjugation 
with glutathione (GSH) which is present in high concentration in the liver, forming 
APAP-GSH22. APAP-GSH is the initial sulfur-containing metabolite of APAP produced by 
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the liver but this complex is converted to its non-toxic metabolic breakdown products, 
namely cysteine (APAP-CYS) and N-acetylcysteine (APAP-NAC) conjugates, which are 
subsequently eliminated via the urine. Therefore, little, if any, APAP-GSH is found in the 
urine of intact animals23. In human adults, the glucuronide conjugate accounts for 60-65%, 
the sulfate for 30-35% and the oxidative conjugates (APAP-GSH, APAP-CYS, APAP-NAC) 
for ca. 5% of the metabolites found in the urine24.
At the normal therapeutic dose, the level of NAPQI is low enough to be detoxified by 
conjugation with GSH. However, after an overdose resulting in a massive production of 
NAPQI due to saturation of the other metabolic pathways, hepatic GSH is depleted and 
can no longer prevent toxicity, leading to the binding of NAPQI to proteins. Covalent 
binding to critical proteins has been postulated to be the one of the mechanisms of APAP 
toxicity25. Reactive metabolites of APAP were found to bind extensively to mitochondrial 
proteins in mouse liver26.
In addition, APAP and/or NAPQI are known to activate a transcription factor nuclear 
factor erythroid 2-related factor 2 (Nrf2) in mouse in vivo27 and in vitro28, indicating that 
these compounds may induce oxidative stress. The mammalian oxidative stress response 
is coordinated by Nrf2, which activates the transcription of antioxidant genes29, 30. Under 
normal conditions, Nrf2 is held inactive in the cytoplasm by a protein known as Kelch-
like ECH-associated protein-1 (Keap1), which negatively regulates Nrf2 activity29. Nrf2-
deficient mice exhibit an increased sensitivity to APAP, resulting in greater severity in 
hepatic damage and increased lethality31, 32, while activation of Nrf2 by oleanolic acid 
protects against APAP-induced hepatotoxicity33. Therefore, Nrf2 is generally considered to 
serve as an endogenous regulator by which cells combat oxidative stress, which also plays 
a role after APAP-induced hepatotoxicity.
Additionally, disturbance of mitochondrial function is also considered as an important 
mechanism of DILI 13, 34. APAP administration was known to deplete mitochondrial 
glutathione and to alter mitochondrial membrane permeability thereby decreasing the 
efficiency of oxidative phosphorylation 35. APAP andmore likely NAPQI are hypothesized 
to cause mitochondrial permeability transition (MPT), i.e. opening of the ‘MPT pore’ 
located in their inner membrane.  This renders mitochondria more susceptible to oxidative 
stress damage, especially during increased reactive oxygen species (ROS) production, 
which leads to apoptosis, and if coupled with the loss of adenosine triphosphate (ATP), 
eventually to necrosis 13, 36. APAP-induced glutathione depletion and mitochondrial 
dysfunction have been associated with c-Jun N-terminal kinase (JNK) pathway activation 





Idiosyncratic DILI is defined as DILI occurring only in a small fraction (< 1:10,000)of the 
patients taking therapeutical doses of a drug, but it is responsible for ~13% of acute liver 
failure cases in the US 38. It is typically not related to the pharmacological effects of the 
drug and does not have an obvious dependence to dose or time. Intrinsic DILI normally 
occurs during drug overdose, while idiosyncratic DILI can occur when patients taking 
normal therapeutical doses of a drug. However, drugs that are administered at doses lower 
than 10 mg/day are generally not associated with idiosyncratic DILI, while the typical 
idiosyncratic DILI-causing drugs are given at higher doses (>100 mg/day) 39. Another 
important characteristic of idiosyncratic DILI is a delay (typically 5-90 days) between the 
drug administration and the onset of the adverse reactions 40, 41. In general, there are two 
widely-accepted categories of idiosyncratic hepatotoxicity, i.e. immunologic idiosyncrasy 
and metabolic idiosyncrasy. Immunologic idiosyncrasy is associated with the presence 
of signs of drug hypersensitivity, such as fever, rash, eosinophilia, antidrug antibodies, 
etc. In contrast, metabolic idiosyncrasy refers to injury in the absence of these signs42, 
43.Drugs causing idiosyncratic DILI are very different compounds and they represent many 
pharmacological classes.For an overview on drugs that cause idiosyncratic liver injury the 
reader is referred to a review by Kaplowitz 44.
Apart from these observed characteristics, relatively little definitive evidence exists 
that can explain the mechanisms of idiosyncratic DILI. There are several factors, including 
drug properties, genetic variation, and environmental factors, which are likely to play 
a role in idiosyncratic DILI simultaneously 8, 45. Many idiosyncratic DILI cases involve 
the biotransformation of drugs into reactive metabolites 46, 47, but not all idiosyncratic 
DILI-associated drugs produce reactive metabolites 48.Several polymorphisms in drug 
metabolizing enzymes are associated with higher prevalence of idiosyncratic DILI49.  It is 
also believed that some idiosyncratic DILI has an association with specific human leukocyte 
antigen (HLA) genotypes. In amoxicillin-clavulanic acid (AC)-induced hepatitis, 57% of 
affected patients possess a specific HLA haplotype, while the prevalence of this haplotype 
in the general population is only 12%50. However, even though it would be useful to study 
the pathogenesis of AC-DILI in relation to these HLA genotypes, their role as biomarkers 
is limited due to the low positive predictive value 51. Moreover, polymorphisms in genes 
encoding cytokines were shown to influence a person’s susceptibility to hepatotoxicity. 
Genes that are associated with high IL-4 and low IL-10 expression were found to be risk 
factors for diclofenac-induced liver toxicity 52. There are many other risk factors associated 
with idiosyncratic DILI, such as age, sex, and weight. For idiosyncratic DILI in adults, 
older age is generally associated with cholestatic damage with male prominence 51 and 
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hepatocellular DILI injury is more common among women 38. A specific example is the 
higher prevalence of halothane-induced hepatitis in women and obese patients 53. 
Several mechanistic hypotheses have been proposed that may explain idiosyncratic 
DILI:
Figure 1.Illustration of the Danger Hypothesis.This figure is republished with permission44.
3.1. Danger Hypothesis
Many idiosyncratic DILI reactions are mediated by adaptive immune responses54, 55. A 
small molecule, such as a chemically-reactive metabolite, cannot induce immune response 
unless it is bound to a protein; such a small molecule is then called a hapten 56. This 
hapten-protein complexformation modifies the protein, which is then seen as a foreign 
antigen that initiates an immunological response against this protein(primary signal) 57. 
However, without the presence of an adjuvant that stimulates the antigen presenting cells 
(APCs), this foreign antigen does not induce a substantial immune response and therefore 
is insufficient to cause injury 58, 59. A secondary ‘danger’ signal, which might be mild 
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cell death or aconcomitant inflammation, is needed to precipitate the primary reaction, 
activating the helper T cells leading to a T-cell response to the antigen. This activation 
then triggers the effector lymphocytes, cytotoxic T cells and B cells, leading to immune-
mediated idiosyncratic DILI 44. The danger hypothesis is illustrated in Figure 1.
Figure 2.Illustration of the PI Hypothesis.This figure is republished with permission54.
3.2. Pharmacological Interaction (PI) Hypothesis
Some parent drugs themselves, without metabolism into reactive metabolites and further 
processing process, can initiate immune responses by binding reversibly to the complex 
of major histocompatibility complex (MHC) on APCs and T cell receptor on helper T cells. 
This is referred to as the PI hypothesis because the drug acts more as a pharmacological 
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agent 60. One example is sulfamethoxazole, which is not chemically reactive per se, but it 
can bind to human T-cell clones via direct, MHC-dependent manner 61.Unlike the danger 
hypothesis, a secondary signal is not includedin this hypothesis. However, the PI and 
danger hypotheses might not be mutually exclusive as a reactive metabolite can act as 
the danger signal, by binding to the MHC - T cell receptor complex without serving as a 
hapten that is presented by the MHC55.The PI hypothesis is illustrated in Figure 2.   
3.3. Multiple Determinant Hypothesis
According to the multiple determinant hypothesis, the low occurrence of idiosyncratic DILI 
might be explained by the requirements of four critical events to occur simultaneously. 
The determinants of these critical events are: chemical properties (formation of reactive 
metabolites, interaction with other drugs); exposure (drug concentration in the plasma 
and/or liver), environmental factors (pre-existing diseases, stress levels, food and alcohol 
consumption), and genetic factors (gene polymorphisms). Each event has an independent 
probability of occurring, but all of them are required to precipitate an idiosyncratic DILI. 
Therefore, the probability for the occurrence of idiosyncratic DILI is the product of the 
probabilities of each independent event, which may explain its low incidence. Based on 
this hypothesis, an individual would suffer idiosyncratic DILI when exposed to a drug 
with a potential to cause idiosyncratic DILI and when the exposure level, environmental, 
and genetic factors all simultaneously favor the expression of the toxicity 62.  
3.4. Inflammatory Stress Hypothesis
Inflammation is traditionally defined as a complex biological response of tissues to 
harmful stimuli, such as injury, infection, or irritation, characterized by the presence of 
redness, swelling, pain, heat and function loss. In addition, it can also be viewed from the 
perspectives of innate immune system cell activation, actions of the mediators produced, 
and changes in inflammatory gene expression and cell signaling 63. Inflammation involves 
not only traditional inflammatory cells (e.g. macrophages, neutrophils) and the mediators 
they produce (e.g. cytokines / chemokines), but also the endothelial cells and parenchymal 
cells in the tissue. Inflammatory episodes, such as those caused by bacterial or viral infection 
and intestinal microbial disturbances, are common in humans and animals 64. 
It was suggested that an acute episode of inflammation can interact with concurrent 
drug therapy to precipitate idiosyncratic DILI. This modest inflammatory stress can lower 
the threshold for drug toxicity, thereby shrinking the therapeutic window resulting in 
a toxic response at an otherwise safe dose of the drug. Alternatively, a drug might also 
augment a mild inflammatory reaction rendering it injurious65, 66. These inflammatory 
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episodes can be caused by inflammagens, such as polyinosinic:polycytidylic acid (poly 
I:C) and lipopolysaccharide (LPS). Poly I:C is a synthetic double-stranded RNA that is 
used experimentally to model viral infections in vivo, while LPS is a component of the 
cell walls of gram-negative bacteria that is capable of inducing inflammation in vivo. 
Poly I:C and LPS activate numerous inflammatory pathways via activation of Toll-
like receptors 3 and 4 respectively 67, 68. These include activation of cellular signaling 
pathways, transcription factors (e.g. p38, nuclear factor κB), and inflammatory mediators 
(e.g. cytokines, chemokines), which in turn activate innate immune cells (e.g. monocytes, 
neutrophils), coagulation, and complement systems, eventually leading to liver injury 63. 
Even though different inflammatory mediators might be involved in injury by different 
drugs, neutrophils and tumor necrosis factor (TNF) were found to be critical mediators of 
injury in many idiosyncratic DILI models based on this hypothesis 69-71. This hypothesis 
does not exclude the involvement of reactive metabolites and in fact can be valid for several 
mechanisms of DILI, including those that involve reactive metabolites.
4. Experimental Models of idiosyncratic DILI
It was estimated that to detect idiosyncratic DILI that occurs in 1 in 10,000 patients, 
approximately 30,000 patients are required in clinical testing 6. Assuming a similar incidence 
in animals, 30,000 animals are needed for toxicity testing to detect idiosyncratic DILI. Since 
such large studies are not feasible, better experimental models to predict idiosyncratic DILI 
need to be developed. According to Shenton and Roth, the most useful idiosyncratic DILI 
experimental models have liver injury as the major endpoint with identical mode of injury 
as in human, can distinguish idiosyncratic DILI-related drugs from those that are not, and 
are reproducible in a large fraction of the subjects in the study 72, 73.  
4.1. In vivomodels
Both in the danger hypothesis and the inflammatory stress hypothesis, an inflammation is 
involved in the precipitation of the idiosyncratic toxicity of a drug. The research group of 
Robert Roth has been the pioneer to develop rodent models that can predict idiosyncratic 
DILI based on the inflammatory stress hypothesis 69-71, 74-76.Several human idiosyncratic 
DILI-causing drugs have been shown to also cause liver injury in rats and mice in vivo when 
coupled with a nontoxic dose of an inflammagen. The use of a low dose of inflammagen, 
such as LPS, is particularly important in developing an idiosyncratic DILI model in animals 
as exposure to large amount of LPS by itself can also result in liver injury, as well as death 
77. Several examples ofcotreatment of rodents with LPS and idiosyncratic DILI-causing 
drugs resulting in hepatotoxicity will be described further. These studies revealed that the 
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drug dose and the interval between LPS and drug administration are crucial to obtain a 
hepatotoxic response and the optimal dose and interval is different for each drug 73.
Cotreatment of rats with LPS and chlorpromazine increased the activities of liver 
transferases and serum creatine kinase, which is associated with human idiosyncratic 
reactions, when compared to the treatment of LPS or chlorpromazine alone 74. The 
hepatotoxicity of monocrotaline (MCT) in rats was also augmented by LPS and the mortality 
rate was much higher than controls when LPS was given one hour before MCT administration 
69. Neutrophil depletion protected against liver injury caused by the cotreatment of rats with 
LPS and diclofenac (DF) 75 or trovafloxacin (TVX) 70. Ranitidine (RAN) treatment caused the 
LPS-induced increase in serum TNF concentration to last longer than in rats given LPS alone 
and LPS/RAN-cotreated rats developed hepatotoxicity 78. Moreover, TNF and plasminogen 
activator inhibitor-1 independently contributed to neutrophil activation, which is critical to 
the hepatotoxicity caused by LPS and sulindac cotreatment in rats 76, 79.  
In addition to the rat models described above, mouse models were also developed for 
Idiosyncratic DILI. LPS renders mice more sensitive to the hepatotoxicity caused by TVX 
and this liver injury appeared to be dependent on TNF and interferon gamma (IFN-γ). 
However, coexposure of LPS and levofloxacin, another fluoroquinolone antibiotic without 
idiosyncratic DILI-properties, did not result in hepatotoxicity 71, 80. Coexposure of halothane-
treated male mice to lipopolysaccharide exacerbated their hepatotoxic response similar to 
the response observed in halothane-treated female mice 81. This finding is consistent with 
the fact that women are more sensitive to halothane-induced hepatitis 53.
From these animal models, we learned that it was possible to predict the propensity of 
drugs to cause idiosyncratic DILI in humans and these drugs can also be distinguished 
from their comparator drugs that do not cause idiosyncratic DILI. The mechanisms of the 
synergistic toxicity observed in these models appeared to be dependent on neutrophils and 
TNF for many idiosyncratic DILI drugs. 
4.2. In vitro models
The most important questions that one should ask when developing animal models 
for toxicity is how predictive are these models for human toxicity and how similar are 
the mechanisms of toxicity of a compound elucidated by these animal models when 
compared to the real situations in humans. It is well known that generally the concordance 
of xenobiotic toxicity in human and animals is alarmingly low. Out of 150 compounds 
tested with human toxicity, concordance was seen in 63% of non-rodent studies (primarily 
dog) and 43% of rodent species (primarily rat). Mouse was actually the least predictive 
species for human toxicity out of 5 species tested. Despite its relatively high incidence in all 
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species, hepatotoxicity in human was surprisingly poorly predicted from animal studies 82. 
One major advantage of using in vitro models is the possibility of working with cells from 
human instead of animal origin. Additionally, in vitro models employing animal cells are 
also useful to make direct comparison to the human in vitro data. Another advantage is that 
the use of animal and human in vitro models contributes to the refinement, reduction, and 
eventually replacement of animal studies. 
Several in vitro models predicting idiosyncratic DILI based on the inflammatory 
hypothesis have been developed. In 2006, Tukov et al. utilized a rat Kupffer cell-hepatocyte 
coculture system to model inflammagen-drug interactions in vitro. It was found that MCT 
alone had no effect on TNF release, but it elevated LPS-induced TNF release in these 
cocultures83. These results were in line with the observations from in vivo experiments, in 
which MCT did not increase plasma TNF concentration when given to rats by itself, but 
augmented and prolonged the increase in plasma TNF concentration in LPS-cotreated rats 
69. Thus, the in vitro results from Kupffer cell-hepatocyte coculture qualitatively mirror 
reported data from whole animal studies. 
Since LPS cannot induce an inflammatory reaction in pure hepatocyte cultures, pro-
inflammatory cytokines, such as TNF, were used instead to induce inflammation-like 
reactions. TNF was found to enhance the cytotoxicity of the metabolite sulindac-sulfide in rat 
primary hepatocytes and also in HepG2 cells, a human liver carcinoma cell line 84. Similarly, 
TNF significantly enhanced DF-induced apoptosis in HepG2 cells, whereasTNF had no 
effects on another structurally different non-steroidal anti-inflammatory drug, naproxen. It 
was found that the DF/TNF-induced apoptosis was dependent on caspase-8, caspase-3, and 
JNK activities and that DF inhibited the TNF-induced nuclear factor-κB activation 85. 
Cosgrove et al. performed experiments cotreating HepG2 cells as well as primary 
human and rat hepatocytes with LPS and a cytokine mix (TNF, IFN-γ, interleukin (IL) 1α, 
and IL 6) and idiosyncratic DILI drugs (TVX, RAN, nefazodone, nimesulide) and found 
synergistic induction of hepatocellular death. However, this synergistic hepatotoxicity was 
not observed with the use of the corresponding comparator drugs that are not associated 
with idiosyncratic DILI (LVX, cimetidine, buspirone, aspirin) instead 86. The intrinsic 
drawback of the use of HepG2 cells for prediction of Idiosyncratic DILI is the well-known 
fact that these cells represent hepatoma cells and have lost most of their phase I and part 
of their phase II metabolism capacity87, 88. Therefore, although it is a useful model to test 
intracellular mechanisms of cell injury including the elucidation of cell signaling pathways, 
it may be difficult to detect metabolism-related toxicity.
An extensive in vitro approach was recently developed by Thompson et al.to assess the 
idiosyncratic DILI risks for 36 known drug candidates. The approach involved several in vitro 
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assays, which quantified the toxicity of the drugs in three different cell lines (representing 
toxicities caused bythe parent drug, the possible reactive metabolite, and mitochondrial 
injury) as well as the inhibitions of the human bile salt export pump (BSEP) and the rat 
multidrug resistance associated protein 2 (Mrp2). Additionally, the covalent binding 
burden of each drug was also estimated. Combination of these aggregated results led to the 
discrimination of 27 drugs that had marked idiosyncratic DILI concern and 9 that had low 
concern of idiosyncratic DILI with high rates of specificity (78%) and sensitivity (100%) 89.  
4.3. Potential ex vivo models
Precision-cut liver slices (PCLS) have been receiving increased attention as a robust ex vivo 
tool to study drug metabolism and toxicity. One definite advantage of the PCLS system 
over other in vitro models is that a PCLS contains all liver cell types in their natural ratio and 
extracellular matrix environment, retaining normal tissue architecture and cell-to-cell and 
cell-to-matrix interactions. PCLS demonstrate higher similarity to intact liver compared to 
primary hepatocytes and cell lines based on the gene expression profiles 90. They possess 
a complete set of active phase I and II drug metabolism enzymes and many experiments 
related to drug metabolism have been performed in PCLS 91-96. Moreover, microarray 
analysis of xenobiotic-treated rat PCLS showed that they could mimic the toxicity as 
observed in vivo and discriminate between different mechanisms of hepatotoxicity 97. A 
relatively stable expression of genes involved in drug transport, metabolism, and toxicity 
was reported for normal incubationof human PCLS for 24h, whereas incubation with 
APAP caused significant changes in these gene expression98. It has also been shown that 
the Kupffer cells in PCLS can be activated by LPS treatment inducing an inflammatory 
response as evidenced by the production of nitric oxide (NO) and inflammatory cytokines, 
such as TNF, IL-1β, and IL-6 99-102. Despite extensive use of this PCLS system in drug 
metabolism and intrinsic toxicity studies, it has never been used to study idiosyncratic 
hepatotoxicity before.
5. Aim and Outline of the Thesis
The research of this thesis was focused on the use of PCLSfor the development of an ex vivo 
model for intrinsic and idiosyncratic DILI. One main objective was to compare and contrast 
the findings in PCLS from animals and humans. Therefore, PCLS from three different 
species, namely, mouse, rat, and human were utilized in the experiments. The goal of 
this research is to contribute to a better early prediction of drugs that cause intrinsic or 
idiosyncratic toxicity in humans before the drug is released on the market with concurrent 
reduction in the use of experimental animals.
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In chapter 2, the toxicity of the intrinsic hepatotoxin, APAP and its regioisomer, 
N-acetyl-meta-aminophenol (AMAP) was compared in mouse, rat, and human PCLS 
by means of ATP content and histomorphology. AMAP possesses similar analgesic and 
antipyretic properties as APAP and has always been described as a non-toxic isomer of 
APAP. AMAP was shown to be non-hepatotoxic in mouse in vivo and in vitro as well as 
in hamster in vivo26, 103-105. The profiles of the proteins released into the media of mouse 
and rat PCLS after exposure of APAP and AMAP were alsoanalyzed. Additionally, the 
metabolites of APAP and AMAP in PCLS media from the three species were determined in 
order to investigate whether species difference in the metabolite production could explain 
the species difference in toxicity.
Chapter 3 focused on the profiling of the proteins in the media of PCLS after 
treatments with several hepatotoxins. The protein profiles following APAP, AMAP, DF, 
or LPS treatments in mouse, rat, and human PCLS were compared. One potential marker 
associated with DILI is the iron-regulating hormone hepcidin, which was decreased in the 
plasma and livers of mice with APAP-induced liver injury as a result of oxidative stress106. 
Therefore,we also measured the concentration of hepcidin in the medium of mouse, rat, 
and human PCLS after treatments with these hepatotoxins. Extrapolation of the ex vivo data 
to in vivo data was performed by comparing the protein profiles of mouse PCLS medium 
and mouse urine and liver homogenates after APAP treatment.
The aims of the studies described in the next two research chapters were to test if PCLS 
can be a suitable ex vivo model to study the inflammatory stress hypothesis, whether 
idiosyncratic DILI-associated drugs could be identified with this model and to discover 
biomarker(s) that can identify drugs as potentially inducing idiosyncratic DILI.In both 
chapter 4 (mouse) and chapter 5 (human), the toxicity of five drugs known to cause 
idiosyncratic DILI in humans: DF, ketoconazole (KC), clozapine (CZ), carbamazepine 
(CBZ), and troglitazone (TGZ) were investigated in the absence and presence of LPS in 
mouse and human PCLS. Additionally, comparator drugs that are in the same chemical 
class of drugs as KC and CZ and are known not to cause idiosyncratic DILI, i.e. voriconazole 
(VC) and olanzapine (OZ) respectively, were also investigated. The viability of PCLS was 
determined by means of ATP content and histomorphology. In mouse PCLS, leakage of 
lactate dehydrogenase was measured as an extra viability test. Aiming to find biomarkers 
that are associated with idiosyncratic liver injury, we also measured the levels of reduced 
and total glutathione in the PCLS and the release of several cytokines in the medium of 
PCLS. Furthermore, each drug’s effect on the LPS-induced release of these cytokines was 
examined. The effects of each drug on LPS-induced nitric oxide release in mouse PCLS and 
on LPS-induced soluble intercellular adhesion molecule-1 release in human PCLS were also 
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investigated. Additionally, it was also of our interest to compare and contrast the effects 
of interaction between LPS and these drugs in mouse and human PCLS to investigate the 
species differences in toxicity.
Finally, a summary, discussion and future directions of the use of PCLS to study intrinsic 
and idiosyncratic DILI are presented in chapter 6.
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Abstract
N-acetyl-meta-aminophenol (AMAP) is generally considered as a non-toxic regioisomer of 
the well-known hepatotoxicant acetaminophen (APAP). However, so far AMAP has only 
been shown to be non-toxic in mice and hamsters. To investigate whether AMAP could 
also be used as non-toxic analog of APAP in rat and human, the toxicity of APAP and 
AMAP was tested ex vivo in precision-cut liver slices (PCLS) of mouse, rat and human. 
Based on ATP content and histomorphology, APAP was more toxic in mouse than in rat 
and human PCLS. Surprisingly, although AMAP showed a much lower toxicity than 
APAP in mouse PCLS, AMAP was equally toxic as or even more toxic than APAP at all 
concentrations tested in both rat and human PCLS. The profile of proteins released into the 
medium of AMAP-treated rat PCLS was similar to that of APAP, whereas in the medium of 
mouse PCLS it was similar to the control. Metabolite profiling indicated that mouse PCLS 
produced the highest amount of glutathione conjugate of APAP, while no glutathione 
conjugate of AMAP was detected in all three species. Mouse also produced ten times more 
hydroquinone metabolites of AMAP, the assumed proximate reactive metabolites, than 
rat or human. In conclusion, AMAP is toxic in rat and human liver and cannot be used as 
non-toxic isomer of APAP. The marked species differences in APAP and AMAP toxicity 
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1. Introduction
In studies on the mechanism of toxicity of a xenobiotic, a non-toxic analog with a 
pharmacological activity similar to that of the toxic compound is frequently taken as 
control to distinguish pharmacological from toxicological effects.Based on studies in mice 
and hamsters, N-acetyl-meta-aminophenol (AMAP), is generally considered as a non-toxic 
comparator drug for acetaminophen (N-acetyl-para-aminophenol, APAP). However, it is 
also known that the concordance of xenobiotic toxicity in human and animals is alarmingly 
low. Out of 150 compounds tested with human toxicity, concordance was seen in 63% of 
non-rodent studies (primarily dog) and 43% of rodent species (primarily rat). Mouse was 
actually the least predictive species for human toxicity out of 5 species tested. Despite its 
relatively high incidence in all species, hepatotoxicity in human was surprisingly poorly 
predicted from animal studies 1. But no data is available on the toxicity of AMAP in the 
human liver.
APAP is a frequently used analgesic and antipyretic agent and is considered to be safe at 
therapeutic doses (≤4g per day). However, APAP overdose may cause severe hepatotoxicity 
that leads to liver failure and death in both man and laboratory animals. N-acetyl-p-benzo-
quinone imine (NAPQI), an electrophilic and oxidative reactive metabolite formed by 
cytochrome P450s, is commonly thought to be primarily responsible for the toxic effects of 
APAP 2. At therapeutic doses, this metabolite is efficiently detoxified by glutathione (GSH) 
conjugation. However, after an overdose, hepatic GSH is depleted and can no longer 
prevent accumulation of NAPQI, leading to its binding to cysteine-sulfhydryls on proteins. 
The mechanism of APAP-induced hepatotoxicity in humans and mice involves covalent 
binding to critical proteins 3, mitochondrial dysfunction and nuclear DNA fragmentation 
4. Furthermore, APAP and/or NAPQI are known to induce oxidative stress and thereby 
activate the nuclear factor erythroid 2-related factor 2 (Nrf2), which may serve as an 
endogenous regulator by which cells combat oxidative stress in vivo5 and in vitro6. 
AMAP, the regioisomer of acetaminophen, possesses similar analgesic and antipyretic 
properties as APAP and was shown to be non-hepatotoxic at doses where APAP showed 
overt toxicity in mouse in vivo and in vitro7, 8, 8, 9 as well as in hamster in vivo10. In mouse 
hepatocyte cultures, AMAP was cytotoxic only at 10-fold higher concentration than APAP 
11. In contrast to APAP, little GSH depletion was observed after the administration of AMAP 
to mice 7. However, pre-treatment of mice with buthioninesulfoximine, which inhibits 
the synthesis of GSH, rendered the mice more susceptible to hepatotoxicity after AMAP 
administration 12. Additionally, the levels of covalent binding of AMAP were comparable 
to that of APAP in mouse 13 or hamster 10. AMAP was also shown to have effects on the 
mouse liver proteome, which was qualitatively similar to that of APAP 14. Despite all these 
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characteristics, AMAP is still widely considered as a non-hepatotoxic analog of APAP 15, 
even though so far AMAP has only been studied in two species, mouse and hamster. 
As we were interested to use AMAP as a non-toxic analog in our studies on the 
mechanism of APAP toxicity in rat and human liver, we investigated the hepatotoxicity of 
both APAP and AMAP in mouse, rat and human precision-cut liver slices (PCLS). PCLS 
retain the normal tissue architecture of an intact liver with all its cell types in their natural 
arrangement and intact intercellular interactions 16-18. The gene expression profile of PCLS 
was shown to have a higher similarity to intact liver compared to primary hepatocytes 
and cell lines 19. Moreover, microarray analysis of toxin-treated rat PCLS showed that they 
could correctly predict the hepatotoxicity as observed in vivo and discriminate between 
different mechanisms of toxicity 20. Relatively stable expression of genes involved in drug 
transport, metabolism and toxicity during normal incubation of human PCLS for 24h was 
reported, whereas incubation with APAP caused significant changes in gene expression 21. 
All phase I and II xenobiotic metabolism pathways are active in PCLS and their metabolism 
and toxicity functions correlate well with in vivo data 18, 22-26.
In the present study, we compared the toxicity of APAP and AMAP in mouse, rat and 
human PCLS by means of ATP content and histomorphology. Proteins released into the 
media of mouse and rat PCLS were also profiled. Additionally, the metabolites of APAP 
and AMAP in PCLS media from the three species were determined in order to investigate 
whether species difference in the metabolite production could explain the species difference 
in toxicity.
2. Materials and methods
2.1. Chemicals
APAP, AMAP, and all other chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) unless stated otherwise. Stock solutions of APAP and AMAP were made in 
DMSO (VWR, Briare, France) as the solvent.  
2.2. Animals
Female C57BL/6 mice weighing 20-24 g and male Wistar rats (HsdCpb:WU) weighing 300-
350 g were obtained from Harlan (Horst, the Netherlands). The mice and rats were housed 
on a 12-h light/dark cycle in a temperature- and humidity-controlled room with food (Harlan 
chow no 2018, Horst, the Netherlands) and tap water ad libitum. The animals were allowed 
to acclimatize for at least seven days before experimentation. The experimental protocols 
were approved by the Animal Ethical Committee of the University of Groningen.
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2.3. Human liver tissue
Pieces of human liver tissue were obtained from patients undergoing partial hepatectomy 
(PH) for the removal of carcinoma or from liver tissue remaining as surgical waste after 
split liver transplantation (TX), as described previously 21. The characteristics of these 
human livers are described in Table 1. The experimental protocols were approved by the 
Medical Ethical Committee of the University Medical Center Groningen.
2.4. Excision of mouse and rat liver
Under isofluorane/O2 anesthesia, the liver was excised and placed into ice-cold University 
of Wisconsin (UW) organ preservation solution (DuPont Critical Care, Waukegab, IL, 
USA). 
2.5. Preparation of mouse, rat and human PCLS
PCLS were made as described previously 27. In brief, cylindrical cores were prepared 
by drilling a hollow metal tube (diameter = 5mm) into the liver. These cores were sliced 
with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) in ice-cold Krebs-
Henseleit buffer saturated with carbogen (95% O2 and 5% CO2). PCLS (5 mm diameter, 
200-300 µm thick and 5 mg wet weight) were stored in ice-cold UW solution until 
incubation. 
2.6. Incubation of mouse, rat and human PCLS
Incubation of PCLS in 12-well plates (Greiner bio-one GmbH, Frickenhausen, Austria) 
was performed as described before 27. In brief, PCLS were pre-incubated  at 37°C for 1 
h individually in 1.3 ml Williams’ medium E with glutamax-1 (Gibco, Paisley, UK), 
supplemented with 25 mM D-glucose and 50 µg/ml gentamicin (Gibco, Paisley, UK) 
(WEGG medium) in a 12-well plate with shaking (90 times/min) under saturated carbogen 
atmosphere. Pre-incubation allows the PCLS to restore their ATP levels. After pre-
incubation, PCLS were transferred to fresh WEGG medium with different concentrations 
of APAP or AMAP or the vehicle, DMSO (final concentration of DMSO during incubation 
≤0.5%) and incubated for 24h. 
2.7. ATP and protein content of PCLS
Viability of mouse (n=3), rat (n=4) and human (n=5) PCLS after 24h incubation with 
APAP, AMAP or solvent control was determined by measuring the ATP content of 
the PCLS according to the method described earlier 27. In brief, at the end of 24h 
incubation, three replicate PCLS were collected individually in 1 ml 70% ethanol 
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(v/v) containing 2 mM EDTA (pH 10.9) and snap-frozen in liquid nitrogen and stored 
at -80°C  until analysis. The samples were homogenized using a Mini-BeadBeater-8 
(BioSpec, Bartlesville, OK, USA) and centrifuged for 3 minutes at 13000 rpm and 4°C. 
The supernatant was diluted 10 times with 0.1 M TrisHCl containing 2 mM EDTA 
(pH 7.8) to reduce the ethanol concentration. The ATP content of the supernatant 
was measured using the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, 
Germany) in a black 96-well plate Lucy1 luminometer (Anthos, Durham, NC, USA) 
using a standard ATP calibration curve.
Liver id. PH/TX Sex Age ATP at 24h             
(nmol/mg protein)
A1 PH male 80 9.7
A2 PH male 59 7.1
A3 PH male 64 4.7
A4 PH male 65 6.2
A5 TX male 10 11.1
H1 PH female 76 9.9
H2 PH female 62 4.0
H3 TX male 27 8.4
H4 PH male 57 6.0
H5 PH male 74 6.2
H6 PH female 70 6.4
M1 TX female 54 5.8
M2 PH female 45 3.2
M3 TX female 57 6.3
M4 TX male 50 3.7
M5 PH male 66 5.5
Table 1. Human liver donor characteristics used in this study (n=5-6 for each endpoint; A 
= ATP, H = histomorphology, M = metabolism), PH is liver tissue after partial hepatectomy, 
TX is liver tissue remaining from donor liver after transplantation. The ATP content of hu-
man PCLS after 24h of incubation is indicated.
The protein content of the PCLS was determined by dissolving the remaining pellet in 5 
M NaOH for 30 min. After dilution with water to a concentration of 1 M NaOH, the protein 
content of the samples was determined using the Bio-Rad DC Protein Assay (Bio-Rad, 
Munich, Germany) using bovine serum albumin (BSA) for the calibration curve. The ATP 
content of the slice was expressed as pmol/µg protein.
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2.8. Histomorphology of PCLS
Mouse (n=3), rat (n=3) and human (n=6) PCLS, incubated with 2 mM of APAP or AMAP 
(24h), were subjected to morphological evaluation. PCLS were fixed in 4% buffered 
formaldehyde in phosphate-buffered saline solution for 24h at 4°C. Thereafter, PCLS were 
stored in 70% ethanol at 4°C. Embedding in paraffin, sectioning (4 µm) and staining with 
hematoxylin and eosin (H&E) was performed as described previously 28. Slice integrity was 
determined by estimation of the percentage of viable cells by two independent observers 
who scored the sections blindly.
2.9. Proteinprofiling of PCLS media
Mouse PCLS (n=3) were incubated with APAP (1 mM) or AMAP (3 mM) and rat 
PCLS (n=3) were incubated with APAP (5 mM) or AMAP (5mM) for 24h. Thereafter, 
medium samples were collected and snap-frozen in liquid nitrogen and stored in -80°C. 
Pretreatment of medium samples using Magnetic Beads-based Hydrophobic Interaction 
Chromatography 8 beads (MB-HIC C8) (BrukerDaltonics, Bremen, Germany), which bind 
hydrophobic proteins was performed as described previously 29. An internal standard 
(synthetic hepcidin-24) (Peptide International Inc., Louisville, KY, USA) was used to enable 
comparison between samples. A 2 µl volume of the prepared sample was applied to a 
MSP 96 polished steel MALDI target plate under nitrogen flow, followed by 1 µl of 5 mg/
mL α-cyano-4-hydroxy-cinnamic acid in 50% acetonitrile and 0.5% trifluoroacetic acid. 
Mass-to-charge (m/z) spectra were generated using MALDI-TOF MS (Microflex LT with 
software flexControl Version 3.0) (BrukerDaltonics, Bremen, Germany) in positive, linear 
ion mode and 350 laser shots. Initial laser power was 50% for 1-20 kDa measurement, Laser 
Attenuator; Offset 25% and Range 20%. Pulsed ion extraction was set to 250 ns. Samples 
were measured in a 1-20 kDa mass range. Calibration was performed using protein 
calibration standard I (BrukerDaltonics, Bremen, Germany).
2.10. Measurement of metabolites of APAP/AMAP 
Metabolites of APAP (0.5 mM) or AMAP (0.5 mM) or DMSO (0.1%) were measured after 24h 
incubation of rat (n=3), mouse (n=3) and human (n=5) PCLS. PCLS and their corresponding 
media were collected and sonicated together to disrupt the tissues or cells. 10% of the 
sample volume of ice-cold 10% HClO4 was added to precipitate the proteins. Samples were 
then centrifuged for 15 min on 14000 rpm. Supernatants were filtered through membrane 
filters before they were analyzed. Metabolites of APAP and AMAP were analysed by LC-
MS/MS using a Luna 5 µm C18 column (150 mm x 4.6 mm i.d.) (Phenomenex, Torrance, CA, 
USA) as the stationary phase. A gradient was constructed by mixing the following mobile 
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phases: solvent A (1% acetonitrile, 99% water, and 0.2% formic acid) and solvent B (99% 
acetonitrile, 1% water, and 0.2% formic acid). The first 5 min were isocratic at 0% solvent 
B; from 5 to 30 min, the concentration of solvent B linearly increased to 75%; from 30 to 35 
min, there was a linear decrease to 0% B, and it was maintained at 0% for re-equilibration 
until 40 min. The flow rate was 0.5 mL/min. Samples were injected at an injection volume 
of 100 µl. Metabolites were identified by mass spectroscopy and quantified by UV/VIS 
detection at 254 nm. APAP and AMAP were quantified using appropriate standard curves. 
The extinction coefficients of APAP, AMAP and the metabolites APAP-glucuronide (APAP-
gluc), APAP-sulfate (APAP-sulf) and APAP-glutathione (APAP-GSH) were determined 
by measuring the absorbance in the UV/VIS detector also at 254 nm. In contrast to what 
was previously reported 30, the extinction coefficient of APAP-GSH (0.00532 M-1cm-1) was 
actually lower than that of APAP itself (0.00837 M-1cm-1), whereas those of APAP-gluc 
(0.00808 M-1cm-1), and APAP-sulf (0.00781 M-1cm-1) were only slightly lower. As APAP-NAC 
was not available, the extinction coefficient of APAP-NAC was assumed to be the same 
as APAP-GSH. The extinction coefficients of all the metabolites of AMAP were assumed 
to be the same as AMAP as these metabolites were not available. For AMAP-gluc and 
AMAP-sulf, which appeared to be the main metabolites, this assumption seems reasonable 
as also for APAP-gluc and APAP-sulf the extinction coefficients were close to that of 
APAP (0.98 fold and 0.94 fold). An Agilent 1200 Series Rapid resolution LC system was 
connected to a hybrid quadrupole-time-of-flight (Q-TOF) Agilent 6520 mass spectrometer 
(Agilent Technologies, Waldbronn, Germany), equipped with electrospray ionization (ESI) 
source and operating in the positive mode with the MS ion source parameters previously 
described 31. Class VP 4.3 software package was used for the determination of peak areas 
in the UV chromatograms. The MassHunter Workstation Software (version B.02.00) was 
used for system operation and data collection. Data analysis was performed using Agilent 
MassHunter Qualitative analysis software. 
2.11. Statistics
Each experiment was performed with a minimum of 3 livers (rat and mouse) or 5 
livers (human) using PCLS in triplicates from each liver. HepG2 experiments were 
performed in three experiments with triplicate incubations in each experiment. 
Results were compared using two-tailed paired Student’s t-test (Fig. 1) or one-way 
ANOVA with a Dunnett post-hoc test (Fig. 3) using GraphPad Prism 5.0 statistics 
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3. Results
3.1 Cytotoxicity of APAP and AMAP in PCLS
Mouse, rat, and human PCLS remained viable in the incubation system during 24h 
incubation (Figs. 1 & 2). The effect of APAP and AMAP was tested at three different 
concentrations (1, 3, 5 mM) by comparing the ATP content of the treated PCLS with that of 
the control PCLS after 24h (Fig. 1). In mouse PCLS, incubation with 1 mM APAP resulted 
in significant toxicity, while both 3 mM and 5 mM APAP turned the slices’ color into black 
and caused total loss of viability (Fig. 1). Less but significant toxicity was also observed in 
rat and human PCLS incubated with APAP at 3 mM and 5 mM. Incubation of mouse PCLS 
with AMAP did not result in any significant toxicity except at the highest dose (5 mM). 
However, incubation with AMAP resulted in significant toxicity in both rat and human 
PCLS at all concentrations tested. Surprisingly, AMAP was actually more toxic than APAP 
at each concentration (Fig. 1).Measurement of LDH leakage in the media of mouse and 
rat PCLS showed comparable results (data not shown).The approximate TC50 values (the 
concentration of drug that reduces the viability to 50%) for APAP were: 1 mM (mouse), 
4.7 mM (rat) and >5 mM (human). The approximate TC50 values for AMAP were: 4.3 mM 
(mouse), 2 mM (rat) and 1 mM (human).  
Viability of PCLS was also assessed by histomorphology of mouse, rat and human 
PCLS incubated with 0.2% DMSO (control), 2 mM APAP or 2 mM AMAP for 24h. The 
histomorphological scoring for control PCLS was approximately 70% taking into account 
the damage of the outer cell layers by the slicing. The histomorphology data were largely 
in accordance with the ATP data. Mouse PCLS incubated with 2 mM APAP showed 
extensive necrotic areas, while incubation with the same concentration of AMAP showed 
minor toxicity. On the other hand, incubation with AMAP of both rat and human PCLS 
resulted in overt toxicity that was equal to or more than the toxicity caused by the same 
concentration of APAP. There were more necrotic areas in AMAP-treated rat PCLS than in 
APAP-treated ones, while the treatment with 2 mM of APAP and 2 mM of AMAP of human 
PCLS resulted in similar levels of necrosis. AMAP-treated PCLS of all 3 species showed 
signs of karyorhexis (destructive fragmentation of the nuclei of dying cells), which was 
not observed in the vehicle-treated or APAP-treated PCLS. Based on histomorphological 
scoring of the PCLS from several individual experiments (Fig. 3), there were more viable 
cells in AMAP-treated (81%) than APAP-treated (7%) mouse PCLS compared to control 
incubated PCLS, while the opposite was true for rat PCLS (APAP-treated: 91%, AMAP-
treated: 68%). APAP and AMAP induced a similar degree of necrosis in human PCLS 
(approximate viability: 67%). 
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3.2. Protein profiling of media from APAP- and AMAP-treated PCLS
The protein profiles in the media following 24h incubation of mouse and rat PCLS with 
vehicle (DMSO), AMAP (3 mM for mouse and 5 mM for rat) or APAP (1 mM for mouse 
and 5 mM for rat) were measured (Fig. 4). The protein profile of APAP-treated mouse PCLS 
were substantially different from those of control PCLS. However, the profile of AMAP-
treated mouse PCLS was similar to that of the control PCLS. In rat PCLS, the protein profiles 
after treatments with APAP or AMAP were similar and clearly different from those of 
the control PCLS. They resembled the protein profile following APAP treatment in mouse 
PCLS. This suggests that, in rat PCLS, AMAP and APAP treatment caused a similar effect. 
Figure 1. Viability of mouse, rat, and 
human PCLS, measured as ATP con-
tent of PCLS after 24h incubation with 
different concentrations of APAP (gray 
bars) or AMAP (black bars). ATP con-
tent was expressed as relative values 
to the corresponding controls: vehicle-
treated PCLS (open bars). The abso-
lute ATP content of the control PCLS 
were: 7.7 (mouse), 13.1 (rat), and 7.8 
(human) nmol/mg protein. Data rep-
resent the average ± SEM of three 
(mouse), four (rat) or five (human) 
individual experiments, using 3 PCLS 
per experiment. Results are compared 
with two-tailed paired Student’s t-test: 
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Figure 2. Histomorphology of PCLS treat-
ed with vehicle only (control), 2 mM APAP 
or 2 mM AMAP for 24h. Three individual 
experiments were performed with mouse 
(M) and rat (R) PCLS and six individual 
experiments were performed with hu-
man (H) PCLS. A representative picture 
is shown for each species. The sections 
were stained by hematoxylin-eosine, bar 
= 100 µm, magnification = 100x. Some 
examples of the necrotic areas are indi-
cated by * symbols.
Figure 3. Viability of PCLS from mouse, rat and human treated for 24h with 2 mM APAP 
(gray bars) or 2 mM AMAP (black bars) based on histomorphological scoring of H&E stained 
sections. The values were expressed as relative to the corresponding control (vehicle-
treated PCLS, open bars) for each species. The absolute values for the controls were 71% 
(mouse), 70% (rat), and 66% (human). Data represent the average of three (mouse and 
rat) or six (human) individual experiments ± SEM, using 3 PCLS per experiment.  Results 
are compared with one-way ANOVA with a Dunnett post-hoc test *P < 0.05 vs. control, **P 
< 0.0001 vs. control.
3.3. Metabolism of APAP- and AMAP-treated PCLS 
Metabolites in the media, which were produced after 24h incubation of mouse, rat and 
human PCLS with 0.5 mM of APAP and AMAP were measured (Fig. 5). The extinction 
coefficients of all AMAP metabolites were assumed to be the same as of AMAP due to the 
unavailability of pure AMAP metabolites. Thus, the calculated amounts of metabolites, 
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especially ones of AMAP, should be considered as an estimation instead of absolute 
values.  The PCLS from all species produced qualitatively the same metabolites of APAP 
and AMAP; however, quantitative differences were observed both in the amount as well 
in the profile. The total amount metabolized during 24 hours was 56%, 45% and 26% for 
APAP and 85%, 67%, 60% for AMAP in mouse, rat and human PCLS respectively. Both 
glucuronide (APAP-gluc and AMAP-gluc) and sulfate (APAP-sulf and AMAP-sulf) 
metabolites were detected as the main metabolites in APAP- and AMAP-treated PCLS. 
Only in APAP-treated PCLS a glutathione-conjugate (APAP-GSH) and N-acetylcysteine-
conjugate (APAP-NAC), which is the breakdown product of APAP-GSH 32, could be 
detected. In AMAP-treated PCLS, three hydroquinone metabolites were detected, namely 
3-hydroxy-acetaminophen (3-OH-APAP); 2,5-dihydroxy-acetanilide (2,5-diOH-AA) and 
3-methoxy-acetaminophen (3-OMe-APAP). 
Figure 4. Representative protein profiles, which were measured by MALDI-TOF MS, of 
media of PCLS from mouse and rat following 24h APAP and AMAP treatment. For each 
profile, the Y-axis was adjusted so that the peak corresponding to the internal standard (IS, 
hepcidin 24; 2673.9 Da) was at 50% of the Y-axis to allow comparison of relative protein 
peak intensity between spectra. The * symbols indicate some of the protein peaks that are 
present in medium of APAP-treated rat and mouse PCLS and AMAP–treated rat PCLS, but 
are low or lacking in medium of control slices or mouse PCLS treated with AMAP.
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In both mouse and human PCLS, APAP was mainly metabolized into APAP-gluc, 
followed by APAP-sulf, while the rat PCLS produced more APAP-sulf than APAP-gluc. 
Both APAP-GSH and APAP-NAC were detected albeit in low quantities (at 24h <10 nmol) 
in all species except in mouse where the amount of APAP-GSH produced (~65 nmol) was 
similar to APAP-sulf. In PCLS from all three species, the two main metabolites of AMAP, 
AMAP-gluc and AMAP-sulf were produced in higher amounts than the equivalent 
metabolites of APAP. The amount of APAP-gluc produced in mouse was twice the amount 
produced in human and three times the amount produced in rat, whereas AMAP-gluc 
was produced more in human than in the other two species. Rat produced much more 
APAP-sulf than mouse and human, while mouse produced the most AMAP-sulf, followed 
by the rat and then human. Interestingly, PCLS of the mouse, the most sensitive species 
for APAP toxicity, produced approximately ten times more APAP-GSH than rat PCLS and 
almost thirty times more than human PCLS. APAP-NAC was produced in small amounts 
in all species with the order of mouse>human>rat. In AMAP-treated PCLS, catechol and 
methylated catechol metabolites were produced in low amounts but surprisingly, in mouse 
PCLS they were produced in much higher amounts than in rat or human PCLS.
Figure 5. Metabolites that were produced by PCLS during 24h incubation with APAP or 
AMAP (0.5 mM, total amount = 650 µmol). The graphs show all major (A and C) and minor 
metabolites (B and D) of APAP (A and B) and AMAP (C and D) from mouse (open bars), rat 
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4. Discussion
AMAP, a regioisomer of APAP with similar analgesic and anti-pyretic properties has been 
frequently used as a non-toxic analog in studies on the mechanism of APAP-induced liver 
injury. APAP is probably the most extensively investigated drug but still its mechanism 
of toxicity is not fully elucidated. The concentration range (1-5 mM) used in this study 
is physiologically relevant because similar concentrations have been reported in plasma 
of APAP overdose patients 33. Our results indicate that mouse (TC50≈1 mM) is the most 
sensitive species to APAP toxicity, followed by rat (TC50≈4.7 mM) and human (TC50>5 
mM) (Fig. 1). The order of the species sensitivity to APAP is in line with that reported 
for primary hepatocytes with TC50 values of 3.8 mM (mouse), 7.6 mM (rat), and 28.2 mM 
(human) 34. In a recent study using the human cell line HepaRG35 and HepG2 cells (Herpers, 
unpublished data), a much higher APAP concentration (5-20 mM) was needed to observe 
toxicity. It can be concluded that species differences are similar in hepatocytes and PCLS, 
but PCLS appear more sensitive to APAP-induced toxicity. This may suggest the possible 
involvement of non-parenchymal liver cells in APAP-induced hepatotoxicity. Kupffer cells 
are thought to exacerbate APAP-induced hepatotoxicity by increasing the synthesis of 
oxygen free radicals 36, although this finding was not confirmed by Juet al., who found that 
Kupffer cells may have a protective role in addition to its pro-toxicant role in drug-induced 
acute liver injury 37. Moreover, they are involved in the regulation of phase II metabolism 
in the adjacent hepatocytes 38.
In contrast to APAP toxicity observed at all concentrations tested (1-5 mM), AMAP was 
toxic only at 5 mM in mouse PCLS, exhibiting a TC50 value of ca. 4.3 mM (Fig. 1). Similar 
findings were observed in mouse TAMH cells and in isolated mitochondria, glutathione 
depletion was more severe with APAP than AMAP 15. So far, the toxicity of AMAP has 
not been reported for rat or human and the mechanism of AMAP toxicity was virtually 
unknown. Surprisingly, AMAP caused significant cytotoxicity even at 1 mM in rat (TC50 = 
2 mM) and human (TC50 = 1 mM) PCLS and appeared more toxic than APAP at all tested 
concentrations in rat and human PCLS (Figs. 1,2,3).
To confirm the observed effects of AMAP, we assessed the profiles of proteins released 
by the PCLS in the medium. We found similar protein profiles after APAP treatment in 
mouse PCLS and after both APAP and AMAP treatments in rat PCLS, which differed from 
the corresponding control PCLS or the profile after AMAP treatment in mouse PCLS (Fig. 
4). The proteins released by mouse and rat PCLS after APAP- or AMAP-induced toxicity 
appear to be related to the resulting liver injury and could potentially represent new 
toxicity biomarkers. 
In order to obtain more insight into the species difference in AMAP and APAP toxicity, 
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we investigated the metabolites produced by mouse, rat and human PCLS. In mouse 
and human PCLS, the main biotransformation pathway for APAP was glucuronidation, 
whereas sulfation was responsible for 76% of all metabolites produced in rat PCLS. The 
relative amount of APAP-gluc (~60% of the total metabolites formed) and APAP-sulf (~30% 
of the total metabolites) produced in human PCLS (Fig. 5A) is in line with the observations 
in vivo39. Among the three species, mouse produced not only the highest amounts of phase 
II metabolites (APAP-gluc and APAP-sulf), but also the amount of APAP-GSH produced 
was approximately 10 and 30 times higher than that in rat and human respectively (Fig. 
5C). This suggests that the rate of formation of the reactive metabolite NAPQI by phase I 
metabolism is also higher in mouse which may explain the higher toxicity found. 
In both mouse and rat PCLS, sulfation was the main metabolic pathway of AMAP 
(Fig. 5B). Conversely, the estimated amount of AMAP-gluc produced in human PCLS 
was almost 5 times higher than AMAP-sulf showing a difference in AMAP detoxification 
pathways between men and animals. In contrast to what might be expected based on the 
toxicity data, AMAP oxidative metabolites comprise approximately 20% of all metabolites 
produced in mouse PCLS, while the percentage is much lower in rat and human (3% 
and 5% respectively). However, no GSH-conjugate of AMAP was found in any species, 
even when a higher concentration of AMAP (2.5 mM) was utilized (data not shown). 
AMAP is reported to be more susceptible to oxidative metabolism than APAP, but in 
contrast to APAP, AMAP cannot be directly oxidized to a reactive quinone imine 11. In 
our study, AMAP was metabolized to three different proximate reactive hydroquinone 
metabolites; 3-OH-APAP, 2,5-diOH-AA and 3-OMe-APAP, in line with previously 
reported data 40. These metabolites can in principle be converted to the reactive quinone 
metabolites, AMAP-o-benzoquinone (AMAP-o-Q), AMAP-p-benzoquinone (AMAP-p-Q) 
and 3-methoxy-acetyl-p-benzoquinone-imine (MAPQI) respectively. The hydroquinone 
metabolites can be subjected to further glucuronidation or sulfation. The reactive quinone 
metabolites of AMAP can be conjugated with GSH 9, but not as extensively as NAPQI and 
this was shown to occur only at very high doses of AMAP 10, 11. Despite the detection of 5-10 
times higher estimated amounts of hydroquinone metabolites in mouse PCLS compared 
to human and rat (Fig. 5D), mouse was the least sensitive species to AMAP toxicity.One 
possible explanation may be that the conversion of the hydroquinone to the ultimate 
quinone metabolites may occur at a higher rate in human and rat liver but these may 
remain undetected as the metabolites rapidly bind covalently to cell components, thereby 
inducing toxicity. Alternatively, quinone metabolites might be more efficiently reduced by 
NAPDH quinoneoxidoreductase1 in mice, which might explain the inverse relationship 
between the level of these proximate reactive metabolites and AMAP-induced toxicity.
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Administration of APAP and AMAP in vivo resulted in similar levels of covalent binding 
to proteins in mice 13 and hamsters 10. Reactive AMAP metabolites were bound more 
extensively to microsomal and cytosolic proteins, whereas reactive metabolites of APAP 
were bound more extensively to mitochondrial proteins in mouse liver 8. Additionally, 
while a large number of APAP adducts were detectable in all hepatic fractions 41, the 
majority of AMAP adducts were found in the endoplasmic reticulum (microsomes). A 
major AMAP adduct was observed at 50 kDa in mouse 13, which was later identified as 
CYP2E1 42. Therefore, AMAP, but not APAP, has the ability to function as a mechanism-
based inhibitor of CYP2E1, which may explain the low toxicity of AMAP in mice. Whether 
this inhibitory effect is stronger in mouse CYP2E1 than in rat or human CYP2E1 is unknown. 
Our results showed that more than 85% of AMAP was metabolized in mouse PCLS, while 
the percentage in rat and human were only 67% and 60% respectively, resulting in a higher 
exposure to AMAP in the human and rat PCLS. Moreover, co-incubation of AMAP and 
1-aminobenzotriazole, a non-selective mechanism-based inactivator of cytochrome P450s 
in both rat and human 43, 44 that was shown not to inhibit UDP-glucuronosyltransferase and 
sulfotransferase activities 45, did not improve the viability of AMAP-treated rat and human 
PCLS (unpublished data). Therefore, it cannot be excluded that AMAP itself is cytotoxic 
to the liver.
In conclusion, there are pronounced species differences in toxicity and metabolism of 
APAP and AMAP. This is the first report on the toxicity of AMAP in human and rat tissue, 
and we have shown that AMAP is at least as toxic as or even more toxic than APAP ex vivo 
in rat and human PCLS. Consequently, AMAP can no longer be considered as a general 
non-toxic isomer of APAP. The concentration of APAP causing toxicity in the human PCLS 
is lower than that previously found by others using HepG2 cells, HepaRG cells and also 
primary hepatocytes, which are considered as the gold standard of in vitro toxicity testing, 
possibly due to the high metabolic competence and the presence of non-parenchymal cells 
in the PCLS. Finally, the observed species differences in the toxicity of AMAP in mouse and 
human emphasize the importance of using human tissue in safety assessment. Therefore, 
the use of human PCLS may contribute not only to the reduction in the use of experimental 
animals but also to a better prediction of human hepatotoxicity.
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Abstract 
Drug-induced liver injury (DILI) is among the leading causes for drug withdrawal. 
Currently, there is a lack of predictive biomarkers. In this study, precision-cut liver slices 
(PCLS) were used to identify biomarkers for DILI from proteins excreted by the liver. 
PCLS from mouse, rat and human origin were incubated with acetaminophen (APAP), 
3-acetamidophenol (AMAP), diclofenac (DF) and lipopolysaccharide (LPS) for 24-48 h. 
Profiling of proteins in the medium of PCLS from all species treated with APAP using 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry demonstrated 
the same proteins in the medium as in urine of mice after APAP treatment. Similar profiles 
were obtained in human and rat PCLS treated with APAP and AMAP, and in mouse PCLS 
treated with APAP or DF, but not with AMAP, which is in line with our findings that 
AMAP is toxic in human and rat but not in mouse PCLS. LPS treatment did not result in a 
profile different from control.  Further analysis showed that the concentration of hepcidin, 
an iron-regulating hormone, was reduced in PCLS medium after APAP, AMAP or DF 
treatment, but increased levels were found after LPS exposure.  In mouse but not in human 
PCLS, superoxide dismutase (SOD) 1 was induced slightly by LPS and to a larger extent by 
DF, whereas in rat PCLS, SOD1 was induced by DF only. In conclusion, the PCLS system 
is a promising, translational model for studying DILI and for identification of species 
differences and potential biomarkers. 
General Introduction
51
Proteomic profiling in medium from mouse, rat and human precision-cut liver slices 
for biomarker detection regarding drug-induced liver injury
1. Introduction
The most common adverse drug reaction leading to drug withdrawal is drug-induced liver 
injury (DILI) 1. The incidence for DILI has been estimated to be at least 10-15 cases per 
100,000 patient years 2. Despite the efforts to study DILI, for most drugs the underlying 
mechanisms have not been fully elucidated yet. In addition, particular drugs can cause a 
rare and severe form of DILI, without a straightforward dose-effect relationship or a relation 
with their therapeutic mode of action. These adverse reactions are, therefore, described 
as idiosyncratic. Currently, there are no adequate biomarkers to detect idiosyncratic DILI 
in patients, in preclinical animal studies or in in vitromodels during drug development 3. 
Because of this, identification of novel biomarkers for DILI is difficult and new methods 
to address this issue are being explored 4, 5. Although for non-idiosyncratic DILI more 
knowledge on potential mechanisms is available compared to idiosyncratic DILI, the 
prediction from preclinical data is limited and better preclinical prediction models with 
their accompanying biomarkers are needed.
Precision-cut liver slices (PCLS) of mouse, rat and human liver are being increasingly used 
to study the hepatotoxic effects of many compounds 5-9. The advantage of this ex vivo model 
over in vitro models, including cell cultures, is that the structure of the liver tissue is maintained 
in PCLS as well as the presence and interactions of all parenchymal and non-parenchymal cell 
types, including cell-matrix interaction 10, 11. Moreover, PCLS retain the expression and activity 
of phase I and phase II metabolizing enzymes well, the function of which is comparable to the 
in vivo situation 7, 12-15. Furthermore, it has been shown that rat PCLS demonstrate the same 
responses to toxic compounds as observed in vivo based on microarray data 6. 
Recently, we have used matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) to assess and identify potential novel biomarkers for DILI 
16. For this, mice were administered a single dose of acetaminophen (APAP) as a model 
compound for hepatocellular liver injury and 24 h urine samples were collected. From the 
urine samples, multiple proteins could be identified that were related to APAP-induced 
liver injury. Although the data suggested that these candidate urinary biomarkers originate 
from the liver, this is difficult to prove in an in vivo experimental setup. Here, we tested 
whether the PCLS system could be used to demonstrate that the proteins we found in urine 
indeed originated from the liver. Furthermore, we aimed to identify protein biomarkers 
that could be used as early and sensitive organ-specific biomarkers, which could be applied 
in human urine samples during clinical studies. To this end, we investigated the protein 
profiles in the PCLS medium after exposure to 3-acetamidophenol (AMAP) and diclofenac 
(DF) in addition to APAP. AMAP was shown previously to induce species-specific toxicity 
in PCLS of human and rat, but not of mouse8. Diclofenac (DF) is a non-steroidal anti-
General Introduction
52
Proteomic profiling in medium from mouse, rat and human precision-cut liver slices 
for biomarker detection regarding drug-induced liver injury
inflammatory drug that has been known to cause idiosyncratic DILI 17 and to induce acute 
hepatotoxicity similar to APAP 18.  
2. Methods
2.1. Animals for PCLS studies
Female C57BL/6 mice weighing 20-24 g and male Wistar rats (HsdCpb:WU) weighing 300-
350 g were obtained from Harlan (Horst, the Netherlands). The mice and rats were housed 
on a 12-h light/dark cycle in a temperature- and humidity-controlled room with food (Harlan 
chow no 2018, Horst, the Netherlands) and tap water ad libitum. The animals were allowed 
to acclimatize for at least seven days before experimentation. The experimental protocols 
were approved by the Animal Ethical Committee of the University of Groningen. Under 
isofluorane/O2 anesthesia, the liver was excised and placed into ice-cold University of 
Wisconsin (UW) organ preservation solution (DuPont Critical Care, Waukegab, IL, USA). 
2.2. Human liver tissue
Pieces of human liver tissue were obtained from patients undergoing partial hepatectomy 
(PH) for the removal of carcinoma or from liver tissue remaining as surgical waste after split 
liver transplantation (TX), as described previously 7, 11. The experimental protocols were 
approved by the Medical Ethical Committee of the University Medical Center Groningen.
2.3. Preparation of the PCLS
PCLS were made as described previously 5, 8, 19. In brief, cylindrical liver cores were made 
using a 5mm biopsy punch (Kai Industries, Seki, Japan). These cores were sliced with a 
Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) in ice-cold Krebs-Henseleit 
buffer saturated with carbogen (95% O2 and 5% CO2). PCLS (5 mm diameter, 200-300 µm 
thick and ca. 4.5-5.5 mg wet weight) were stored in ice-cold UW solution until incubation. 
2.4. Incubation of the PCLS
Incubation of PCLS in 12-well plates (Greiner bio-one GmbH, Frickenhausen, Austria) 
was performed as described before 19. In brief, PCLS were pre-incubated  at 37°C for 1 
h individually in 1.3 ml Williams’ medium E with glutamax-1 (Gibco, Paisley, UK), 
supplemented with 25 mM D-glucose and 50 µg/ml gentamicin (Gibco, Paisley, UK) 
(WEGG medium) in a 12-well plate with shaking (90 times/min) under saturated carbogen 
atmosphere. Pre-incubation allows the PCLS to restore their ATP levels. After pre-
incubation, PCLS were transferred to fresh WEGG medium and incubated with vehicle 
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(final concentration of DMSO during incubation ≤0.5%), APAP, AMAP, DF or LPS further 
for 24h. The human PCLS were incubated with APAP or AMAP for 48 h instead of 24 h, 
as no changes were observed after 24 h in protein profiles compared to control slices. The 
concentration of drugs used were based on previous dose-response studies and aimed to 
induce low to moderate damage to the slices, and were 1 mM APAP and 3 mM AMAP for 
mouse, 5 mM APAP and AMAP for rat and 3 mM APAP and AMAP for human PCLS. LPS 
was used in a concentration of 20,000 EU/mL for all species. The concentration of DF was 
200 µM in mouse, 350 µM in rat and 500 µM in human PCLS. The medium was collected, 
snap frozen in liquid nitrogen and stored at -80 °C until further use.
2.5. ATP content of PCLS
Viability of PCLS was determined after incubation by measuring the ATP content of the 
PCLS according to the method described earlier 19. In brief, at the end of  incubation, three 
replicate PCLS were collected individually in 1 ml 70% ethanol (v/v) containing 2 mM 
EDTA (pH 10.9) and snap-frozen in liquid nitrogen and stored at -80°C  until analysis. The 
samples were homogenized using a Mini-BeadBeater-8 (BioSpec, Bartlesville, OK, USA) 
and centrifuged for 3 minutes at 13000 rpm and 4°C. The supernatant was diluted 10 times 
with 0.1 M TrisHCl containing 2 mM EDTA (pH 7.8) to reduce the ethanol concentration. 
The ATP content of the supernatant was measured using the ATP Bioluminescence Assay 
kit CLS II (Roche, Mannheim, Germany) in a black 96-well plate Lucy1 luminometer 
(Anthos, Durham, NC, USA) using a standard ATP calibration curve.
The protein content of the PCLS was determined by dissolving the remaining pellet in 
200 µl of 5 M NaOH for 30 min. After dilution with water to a concentration of 1 M NaOH, 
the protein content of the samples was determined using the Bio-Rad DC Protein Assay 
(Bio-Rad, Munich, Germany) using bovine serum albumin (BSA) for the calibration curve. 
2.6. Mouse urine samples
For validation of the PCLS model, urine samples obtained from a previously performed 
mouse study 16 were used. In short, male FVB mice were treated with a single i.p. dose of 
0-350 mg/kg APAP and placed in a metabolic cage for 24 h to collect urine. After 24 h, liver 
tissue was collected and homogenized using a Mikrodismembrator U (Sartorius Stedim, 
Nieuwegein, the Netherlands).  
2.7. Protein profiling 
Proteins were isolated from urine, liver homogenates or PCLS medium using Magnetic 
Beads based Hydrophobic Interaction Chromatography 8 beads (C8; BrukerDaltonics 
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GmbH, Bremen, Germany) that bind hydrophobic proteins 20. Synthetic hepcidin-24 
(Peptide International Inc., Louisville, KY, USA) was used as internal standard (IS) to 
enable comparison between samples. For protein profiling, MALDI-TOF MS (Microflex 
LT with software flexControl Version 3.0, BrukerDaltonics) was used. Of the prepared 
sample, 1 µl was applied to a MSP 96 polished steel MALDI target plate under nitrogen 
flow, followed by 1 µl of energy absorbing matrix, 5 mg α-Cyano-4-hydroxy-cinnamic 
acid (CHCA) in 1 ml 50% acetonitrile (ACN) and 0.5% trifluoro acetic acid (TFA). Mass-
to-charge (m/z) spectra were generated using MALDI-TOF MS in positive, linear ion 
mode and 350 laser shots. Initial laser power; 50% for 1-20 kDa and 60% for 10-160 kDa 
measurements, Laser Attenuator; Offset 25% and Range 20%. Pulsed ion extraction was 
set to 250 ns. Samples were measured in the 1-20 kDa mass range and 10-160 kDa mass 
range. Calibration was performed using protein calibration standard I for 1-20 kDa 
measurements and protein calibration standard II (both BrukerDaltonics) for 10-160 kDa 
measurements. Spectra were analyzed by means of the ClinProTools software (Bruker). 
Relative peak intensities were calculated by dividing mass peak intensity by the peak 
intensity of the IS.
2.8. Protein identification
Protein identification was performed at the Nijmegen Proteomics Facility (Nijmegen , 
the Netherlands) using an electrospray ionization mass spectrometer (ESI LTQ; Thermo 
Fisher Scientific) with a liquid chromatography column placed in front of the ESI probe. 
Peptide and protein identifications were extracted from the ESI data by means of the 
search program Mascot using a musmusculus RefSeq36 database. Finally, the peptides 
and proteins found by Mascot were validated with the in-house designed script PROTON, 
as described elsewhere 21.
2.9. Hepcidin determination
The concentration of hepcidin in PCLS medium was determined using MALDI-TOF MS 
analysis as previously described 22. 
2.10. Statistical analysis
All experiments were performed in 3 slices of 5 (mouse and human) or 4 (rat) individual 
livers. Statistics were performed using GraphPad Prism 5.02 (La Jolla, USA), unless 
indicated otherwise. A p-value of less than 0.05 was considered statistically significant. 
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3. Results
3.1. Species difference in drug sensitivity
The effect of the drugs on PCLS viability was determined by measuring ATP levels after 
incubation with the different drugs. For APAP and AMAP, previous studies have shown 
that with the concentrations used in this study, APAP significantly decreased ATP levels 
in mouse, rat and human PCLS, whereas AMAP treatment did not change ATP levels in 
mouse PCLS, but significantly reduced ATP levels in rat and human tissue. 8. This indicated 
that AMAP was just as toxic as APAP in human PCLS and even more toxic than APAP in 
rat PCLS. In figure 1, the effe cts of DF and LPS treatment on ATP levels in mouse, rat and 
human PCLS are demonstrated. Whereas DF reduced the ATP content to 75%, this effect was 
not significant. Also LPS treatment had no significant effect on ATP levels in mouse PCLS.
Figure 1. PCLS viability after treatment with DF and LPS
Effect of 24 h incubation of DF and LPS on the ATP content of PCLS prepared from mouse 
(a), rat (b) and human (c). ** p< 0.01 *** p < 0.001 compared to control.
3.2. Protein profiles of PCLS medium resemble in vivo mouse urinary profiles of 
APAP-induced liver injury
Previously, we have identified a specific protein profile of mouse urine that correlated 
with APAP-induced liver injury 16. By profiling the proteins of mouse liver homogenates, 
we now demonstrate that the proteins observed in urine of mice with APAP-induced 
liver injury could originate from the liver (Figure 2). However, there was no difference 
in the protein profiles of liver homogenates obtained from control mice and mice with 
APAP-induced liver injury. After profiling mouse PCLS medium samples, the same 
protein peaks found in urine of mice with APAP-induced liver injury, were found 
in medium of mouse liver slices upon incubation with APAP 8. Protein identification 
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revealed that the same key proteins that differentiated between control and APAP-
induced liver injury in mouse urine samples, differed between control and APAP-
treated PCLS medium (Table 1). 
3.3. Similar toxicity profiles in mouse, rat and human PCLS after APAP treatment
We profiled mouse and rat PCLS medium samples incubated with APAP or AMAP for 24 
h and human PCLS medium incubated with APAP or AMAP for 48 h. We confirmed the 
data previously presented by Hadi et al 2012b, as we demonstrated that APAP and AMAP 
caused a similar toxicity profile in rat PCLS as APAP in mouse PCLS, whereas AMAP 
treatment in mouse PCLS did not lead to a toxicity protein profile (Figure 3A). In addition, 
we showed that both  APAP and AMAP treatment in human PCLS led to a toxicity profile 
similar to APAP treatment in mouse PCLS. It thus appears that, besides rat PCLS, AMAP 
is also toxic in human PCLS as opposed to mouse PCLS.
Figure 2. Protein profiles of mouse urine and liver homogenate, and mouse PCLS 
medium after APAP treatment
Protein profiles of protein masses (m/z in Da) versus peak intensity (arbitrary units) of 
mouse urine, PCLS medium and liver homogenate of control and APAP treatment. Shaded 
areas indicate proteins that differ between control and APAP treatment. 
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One potential marker associated with DILI is hepcidin, for which it was demonstrate 
that hepatic and plasma levels were down-regulated in mice with APAP-induced liver 
injury as a result of oxidative stress 23. To investigate whether acute APAP-induced 
hepatotoxicity in PCLS is mediated by a similar mechanism as observed in vivo, we 
measured the concentration of the iron-regulating hormone hepcidin in PCLS medium. 
Lipopolysaccharide (LPS) was used as a positive control in these experiments to assess 
the physiological response of hepatic hepcidin regulation in the PCLS, as LPS is a strong 
inducer of hepcidin22.In concordance with the mouse in vivo data 23, hepcidin concentration 
was also decreased in PCLS medium of all species after APAP treatment (Figure 3B). AMAP 
treatment did not affect hepcidin concentration in mouse PCLS medium, but hepcidin 
concentration was decreased in rat and human PCLS after AMAP treatment. Hepcidin 
concentrations are known to vary substantially between individual patients 24, which 
hampers the assessment of statistical significant changes. To demonstrate that the effects of 
APAP and AMAP on hepcidin in PCLS of all individual donors were similar, we included 
line graphs that show the hepcidin concentration for all treatments in PCLS obtained in 
each mouse, rat or human liver slice (Figure 3C).
3.4. DF treatment resembles the toxicity profile of APAP
Incubation of mouse PCLS with DF resulted in protein profiles of PCLS medium that 
resembled the toxicity profile of APAP, albeit with lower peak intensities (Figure 4A). LPS 
had minimal effects on the protein profiles. The medium samples of rat and human PCLS 
treated with DF proved to be difficult to profile using MALDI-TOF MS and as a result 
the protein profiles were of insufficient quality, as they showed high background signals 
and low peak intensities. Therefore, we could not compare the protein profiles of rat and 
human PCLS medium samples after DF incubation with those of mouse PCLS. However, 
we were able to compare the concentration of superoxide dismutase (SOD) 1 at 15.9 kDa, 
one of the protein masses identified in the urine of mice with APAP-induced liver injury 
(Figure 2) that was also present in medium samples of DF-treated mouse PCLS (Figure 
3A). SOD1 was absent in control mouse PCLS medium samples, slightly induced after 
LPS incubation, and greatly induced after DF treatment (Figure 4B). Similarly, SOD1 was 
absent in control rat PCLS medium samples and was induced by DF, however, not by LPS. 
In the human PCLS medium samples, SOD1 could already be detected in control samples, 
whereas levels did not increase after LPS or DF.
In addition, hepcidin concentrations in PCLS medium samples were determined (Figure 
5A). Similar to the findings in mouse plasma and PCLS medium after APAP-induced 
hepatotoxicity, incubation of PCLS with DF resulted in decreased hepcidin concentrations 
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in the medium samples of mouse, rat and human PCLS. The effect of DF was not statistically 
significant in rat and human PCLS medium samples due to the high variation, but the 
line graphs demonstrate that DF treatment decreased the hepcidin concentrations in each 
sample (Figure 5B). Incubation with LPS induced the hepcidin concentration in all species, 
which is in agreement with a previously described effect of the endotoxin 22. These findings 
confirmed that the PCLS have maintained their physiological regulation of hepcidin. 
Figure 3. Protein profiles and hepcidin concentration of mouse, rat and human PCLS 
medium after APAP orAMAP treatment.
 Protein profiles of protein masses (m/z in Da) versus peak intensity (arbitrary units) of me-
dium from mouse, rat and human PCLS of control, APAP or AMAP treatment (a). Shaded 
areas indicate proteins that differ between control and APAP/AMAP treatments. Hepcidin 
concentrations in medium of control PCLS and after APAP or AMAP treatment for all spe-
cies (b). Every line represents the hepcidin concentrations for a single PCLS in control 
situation and after APAP and AMAP treatment. * p< 0.05 compared to control.
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Figure 4. Comparison of PCLS medium protein profiles after incubation of APAP, 
DF orLPS
Profiles of protein masses (m/z in Da) versus peak intensities (arbitrary units) of medium 
from mouse PCLS of control and treatment with APAP, LPS and DF (a). Shaded areas 
indicate proteins that differ between control and APAP or DF treatment. For rat and human 
PCLS the peak intensity of SOD1 at 15.9 kDa in medium after DF and LPS treatment was 
compared to SOD1 peak intensity in medium of mouse PCLS (b). Shaded areas here show 
the SOD1 mass peak.
Figure 5.Hepcidinconcentration in PCLS medium after DF or LPS treatment
Hepcidin concentration in medium of mouse (a), rat (b) and human (c) PCLS after treat-
ment with DF or LPS.* p< 0.05; ** p < 0.01 compared to control.
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4. Discussion
DILI remains a major problem in drug development, but also is a dangerous complication 
of drug treatment in patients. Because of species differences and the lack of mechanistic 
insight for many drugs, identification of biomarkers predictive for DILI is difficult. This 
study demonstrates the potential of PCLS to identify biomarkers for DILI in a translational 
approach using model compounds, such as APAP and DF.
Using the PCLS system, we confirmed that the proteins observed previously in 24 h 
urine samples in response to APAP-induced liver injury 16, including fatty acid binding 
protein, carbonic anhydrase 3, SOD1 and regucalcin, are released by the liver tissue upon 
APAP treatment, as they were found in the medium surrounding the PCLS (Table 1 and 
Fig 2). These proteins all play a role in processes known to be involved or affected in acute 
liver injury, such as oxidative stress, disruption of calcium homeostasis and mitochondrial 
dysfunction 25-30. There were no differences between the protein profiles of liver homogenates 
of control mice and mice with APAP-induced liver injury. This indicates that the proteins 
found in PCLS medium and mouse urines with APAP-induced liver injury are normally 
present in liver tissue and are not produced upon injury. Furthermore, in the in vivo study 
we could not find any signs of kidney injury as a result of APAP administration, which 
could potentially have influenced the urinary protein composition. We thus found strong 
support for the hypothesis that with APAP-induced injury, proteins are released by liver 
tissue and excreted into the urine via the blood. 
An advantage of using the PCLS system compared to assessment of biomarkers in urine 
is that there is less hindrance caused by major urinary proteins, which are abundantly 
present in rodent urine. The PCLS medium lacks the presence of such proteins and, hence, 
additional potential biomarkers might be easier to detect. Moreover, because PCLS can be 
made from organs of multiple species, the system has potential for translational research 
and can detect species differences in responses to toxic drugs. We analyzed if similar toxicity 
profiles as caused by APAP in mouse PCLS could also be observed in rat and human PCLS. 
Not only did APAP treatment result in similar protein profiles in all species, for AMAP 
toxicity-related protein profiles were found comparable to APAP in rat and human PCLS. 
Therefore, this study confirmed the species differences with respect to toxicity of AMAP, 
which is often incorrectly  designated as the non-toxic isomer of APAP 8, 31.
PCLS of mouse, rat and human origin were incubated with APAP, AMAP and DF. The 
doses of these compounds were carefully selected from initial dose-response studies based 
on the criteria that each drug concentration elicits minimal hepatotoxicity and is within a 
physiologically relevant concentration limit of 50-times its maximum plasma concentration 
(Cmax) value 32. For LPS, a dose was selected that was predicted to be of minimal toxicity, 
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but would elicit an inflammatory response by the release of cytokines (Hadi et al 2012b). 
Accordingly, LPS treatment had minimal effects on ATP levels and protein profiles in 
the medium compared to the other compounds. In general, the changes in ATP levels 
corresponded to a large extent with the protein profiles in all species studied. APAP induced 
a toxicity-related protein profile for all species and decreased the ATP levels. AMAP did 
not have any effects on ATP level and protein profile in mouse PCLS, whereas it resembled 
the toxicity pattern of APAP in rat and human PCLS. Although the dose of 200 µM DF did 
not affect ATP levels in mouse PCLS in these experiments, the protein profile resembled 
that of APAP, indicating a hepatotoxic effect. It appears that the protein profiles of PCLS 
medium are a more sensitive read-out of toxicity than ATP levels. Moreover, just slightly 
higher doses of DF in mouse PCLS decreased ATP levels dramatically (data not shown). In 
addition, DF treatment significantly decreased ATP levels in rat and human PCLS.  
Profiling of rat and human PCLS medium samples after DF treatment proved to be 
difficult. For some unknown reason, the protein profiles of these PCLS medium samples 
demonstrated high background signals and generally low peak intensities. Nevertheless, 
the presence of SOD1 could be confirmed from these spectra and levels were increased in 
rat PCLS treated with DF. In human PCLS, however, SOD1 was already present in control 
samples. Human PCLS are prepared from tissue that is more extensively handled before 
slicing compared to rodent PCLS, as they originate from human left-over tissue from 
surgery. The presence of SOD1 in control human PCLS indicates that the tissue already 
showed a stress response and that incubation of DF for 24 h did not have an additional 
effect on the peak intensity of this protein. Moreover, human PCLS required 48 h instead of 
24 h of incubation with APAP and AMAP before substantial effects on the protein profiles 
in PCLS medium regarding toxicity could be observed. 
Hepcidin, an iron-regulating hormone, was recently shown to be involved in APAP-
mediated liver injury by increasing hepatic iron loading 23. Plasma levels of hepcidin were 
reduced upon APAP treatment by the oxidative stress caused by APAP. In the current 
study, all drug treatments, except for AMAP in mouse PCLS, resulted in decreased 
hepcidin concentrations in PCLS medium samples of all species. For APAP and AMAP, 
this indicated that the same mechanisms as observed in vivo are likely to be involved in 
hepatotoxictyin vitro. For DF treatment, this suggests that oxidative stress might play a 
role in the mechanisms leading to liver injury 33, 34. Although DF-treated human PCLS 
medium did not demonstrate any effects on SOD1 release, hepcidin concentration was 
decreased after 24 h of incubation. Hepcidin might, therefore, be involved early on in the 
manifestation of liver injury. Furthermore, LPS incubation induced hepcidin concentration 
dramatically, which is confirmative to what has been reported in vivo22.
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In conclusion, this is the first study on protein profiling in medium of human, mouse 
and rat PCLS, demonstrating that similar toxicity-related protein profiles were identified 
in mouse urine (in vivo) and in PCLS (ex vivo) prepared from mouse, rat and human. Hence, 
the PCLS system proves to be a promising, translational model for the identification of 
potential protein biomarkers, which could be developed as urinary biomarkers for human 
DILI, and provide insight into the mechanisms behind these adverse reactions. 
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Abstract
Idiosyncratic drug-induced liver injury (IDILI) has been the top reason for withdrawing 
drugs from the market or for black box warnings. IDILI may arise from the interaction of a 
drug’s reactive metabolite with a mild inflammation that renders the liver more sensitive to 
injury resulting in increased toxicity (inflammatory stress hypothesis). Aiming to develop 
a robust ex vivo screening method to study inflammatory stress-related IDILI mechanisms 
and to find biomarkers that can detect or predict IDILI, mouse precision-cut liver slices 
(mPCLS) were co-incubated for 24h with IDILI-related drugs and lipopolysaccharide. 
Lipopolysaccharide exacerbated ketoconazole [15 µM] and clozapine [45 µM] toxicity but 
not their non-IDILI-related comparators, voriconazole [1500 µM] and olanzapine [45 µM]. 
However, the other IDILI-related drugs tested (diclofenac [200 µM], carbamazepine [400 
µM] and troglitazone [30 µM]) did not cause synergistic toxicity with lipopolysaccharide 
after 24h incubation. Lipopolysaccharide further decreased the reduced glutathione levels 
caused by ketoconazole or clozapine in mPCLS after 24h incubation, which was not the 
case for the other drugs. Lipopolysaccharide significantly increased NO, cytokine and 
chemokine release into the mPCLS media, while the treatment with the drugs alone did 
not cause any substantial change. All seven drugs drastically reduced lipopolysaccharide-
induced NO production. Interestingly, only ketoconazole and clozapine increased the 
lipopolysaccharide-induced G-CSF and GM-CSF release. Pilot experiments showed that 
diclofenac and troglitazone, but not carbamazepine, demonstrated synergistic toxicity 
with lipopolysaccharide after a longer incubation of 48h in mPCLS.  In conclusion, we 
have developed an ex vivo model to detect inflammatory stress-related liver toxicity and 
identified ketoconazole, clozapine, troglitazone and diclofenac as drugs that showed 
synergistic toxicity with lipopolysaccharide. Reduced glutathione, G-CSF, and GM-
CSF were identified to be potential biomarkers for IDILI-inducing drugs mediated by 
inflammatory stress and mPCLS appear to be a promising screening tool to further unravel 
the mechanism of IDILI. 
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1. Introduction
Idiosyncratic drug reactions (IDRs) can be defined as adverse drug reactions (ADRs) that 
occur in a small minority (0.01-1%) of the patients taking clinically-relevant doses and do 
not involve the known pharmacological effects of the drug.1 IDRs are a major issue for 
drug development as over 10% of newly approved drugs in the US were withdrawn or 
restricted in use due to ADRs that were not predicted by pre-clinical and clinical trials.2, 3 
Drug-induced liver injury (DILI) has been the top reason for withdrawing drugs from the 
market.4, 5 DILI accounts for more than 50% of acute liver failure cases and idiosyncratic 
DILI (IDILI) accounts for 13% of them.3 It can be estimated that about 30,000 patients are 
required in clinical testing to detect IDILI that occurs in 1 in 10,000 patients.3 Assuming a 
similar incidence in animals, 30,000 animals are needed for toxicity testing to detect IDILI. 
Because such large studies are not feasible, mechanisms of action of IDILI need to become 
better understood in order to develop IDILI predictive models and to identify biomarkers 
that can detect IDILI. The frequently stated notion that IDILI is dose-independent in fact 
refers to its response. However, the total dose has a bearing on IDILI as drugs that are 
administered at doses lower than 10 mg/day (e.g. OZ) are generally not associated with 
IDILI, while the typical IDILI-causing drugs (e.g. CZ) are given at higher doses.6
In many cases, metabolism of the drug to reactive metabolites and free radicals seems 
to be associated with DILI.7 While it was suggested that reactive metabolites may also be 
responsible for many IDILI cases,8, 9 there are also drugs that form reactive metabolites but 
are not related to any IDRs and IDR-related drugs that do not form reactive metabolites.10 
Several hypotheses regarding the mechanism of IDILI have been described extensively 
in recent reviews and many involve the formation of reactive metabolites.1, 11, 12 Two of 
them, the danger hypothesis and the inflammatory stress hypothesis additionally propose 
inflammation as a cofounding factor for IDILI.12 Such a reactive metabolite can bind to 
an endogenous protein forming a hapten,13 which has been shown to trigger antibody 
formation. The danger hypothesis proposes that the formation of this hapten is insufficient 
to cause IDILI and a secondary “danger” signal is needed that acts as an adjuvant to 
initiate the injury.14 This signal could be an inflammatory episode by bacterial or viral 
infection leading to cytokine release, which activates the immune system to induce allergic 
hepatotoxicity.15 Alternatively, the inflammatory stress hypothesis suggests that an 
episode of mild inflammation could play a role in lowering the threshold for drug toxicity, 
thereby precipitating a toxic response and rendering an individual susceptible to IDILI.16, 
17The low incidence of the concurrence of the danger signal with the drug exposure is 
supposed to be the basis of IDILI. Several animal models have been developed employing 
this hypothesis with the aim to mimic human IDILI, where drugs that cause human IDILI, 
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such as chlorpromazine, trovafloxacin and sulindac, were rendered more toxic in rats or 
mice by co-treatment with lipopolysaccharide (LPS), a potent inflammation inducer.18-21
The insights provided by animal models of IDILI could lead to the development of more 
robust in vitro/ex vivo predictive tests based on the elucidated mechanisms of action. One 
advantage of in vitro/ex vivo tests is the possibility to compare the toxicity and metabolism 
of drugs in animal and human. Precision-cut liver slices (PCLS) could be a promising ex 
vivo model to test this inflammatory stress hypothesis as PCLS retain the normal tissue 
architecture of a whole liver with all its cell types in their natural arrangement and integral 
intercellular interactions.22-24 Phase I and II drug metabolism enzymes are active in PCLS 
and their metabolic functions and toxicity characteristics correlate with in vivo data.24-
29 Moreover, microarray analysis of xenobiotic-treated rat PCLS showed that they could 
mimic the toxicity as observed in vivo and discriminate between different mechanisms of 
hepatotoxicity.30 It has also been shown that treatment of PCLS with LPS activated the Kupffer 
cells and induced an inflammatory response in the liver as evidenced by the production of 
nitric oxide (NO) and inflammatory cytokines, such as tumor necrosis factor-α (TNF) and 
interleukin 1β (IL-1β) both in rat and human liver slices,31-33 indicating that the PCLS model 
can be used as translational model when animal and human tissue is employed. 
In the present study, we investigated the toxicity of five drugs known to cause IDILI in 
patients: ketoconazole (KC), clozapine (CZ), diclofenac (DF), carbamazepine (CBZ), and 
troglitazone (TGZ) in the presence or absence of LPS in mPCLS. Additionally, non-IDILI-
causing comparator drugs of KC and CZ in mice, voriconazole (VC) and olanzapine (OZ) 
respectively, were also investigated. VC and OZ are in the same chemical class of drugs as 
KC and CZ respectively, but do not induce liver toxicity in our model at the concentrations 
used.  The viability of mPCLS was determined by means of adenosine triphosphate (ATP) 
content, leakage of lactate dehydrogenase (LDH), levels of reduced glutathione (GSH) and 
total glutathione, and histomorphology. We also examined each drug’s effect on LPS-induced 
nitric oxide (NO), cytokine, and chemokine release in the mPCLS. The aim of our study was 
to test if mPCLS can be a suitable ex vivo model to study the inflammatory stress hypothesis, 
which of the IDILI-associated drugs could be identified with this model and to discover 
biomarker(s) that can identify drugs as potentially inducing IDR in mouse mPCLS.
2. Materials and Methods
2.1. Chemicals
Troglitazone (TGZ) was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
Ketoconazole (KC), clozapine (CZ), diclofenac sodium salt (DF), carbamazepine (CBZ) and 
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LPS derived from Eschericia coli serotype B55:O55 (Lot 050M4014, 600,000 EU/mg) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Olanzapine (OZ) and voriconazole 
(VC) were kind gifts from Dr. Willem Schoonen (MSD, Oss, the Netherlands) and Jan-
Willem Alffenaar (UMCG, Groningen, the Netherlands) respectively. All other drugs 
and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless stated 
otherwise. Stock solutions of each drug were made in DMSO (VWR, Briare, France) as the 
solvent.  
2.2. Animals
Female C57BL/6 mice weighing 20-24 g were obtained from Harlan (Horst, the Netherlands). 
The mice were housed on a 12-h light/dark cycle in a temperature- and humidity-controlled 
room with food (Harlan chow no 2018, Horst, the Netherlands) and tap water ad libitum. 
The animals were allowed to acclimatize for at least seven days before experimentation. The 
experimental protocols were approved by the Animal Ethical Committee of the University 
of Groningen.
2.3. Excision of mouse liver
Under isofluorane/O2 anesthesia, the liver was excised and placed into ice-cold University 
of Wisconsin (UW) organ preservation solution (DuPont Critical Care, Waukegab, IL, 
USA). 
2.4. Preparation of the mPCLS
mPCLS were made as described previously for rat and human PCLS34 with one minor 
modification: the cylindrical liver cores were made using a 5mm biopsy punch (Kai 
Industries, Seki, Japan) instead of using a drill. These cores were sliced with a Krumdieck 
tissue slicer (Alabama R&D, Munford, AL, USA) in ice-cold Krebs-Henseleit buffer 
saturated with carbogen (95% O2 and 5% CO2). PCLS (5 mm diameter, 200-300 µm thick 
and ca. 4.5-5.5 mg wet weight) were stored in ice-cold UW solution until incubation. 
2.5. Incubation of the mPCLS
Incubation of mPCLS in 12-well plates (Greiner bio-one GmbH, Frickenhausen, Austria) 
was performed as described before.34 In brief, mPCLS were pre-incubated  at 37°C for 1h 
individually in a well containing 1.3 ml Williams’ medium E with glutamax-1 (Gibco, 
Paisley, UK), supplemented with 25 mM D-glucose and 50 µg/ml gentamicin (Gibco, Paisley, 
UK) (WEGG medium) in a 12-well plate with shaking (90 times/min) under saturated 
carbogen atmosphere. As was described for rat and human slices, pre-incubation allows 
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the mPCLS to restore their ATP levels (data not shown). After pre-incubation, mPCLS were 
transferred to fresh WEGG medium in the presence or absence of LPS (20,000 EU/ml) and 
in combination with KC [15 µM] or its analog VC [1500 µM], CZ [45 µM] or its analog OZ 
[45 µM], CBZ [400 µM], DF [200 µM], TGZ [30 µM] or the vehicle (final concentration of 
DMSO during incubation ≤0.5%) and incubated further for 24-48h without any further 
change in medium. The LPS and the drug were administered simultaneously. Pilot studies 
showed no differences in response when the drug was added 4h earlier or later than LPS. 
Preliminary dose-response studies were performed for LPS, with the objective to identify 
a low-toxic dose of LPS that generated significant inflammatory responses based on the 
measurements of pro-inflammatory cytokines. The concentrations of drugs used in this 
study were also selected from initial dose-response relationship studies based on the criteria 
that each drug concentration elicits slight drug-only hepatotoxicity. For all the IDILI-related 
drugs, the concentration was lower than 25-fold its plasma maximum concentration (Cmax) 
value, whereas for the non-IDILI-related comparator drugs, voriconazole and olanzapine, 
a concentration of even ~100-fold Cmax was selected. Cmaxvalues were obtained from a 
combination of literature searches and available databases, as in Xu et al.35 Therapeutically 
appropriate drug exposure levels were defined by Cmax values observed in humans upon 
single- or multi-dose administration. A concentration of 100-fold Cmax was considered as 
a therapeutically relevant concentration limit for each drug incorporating a scaling factor 
to account for human population pharmacokinetic and toxicodynamicvariabilities35. 
Cosgrove et al. also used this parameter.36
2.6. ATP and protein content of mPCLS
Viability of mouse mPCLS after 24h incubation with various treatments was determined 
by measuring the ATP content of the mPCLS according to the method described earlier.34 
In brief, at the end of 24h incubation, three replicate mPCLS were collected individually 
in 1 ml 70% ethanol (v/v) containing 2 mM EDTA (pH 10.9) and snap-frozen in liquid 
nitrogen and stored at -80°C  until analysis. The samples were homogenized using a Mini-
BeadBeater-8 (BioSpec, Bartlesville, OK, USA) and centrifuged for 3 minutes at 13000 rpm 
and 4°C. The supernatant was diluted 10 times with 0.1 M TrisHCl containing 2 mM EDTA 
(pH 7.8) to reduce the ethanol concentration. The ATP content of the supernatant was 
measured using the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, Germany) 
in a black 96-well plate Lucy1 luminometer (Anthos, Durham, NC, USA) using a standard 
ATP calibration curve.
The remaining pellet was used to determine the protein content of the mPCLS by 
dissolving the pellet in 200 µl of 5 M NaOH for 30 min. After dilution with water to a 
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concentration of 1 M NaOH, the protein content of the samples was determined using 
the Bio-Rad DC Protein Assay (Bio-Rad, Munich, Germany) using bovine serum albumin 
(BSA) for the calibration curve. 
Control mPCLS LPS-treated mPCLS
ATP (nmol/slice) 4.3 ± 0.2 3.6 ± 0.3**
Glutathione levels:
       - GSH (nmol/slice)





NO (µM) 3.5 ± 0.6 102 ± 11.6***
Cytokines:
       - IL-1β (pg/ml)
       - IL-6 (pg/ml)
       - IFN-γ (pg/ml)










       - CCL3 (pg/ml)
       - CCL5 (pg/ml)
       - G-CSF (pg/ml)









Table 1.The levels of ATP, glutathione, NO, cytokines, and chemokines following 24h incu-
bation of mPCLS in the absence (control) and presence of LPS. Data are given as mean ± 
SEM of at least 5 mice per group. Means of control and LPS-treated groups were compared 
by paired t-test, **p<0.01 and ***p<0.001 (LPS-treated mPCLS vs. control mPCLS).
2.7. LDH leakage of mPCLS
The leakage of the enzyme LDH to the media was assessed as an additional viability marker. 
For this assay, 50 µl of medium was collected from each of the three replicate mPCLS after 
24h incubation and these three samples were mixed into one sample. The amount of LDH 
in the medium sample was analyzed using the Roche/Hitachi Modular system (Roche, 
Mannheim, Germany) according to a routine laboratory procedure. To determine the total 
LDH content in fresh mPCLS, three mPCLS were collected after 1h pre-incubation each 
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in 1.3 ml of fresh medium. They were homogenized using a Mini-BeadBeater-8 (BioSpec, 
Bartlesville, OK, USA) and centrifuged for 3 minutes at 13000 rpm and 4°C.The supernatant 
was then analyzed to determine the initial LDH content in fresh mPCLS. 
2.8. Histomorphology of mPCLS
mPCLS, incubated with the drugs or solvent control for 24h, were subjected to morphological 
evaluation. mPCLS were fixed in 4% formaldehyde in phosphate-buffered saline solution 
for 24h at 4°C and stored in 70% ethanol at 4°C. Embedding in paraffin, sectioning (4 µm) 
and staining with hematoxylin and eosin (H&E) was performed as described previously.37
2.9. Glutathione content of mPCLS
Glutathione exists in the cells in reduced (GSH) and oxidized (GSSG) state. The GSH and 
total glutathione (GSH+GSSG) levels were measured in mPCLS following 24h incubation. 
Three replicate mPCLS were washed briefly in 0.9% NaCl solution, collected and snap-
frozen in liquid nitrogen for further storage at -80°C until the analysis. Each slice was 
homogenized in 400 µL ice-cold 50 mMTris-HCl buffer, which contains 1mM EDTA (pH 
7.4) and centrifuged for 3 minutes at 13000 rpm and 4°C. The supernatant was used for 
GSH and total glutathione assays separately using standard solutions of GSH. 
To measure the content of total glutathione, 15 µL of 1mM NADPH solution (Roche 
Diagnostics GmbH, Manheim, Germany) and 7.5 µL of 20U/ml glutathione reductase 
solution (Sigma-Aldrich, St. Louis, MO, USA) were added to 150 µLof the supernatant and 
incubated for 15 min at 37ºC to reduce GSSG into GSH. 15 µL of 50% Trichloroacetic acid 
solution was used to precipitate the proteins which may disturb GSH measurement due to 
the presence of the SH-groups. After 5 min on ice, the samples were centrifuged for 5 min 
at 4°C at 4600 rpm for total GSH assay. 
To measure reduced GSH, another 150 µL of the supernatant of the slice homogenate 
was taken to precipitate the proteins with 15 µL of 50% Trichloroacetic acid. After 5 min 
on ice, the samples were centrifuged for 5 min at 13000 rpm. From both samples, 50 µL of 
the supernatant was transferred to micro-titer 96-well plate and 200 µL of Ellman’s reagent 
(1 mM solution of 5,5’-dithio-bisnitrobenzoic acid in 0.5 M Tris/10 mM EDTA buffer 
containing 10% v/v ethanol, pH 8.0) was added to each well and the absorbance was read 




The concentrations of nitrate and nitrite were determined in the media of mPCLS after 24h 
incubation. The assay involves enzymatic reduction of nitrate (NO3ˉ) to nitrite (NO2ˉ) and 
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the NO production was measured as nitrate/nitrite (NOx) concentrations in the media of 
mPCLS as described previously.38
2.11. Cytokine or chemokine measurement 
The media after 24h mPCLS incubation were analyzed for cytokine production by 
cytometric bead array (CBA). The levels of ten pro-inflammatory cytokines/chemokines, 
namely, tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 1 beta 
(IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), CC chemokine 
ligand 3(CCL3), CC chemokine ligand 5(CCL5), granulocyte colony-stimulating factor 
(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), were measured. 
These ten cytokines/chemokines were chosen because they are known to be involved in 
inflammatory reactions and the kits to measure them are commercially available. The 
measurement was done using mouse CBA flex sets (BD Biosciences, San Jose, CA, USA) 
according to the manufacturer’s instruction manual. 
2.12. Statistics
Each experiment was performed with a minimum of 4 livers using three mPCLS for 
each experimental condition from each liver. Comparisons of two different groups 
were performed using two-tailed paired Student’s t-test. P-value <0.05 was considered 
statistically significant. Comparisons between multiple groups were performed using two-
way ANOVA using GraphPad Prism 5.0 statistics program (GraphPad Software Inc., San 
Diego, CA, USA). A level of significance of 5% was chosen to denote significant difference 
between means.
3. Results
3.1. Viability of mPCLS following 24h incubation
The viability of mPCLS was determined by comparing the ATP content of the treated 
mPCLS with that of control mPCLS and by comparing the percentage of LDH leaking 
to the media following 24h incubation (Figure 1). The average ATP content of mPCLS 
following 24h incubation was 4.3 nmol/slice (Table 1) or 7.0 nmol/mg protein. The average 
initial LDH activity in pre-incubated mPCLS is 2.75 mU/slice and approximately 11% of 
the LDH content in control mPCLS had leaked into the media after 24h incubation. Based 
on ATP content and/or LDH leakage of mPCLS, all IDILI-related drugs were used in doses 
that caused slight toxicity (max ~20% decrease in ATP) after 24h incubation without LPS. 
Nevertheless, the comparator drugs, VC and OZ were not toxic even at very high supra-
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therapeutical concentrations (1500 and 45 µM respectively). LPS itself caused slight though 
significant toxicity in 24h-incubated mPCLS (15% loss of ATP content when compared with 
the control). 
Synergistic toxicity was observed when the mPCLS were incubated with LPS+KC 
or LPS+CZ compared to LPS or KC or CZ alone. Their ATP levels were reduced below 
half of the value of the control mPCLS and more than 40% of the LDH content of the 
mPCLS leaked into the medium. This synergistic toxicity was substantial considering 
that treatments with KC or CZ or LPS alone only caused slight toxicity. In contrast, the 
respective comparator drugs VC and OZ did not show this phenomenon. However, LPS 
did not enhance the toxicity of the other 3 IDILI drugs DF, CBZ or TGZ in the mPCLS 
following 24h incubation.
Figure 1. Viability of mPCLS indicat-
ed by the ATP content and LDH leak-
age after 24h incubation with various 
drugs in the absence (open bars) or 
presence (black bars) of LPS. ATP 
content is expressed as relative val-
ues to the control mPCLS without 
LPS-treatment, while the LDH leak-
age was expressed as the percent-
age of the total LDH content in a slice. 
Data represent the average ± SEM 
of 4-8 experiments (ATP) or 7-26 ex-
periments (LDH), using 3 PCLS per 
experiment. *P<0.05 vs control by t-
test and #P<0.05 by two-way ANOVA 
of the four different groups together, 
namely, the control, LPS-only, drug-
only and LPS+drug groups.
The viability of mPCLS following 24h incubation was also assessed by histomorphology. 
The histomorphology data (Figure 2) confirmed the findings from the ATP and LDH data. 
mPCLS incubated with the combination of LPS and KC (Figure 2D) or CZ (Figure 2F) 
showed extensive necrotic areas as indicated by the massive loss of nuclei (dark purple 
dots), while incubation with LPS alone (Figure 2B), KC alone (Figure 2C) or CZ alone 
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(Figure 2E) showed only minor toxicity. Yet again, mPCLS that were treated with VC or OZ 
both in the absence and presence of LPS demonstrated similar morphology as the control 
mPCLS (Figure 2A) and LPS-treated mPCLS (Figure 2B) respectively (data not shown). 
There was also no significant difference between the histomorphology of mPCLS treated 
with TGZ (Figure 2G) or LPS+TGZ (Figure 2H). Similarly, 24h treatments with DF and 
CBZ did not show any significant difference in morphological damage in the absence or 
presence of LPS (data not shown). 
Figure 2. Histomorphology of mPCLS treated respectively with DMSO, KC, CZ, and TGZ 
in the absence of LPS (A, C, E, G) and in the presence of LPS (B, D, F, H) for 24h. Three 
individual experiments were performed with mPCLS. Representative images are shown. 
The sections were stained by hematoxylin-eosine, bar = 100 µm, magnification 200x. 
3.2. Glutathione content of mPCLS
The reduced and total glutathione levels in mPCLS after 24h incubation were measured 
(Figure 3). When compared to the GSH content of the control mPCLS, all drugs caused a 
slight to significant reduction in the GSH level except for OZ that had no effect and TGZ, 
which increased the GSH level instead. Though not significant, LPS itself slightly increased 
both the levels of GSH and total glutathione. However, mPCLS co-incubated with LPS and 
either KC or CZ had significantly and substantially lower levels of both GSH and total 
glutathione when compared to the control, LPS-treated or KC- or CZ-treated mPCLS. The 
GSH levels in LPS+KT and LPS+CZ groups dropped to 14% and 21% of the control value 
respectively and the total glutathione concentrations of these groups were reduced into 
less than half of the concentration of the control. This reduction was not observed in the 
cases of the other drugs in combination with LPS and was only observed in the two drugs 
(KC and CZ) that caused synergistic toxicity with LPS (Figure 1). 
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Figure 3. Reduced glutathione 
(GSH) and total glutathione 
levels in mPCLS following 24h 
incubation with various drugs 
in the absence (open bars) or 
presence (black bars) of LPS. 
The glutathione levels are ex-
pressed as relative values to the 
control, DMSO-treated mPCLS 
without LPS-treatment. Data 
represent the average ± SEM 
of 4-5 experiments using 3 mP-
CLS per experiment. *P<0.05 vs 
control by t-test and #P<0.05 by 
two-way ANOVA of four differ-
ent groups together, namely, the 
control, LPS-only, drug-only and 
LPS+drug groups.
Figure 4. LPS-induced NOx production by mPCLS co-incubated with various drugs for 24h. 
The level of NOx production is expressed as relative values to the LPS-treated mPCLS. 
Treatmentwith any drug alone had no effect in NOx concentration when compared to con-
trol mPCLS.Data represent the average ± SEM of 8-19 experiments, using 3 mPCLS per 
experiment. **P < 0.01 and ***P < 0.001 vs. LPS-treated group (t-test).
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Figure 5. LPS-induced release of cytokines (IL-1β, IL-6, IFN-γ, TNF-α) and chemokines 
(CCL-3, CCL-5, G-CSF, GM-CSF) from mPCLS incubated with various drugs for 24h. The 
levels of cytokine or chemokine release are expressed as relative values to the LPS-treated 
mPCLS. Treatment with any drug alone had no effect in cytokine/chemokine release when 
compared to control mPCLS. Data represent the average ± SEM of 4-23 experiments, us-
ing 3 mPCLS per experiment. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. LPS-treated group 
(t-test).
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3.3. LPS-induced NO production in mPCLS
LPS induced a significant NO production in mPCLS (Figure 4), measured as nitrate/nitrite 
(NOx) concentrations in the media of the slices following 24h incubation. Treatments of 
PCLS with any drug alone did not result in a significant change in NOx concentration 
when compared to control mPCLS. However, all IDILI-drugs and comparator drugs tested 
reduced the LPS-induced NO production extensively. The levels of LPS-induced NO 
production were reduced in the range from 41% by CBZ to 87% by DF of the control value 
(treatment with LPS alone). 
3.4. LPS-induced release of cytokines and chemokines in mPCLS
LPS induced significant release of cytokines or chemokines in mPCLS (Figure 5). The 
release of ten pro-inflammatory cytokines (IL-1β, IL-6, IL-10, IL-12, IFN-γ, TNF-α) and 
chemokines (CCL-3, CCL-5, G-CSF, GM-CSF) were measured in the media following 24h 
incubation of the mPCLS. IL-1β, IL-6, IFN-γ, TNF-α CCL-3, CCL-5, G-CSF, GM-CSF were 
excreted into the medium after treatment with LPS. IL-10 and IL-12 leakage could not be 
quantified because the concentrations were below the detection level and thus no data 
could be shown for these cytokines. Treatment of mPCLS with any of the drugs alone 
did not result in a significant change in cytokine or chemokine release when compared 
to control mPCLS. In general, all drugs influenced the LPS-induced release of some of 
the cytokines or chemokines in mPCLS. KC, CZ, and CBZ significantly increased the 
LPS-induced IL-1β release, while DF and VC significantly decreased it. Both DF and CBZ 
reduced the LPS-induced IL-6 release. LPS-induced IFN-γ release was enhanced only by 
KC, while OZ, DF, and TGZ attenuated it. DF was the only drug that increased the release 
of TNF-α, while TGZ was the only drug that decreased it. Moreover, KC, CZ, and DF 
substantially reduced the LPS-induced CCL3 and CCL5 release, while CBZ reduced only 
the CCL3 release. Interestingly, KC and CZ, the only two drugs that showed synergistic 
toxicity with LPS, were also the only drugs that significantly increased the LPS-induced 
release of G-CSF (~2.5 and ~3.5 folds respectively) and GM-CSF (~2 fold). In contrast, 
the other drugs did not have any influence on their release, except for DF, which even 
decreased the G-CSF release.   
3.5. Viability of mPCLS following 48h incubation
The lack of synergistic toxicity in mPCLS co-incubated with LPS and either DF or CBZ or 
TGZ after 24h was unexpected and therefore, we incubated the mPCLS for a longer period 
i.e. 48h (Figure 6). The average ATP content of mPCLS following 48h incubation was 4.3 
nmol/slice, which was the same content as after 24h incubation. Two of the IDILI-related 
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drugs that did not cause synergistic toxicity with LPS after 24h incubation, namely DF and 
TGZ, demonstrated synergistic toxicity with LPS following 48h incubation based on the 
ATP contents of mPCLS. The contents of the ATP in mPCLS co-incubated with LPS+DF and 
LPS+TGZ were reduced to below 45% of the total content of control PCLS. However, even 
after 48h, LPS still did not enhance the toxicity of carbamazepine.
ATP Level (48h)












Figure 6. Viability of mPCLS indicated by the ATP content after 48h incubation with DF 
(200 µM), CBZ (400 µM), and TGZ (30 µM) in the absence (open bars) or presence (black 
bars) of LPS (30 µg/ml). ATP content is expressed as relative values to the control mPCLS 
without LPS-treatment. Data represent the average ± SEM of 4 experiments, using 3 PCLS 
per experiment. *P<0.05 vs control by t-test and #P<0.05 by two-way ANOVA of the four 
different groups together, namely, the control, LPS-only, drug-only and LPS+drug groups.
4. Discussion
IDILI has been difficult to predict and prevent due to its relatively rare occurrence, its 
relatively unknown mechanisms, and the lack of reliable screening methods.39 Therefore, 
it is important to develop robust and accurate screening methods for early detection of 
IDILI in pre-clinical development since every new drug has a potential IDILI liability.40 
Therefore, we investigated the suitability of mPCLS for this purpose. Female mice might 
be a better model than male mice as DILI in human is more common among women.41 
Roth and Ganey proposed that a good model for IDILI should have liver injury as the 
major endpoint, since it is hepatotoxicity in humans that is being modeled.42 They used 
LPS and drug co-administration in rat and mouse in vivo as a model for the inflammatory 
stress hypothesis and found indeed synergistic toxicity with some of the well-known IDILI 
drugs. The use of PCLS as an ex vivo model to test this hypothesis has a disadvantage 
i.e. the absence of hepatic neutrophil accumulation and infiltration after LPS treatment. 
Neutrophils were found to be a mediator of injury in LPS-potentiated toxicity model.19, 43, 
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44 However, it cannot be excluded that the neutrophils present in the liver tissue during 
harvesting may play a role in the synergistic toxicity in PCLS. An important impediment to 
developing animal models of IDILI is the lack of possibilities to unravel the mechanisms of 
these reactions in humans.42 In order to develop an ex vivo model for IDILI that represents 
the liver histology and all the cells present in the liver, we studied co-administration of 
LPS and drugs in the PCLS. This is the first attempt to study idiosyncratic drug reactions in 
PCLS. An additional advantage of an ex vivo model is that it contributes to the reduction in 
animal use and has the potential to compare animal and human tissue.34
Five reactive metabolite-producing hepatotoxicants, which are known to cause IDILI 
in humans (along with two non-toxic comparator drugs), were tested in the absence or 
presence of LPS in mPCLS system. The concentrations of the IDILI-drugs used in this 
study were chosen to induce a low level of toxicity and are below 25*Cmax in human 
plasma, which is considered physiologically relevant35 and to obtain a low false positive 
rate as many non-hepatotoxic drugs induce hepatocyte death at concentrations exceeding 
100*Cmax.36The concentration of KC (15 µM) used here was similar to its Cmax, while the 
CZ concentration used (45 µM) was approximately 15*Cmax. Interestingly, there was no 
toxicity or synergistic toxicity attributed to VC or OZ, the comparator drugs of KC and 
CZ, even though much higher relative concentrations (approximately ~100*Cmax) of VC 
(1500 µM) or OZ (45 µM) were used. Based on the ATP levels and LDH leakage, mPCLS 
co-incubated with LPS and KC or CZ showed synergistic hepatotoxicity when compared 
to the mPCLStreated with LPS or drug alone (Figure 1). The histomorphology data 
confirmed this finding as extensive necrotic areas can be seen in mPCLS co-incubated 
with LPS and KC or CZ (Figure 2).Our results are in line with the results obtained in vivo 
where co-exposure of LPS and trovafloxacin, but not levofloxacin, caused IDILI both in 
mice20 and rats.19 Additionally, co-exposure of LPS and monocrotaline in rats also resulted 
in synergistic hepatotoxicity and inhibition of Kupffer cell function attenuated the injury 
suggesting that Kupffer cells are important mediators in this synergistic toxicity.43 This 
is in line with the observation that LPS significantly enhanced ranitidine toxicity, but 
not its corresponding negative control famotidine, in 3D co-cultures of hepatocytes and 
non-parenchymal cells to a much higher extent than in a monoculture containing mainly 
hepatocytes.45 In addition, Cosgrove et al. also observed dose-dependent hepatotoxicity 
synergies in primary rat hepatocytes between LPS in the presence of a pro-inflammatory 
cytokines mix and multiple IDILI-related drugs (e.g. ranitidine and trovafloxacin) and not 
with the non-toxic comparator drugs (e.g. cimetidine and levofloxacin).36 These synergistic 
hepatotoxicity phenomena have been described from the standpoint of an inflammatory 
stress caused by LPS enhancing the toxicity of a drug. However, it is equally plausible 
Mouse precision-cut liver slices as an ex vivo model to study 
idiosyncratic drug-induced liver injury
81
that a drug could enhance the sensitivity of the liver to a subtoxic dose of a potentially 
hepatotoxic inflammagen such as LPS.46
Unexpectedly, in our study co-exposure of LPS and three IDILI-related drugs (DF, CBZ, 
and TGZ) did not show synergistic hepatotoxicity in mPCLS after 24h incubation (Figure 
1). Subsequently, we did a pilot experiment to test whether prolonged incubation would 
reveal this synergism. ATP content of mPCLS following 48h incubation with TGZ and DF, 
but not CBZ, in the presence of LPS indeed showed synergistic toxicity (more than 50% 
depletion of ATP) (Figure 6). These data show that different drugs may require a different 
exposure time to develop synergistic toxicity, which is in line with the data of Roth and 
Ganey, who showed that various doses of LPS and various administration times of LPS and 
drug might be needed to observe this synergistic hepatotoxicity in vivo for different drugs.42 
In addition lack of synergistic effects of LPS with CBZ may be due to species differences 
in sensitivity for IDILI effects of these drugs. The drugs selected for this study are well 
known IDILI drugs in human, but it remains unknown whether these drugs would also 
induce IDILI in mice as to the best of our knowledge no data were published on the effects 
of CBZ and LPS in mouse in vivo. Idiosyncratic reactions can even be strain dependent as 
a combination of penicillamine and poly-IC induced autoimmunity in Brown Norway rats 
but not in Lewis rats.47 An alternative explanation for this lack of synergistic toxicity of 
LPS with CBZ might be that this drug causes IDILI via another mechanism than the one 
proposed in the inflammatory stress hypothesis. A model based on a single hypothesis 
might not predict adequately all drugs causing IDILI in humans as it is likely that different 
IDILI-related drugs would exert their toxicity via different mechanisms of action and even 
various mechanisms may be involved with IDILI from a single drug.42
The depletion of GSH has been suggested as cofounding factor in addition to the 
formation of reactive metabolites in the development of IDILI.48 Based on an observation 
that LPS treatment in vivo decreased the intracellular GSH concentration in rat livers,49 we 
investigated the amount of GSH and total glutathione in mPCLS following 24h incubation. 
In contrast to their finding, LPS did not reduce the GSH concentration but there was 
even a tendency that LPS slightly increased the GSH concentration in mPCLS (Figure 
3). Interestingly, this increase was also found in rat Kupffer cells and endothelial cells in 
vivo after LPS treatment.50 The synergistic toxicity caused by LPS and KC or CZ may be 
explained by the substantially lower GSH levels in mPCLS co-incubated with KC or CZ in 
the presence of LPS when compared to the ones incubated without LPS (Figure 3). It might 
be of interest to investigate in the future whether the metabolism of these drugs is changed 
and particularly if GSH conjugation is increased when these drugs are dosed together 
with LPS. However, similar experiments performed in our laboratory with human PCLS 
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indicated that co-exposure of the slices to LPS and CZ also resulted in lower GSH levels 
but did not change the types and the amounts of CZ phase 1 metabolites nor did it change 
the amount of GSH or cysteine conjugates formed compared to CZ alone (manuscript in 
preparation). 
Mechanisms by which interactions between LPS and xenobiotics occur are largely 
unknown.51 In light of this, we investigated the drugs’ effects on LPS-induced inflammatory 
responses. LPS has been shown to induce substantial NO production in rat PCLS.31 
Accordingly, the NOx concentration was almost 30-fold upregulated in the LPS-treated 
mPCLS (Table 1). It was reported that NO might play a protective role in LPS-induced liver 
injury because nonselective inhibitors of NO synthase exacerbated the toxicity.52However, 
NO produced by the inducible NO synthase can either be detrimental or protective to 
the liver depending on the conditions.53 Interestingly, all seven drugs tested attenuated 
LPS-induced NO production (Figure 4). Moreover, we did not observe any difference 
in the extent of reduction of NO production between the drugs that showed synergistic 
hepatotoxicity with LPS (KC, CZ), and their non-IDILI-causing comparators (VC, OZ), and 
with the other IDILI drugs (DF, CBZ, TGZ) (Fig 4). Based on these results, we concluded that 
NO does not play a role in inflammatory stress-related mechanism of IDILI in mPCLS.
Cytokines or chemokines that are derived primarily from Kupffer cells might be 
critical inflammatory mediators that contribute to the synergistic toxic responses in the 
LPS+drug model.51 LPS has been shown to elevate the release of inflammatory cytokines 
in both rat31 and human33 PCLS. Correspondingly, LPS substantially induced the cytokine 
or chemokine release in mPCLS (Table 1). TNF-α is probably the most widely studied 
cytokine that plays a critical role in inflammatory stress-related IDILI mechanism.44 
Ranitidine treatment in vivo caused the LPS-induced serum TNF-α concentration increase 
to last longer than in rats given LPS alone and LPS/ranitidine-co-treated rats developed 
synergistic hepatotoxicity,54 although it is still controversial whether ranitidine causes 
IDILI in man.11 Additionally, trovafloxacin administered prior to LPS caused significant 
hepatotoxicity and greater elevation of TNF-α and IFN-γ concentrations in the plasma 
compared to LPS-treated mice, while levofloxacin co-treatment had no toxicity and no 
effect on LPS-induced changes in plasma TNF-α or IFN-γ concentration.20, 55 Moreover, 
the IFN-γ-/- mice, which have decreased plasma concentrations of TNF-α and IL-1β when 
compared to wild-type mice after LPS+trovafloxacin treatment, were significantly protected 
from LPS+trovafloxacin-induced liver injury.55 It was also shown that administration of 
TNF-α instead of LPS to rats in vivo could induce inflammatory reactions that potentiated 
the hepatotoxicity of trovafloxacin in rats, although the pattern of mRNA gene expression 
changes was only partly overlapping suggesting that the TNF-α mediated inflammatory 
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reaction is not identical to the LPS-mediated reaction.56 Our results indicate that none of 
the drugs change the LPS-induced TNF-α release in mPCLS except TGZ that decreased 
it and DF that elevated it (Figure 5).This may indicate that although TNF-α is important 
for the inflammatory reaction, synergistic toxicity in mPCLS is not related to the level of 
TNF-α per se. DF decreased the LPS-induced release of all other cytokines and chemokines. 
This is in line with the anti-inflammatory effects exerted by DF as a non-stereoidal anti-
inflammatory drug (NSAID). DF inhibits prostaglandin synthesis by the inhibition of 
cyclooxygenase (COX).57 COX-2 is expressed in the liver almost exclusively in the non-
hepatocyte cell population and under rapid response to a pro-inflammatory challenge.58 
The non-IDILI-causing OZ and VC only reduced the LPS-induced release of IFN-γ and 
IL-1β respectively. DF and TGZ reduced both the LPS-induced IFN-γ and IL-6 release in 
mPCLS, while KC was the only drug to increase the IFN-γ release. Taken the IFN- γ data 
together, we cannot conclude that increased IFN- γ plays a major role in the development 
of the synergistic toxicity in mPCLS. Moreover, KC and CZ, the two drugs that showed 
synergistic hepatotoxicity with LPS, increased LPS-induced IL-1β release, which may 
suggest a role for IL-1 β in the synergistic effect. However, CBZ, which did not show 
synergistic toxicity, also increased it, even to a higher extent. Furthermore, a pilot study 
showed that anti-IL-1β neutralizing antibody did not reduce the synergistic toxicity after 
LPS+KC or LPS+CZ co-exposure (unpublished data). The chemokine measurement data 
revealed that IDILI-related drugs except TGZ actually decreased LPS-induced release of 
CCL3 and/or CCL5, while the non-IDILI-related drugs did not change the LPS-induced 
release of these chemokines. Further studies are needed to investigate if these chemokines 
may be potential biomarkers for IDILI. Interestingly, we found a correlation between the 
synergistic hepatotoxicity and the elevation of LPS-induced release of G-CSF and GM-CSF 
in mPCLS (Figures 1 & 5) as KC and CZ were the only two drugs that increased the LPS-
induced release of these chemokines. This is in line with the findings of Waring et al. that 
the mRNA expression of GM-CSF was also significantly upregulated in rats co-treated 
with LPS and trovafloxacin but not with LPS+levofloxacin or LPS alone when compared 
to the control rats19Moreover, the toxicity of LPS was increased in mice pre-treated with 
GM-CSF.59 But up to now, the role of G-CSF in IDILI has not been investigated. These data 
altogether may indicate a potential role for G-CSF and GM-CSF as biomarkers to identify 
drugs that cause IDILI via an inflammatory stress related mechanism.
In conclusion, we have developed an ex vivo model utilizing mPCLS to detect 
inflammatory stress-related IDILI. Four of the five tested IDILI-associated drugs (KC 
and CZ after 24 h and DF and TGZ after 48h) were identified by this model by showing 
synergistic toxicity with LPS according to the inflammatory stress hypothesis. For KC and 
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CZ, the synergistic toxicity phenomenon after 24h was accompanied by synergistic GSH 
depletion and upregulation of LPS-induced G-CSF and GM-CSF release in mPCLS after 
co-incubation with LPS. Therefore, GSH, G-CSF, and GM-CSF are potential biomarkers in 
this model to detect IDILI related to inflammatory stress. Further research should involve 
the measurement of these markers in mPCLS after 48h incubation and also the inclusion 
of more IDILI-related drugs together with their non-IDILI-related comparator drugs to be 
tested in mPCLS. An important advantage of this PCLS model is the possibility of using 
human tissue to detect species differences and to better mimic IDILI reactions in humans. 
Therefore, the PCLS system may be a prospective ex vivo translational screening tool that 
can be utilized in the preclinical and clinical settings to characterize IDILI at various stages 
of drug development. 
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Abstract
Idiosyncratic drug-induced liver injury (IDILI) is a major problem during drug development 
and has caused drug withdrawal and black-box warnings. Due to the low concordance of 
the hepatotoxicity of drugs in animals and humans, robust screening methods using human 
tissue are needed to predict IDILI in human. According to the inflammatory stress hypothesis, 
the effects of inflammation interact with the effects of a drug or its reactive metabolite 
precipitating toxic reactions into the liver. As a follow–up of our recently published mouse 
precision-cut liver slices (PCLS) model, an ex vivo model involving human precision-cut 
liver slices (hPCLS), co-incubated for 24h with IDILI-related drugs and lipopolysaccharide 
(LPS), was developed to study IDILI mechanisms related to inflammatory stress in humans 
and to detect potential biomarkers. LPS exacerbated ketoconazole and clozapine toxicity 
but not their non-IDILI-related comparators, voriconazole and olanzapine. However, the 
IDILI-related drugs diclofenac, carbamazepine and troglitazone did not show synergistic 
toxicity with LPS after 24h incubation. Coincubation of ketoconazole and clozapine with 
LPS decreased the glutathione levels in hPCLS, but not for the other drugs. All drugs 
affected LPS-induced cytokine release, but interestingly, only ketoconazole and clozapine 
increased the LPS-induced TNF release. Decreased glutathione- and cysteine-conjugates 
of clozapine were detected in IDILI-responding PCLS following cotreatment with LPS. In 
conclusion, we identified ketoconazole and clozapine as drugs that exhibited synergistic 
toxicity with LPS, while glutathione and TNF were found to be potential biomarkers for 
IDILI-inducing drugs mediated by inflammatory stress. hPCLS appear suitable to further 
unravel the mechanisms of inflammatory stress-associated IDILI. 
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1. Introduction
Drug-induced liver injury (DILI) is the number one cause of acute liver failure that often 
results in liver transplantation or death1and it is also the top reason for drugs’ black box 
warnings and withdrawal from the market 2. The low predictivity of DILI relates back to 
the preclinical and clinical trials of such xenobiotics, as in general, the concordance rate of 
toxicity of drugs in animals and humans is distressingly low, being only 43% for rodent 
species alone. Hepatotoxicity is one of the two human toxicities with the poorest correlation 
with animal studies despite its relatively high incidence 3. Therefore, the prediction of 
DILI relies largely on clinical studies and human in vitro studies. Even more difficult is 
the prediction of idiosyncratic DILI (IDILI). IDILI occurs only in a small subset of the 
population (0.01-1%) and its mechanisms of action have not been elucidated, although 
it is generally accepted that it is not related to the pharmacology of the drugs 4. It was 
estimated that to detect IDILI that occurs in 1 in 10,000 patients, approximately 30,000 
patients are required in clinical testing 5. The low incidence of this IDILI reaction coupled 
to the insufficient predictive power of the current methods makes it virtually impossible to 
detect IDILI during preclinical and clinical trials. 
There are several proposed mechanisms of action of IDILI, which have been described 
extensively in recent reviews and many involve the formation of reactive metabolites 4, 
6-9, but not all drugs that form reactive metabolites are associated with IDILI 10. Another 
common finding during IDILI is the presence of hepatic inflammation 11, which might 
originate from bacterial or viral infection leading to cytokine release 12. This inflammatory 
episode could play a role in lowering the threshold for drug toxicity, thereby precipitating 
a toxic response and rendering an individual susceptible to IDILI 13, 14. This has been 
the basis of both the inflammatory stress hypothesis 13, 15 and the danger hypothesis 16, 
17. Several animal models have been developed based on this hypothesis with the aim 
to mimic IDILI, where IDILI-related drugs, such as chlorpromazine, trovafloxacin and 
sulindac, were rendered more toxic in rats or mice in vivo during inflammation, for 
instance by co-treatment with lipopolysaccharide (LPS), a potent inflammation inducer 
18-21. The insights provided by these animal models of IDILI could lead to the development 
of human IDILI-predictive models to be used during preclinical studies to detect and 
eliminate new drug candidates which have the potential to cause human IDILI.  Recently, 
we have developed an ex vivo model to test the inflammatory stress hypothesis for 
inflammation-induced IDILI and found synergistic toxicity when mouse precision-cut 
liver slices (PCLS) were coincubated with LPS and 4 out of 5 IDILI-associated drugs, but 
not with the pharmacologically-similar comparator drugs that have not been associated 
with IDILI 22.  
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These PCLS represent an in vitro system which retains the normal tissue architecture of 
an intact liver with all its cell types in their natural arrangement and integral intercellular 
and cell-matrix interactions 23-25. They are metabolically fully competent with active phase 
I and II drug metabolism enzymes during 24 h of incubation 25-30. The gene expression 
profile of PCLS was shown to have a higher similarity to intact liver compared to primary 
hepatocytes and cell lines 31. Moreover, microarray analysis of xenobiotic-treated rat 
PCLS showed that they could mimic the toxicity as observed in vivo and discriminate 
between different mechanisms of hepatotoxicity 32. Relatively stable expression of genes 
involved in drug transport, metabolism and toxicity during normal incubation of human 
PCLS for 24 h was reported, whereas incubation with acetaminophen caused significant 
changes in gene expression 33. It has also been shown that the Kupffer cells in PCLS 
can be activated by LPS treatment inducing an inflammatory response as evidenced by 
the production of nitric oxide (NO) and inflammatory cytokines, such as tumor necrosis 
factor-α (TNF) and interleukin 1β (IL-1β) and IL-6 22, 34-36. The objectives of our study 
were to test if hPCLS can be a suitable ex vivo model to study the inflammatory stress 
hypothesis in humans, which of the IDILI-associated drugs could be identified with 
this model and to discover biomarker(s) that could be used to predict human IDILI in a 
translational model. 
Although there is no evident dose-effect relationship for drugs causing IDILI, which 
occurs often at therapeutical doses, drugs administered at doses lower than 10 mg/day are 
generally not associated with IDILI 37. In this study, we investigated whether cotreatment 
with LPS could aggravate the toxicity of five reactive metabolite-producing human IDILI 
drugs that are used at doses higher than 10 mg/day, namely, ketoconazole (KC), clozapine 
(CZ), diclofenac (DF), carbamazepine (CBZ), and troglitazone (TGZ) in hPCLS. Additionally, 
voriconazole (VC) and olanzapine (OZ) were investigated as comparator drugs of KC and 
CZ, respectively, which are in the same chemical class of drugs as KC and CZ respectively, 
but are not clinically associated with IDILI. VC causes dose-dependent hepatotoxicity that 
occurs in approximately 51% of patients 38, 39, but is not known to be idiosyncratic. OZ is 
not associated with DILI or with any idiosyncratic reaction and is commonly used as the 
negative control for CZ 40. The effect of cotreatment with LPS on the viability of hPCLS 
was determined by means of adenosine triphosphate (ATP) content, levels of reduced 
glutathione (GSH) and total glutathione, and histomorphology. As the inflammatory 
reaction was hypothesized to play a role in IDILI, we also examined each drug’s effect on 
LPS-induced release of soluble intercellular adhesion molecule-1 (sICAM-1) and cytokines 
in the media of hPCLS. The results were compared with the previously obtained data from 
mouse PCLS 22.  
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2. Materials and Methods
2.1. Chemicals
Troglitazone (TGZ) was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
Ketoconazole (KC), clozapine (CZ), diclofenac sodium salt (DF), carbamazepine (CBZ) and 
LPS derived from Eschericia coli serotype B55:O55 (Lot 050M4014, 600,000 EU/mg) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Olanzapine (OZ) and voriconazole 
(VC) were kind gifts from Dr. Willem Schoonen (MSD, Oss, the Netherlands) and Jan-
Willem Alffenaar (UMCG, Groningen, the Netherlands) respectively. All other drugs 
and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless stated 
otherwise. Stock solutions of each drug were made in DMSO (VWR, Briare, France) as the 
solvent. 
2.2. Human liver tissue
Pieces of human liver tissue were obtained from patients undergoing partial hepatectomy 
(PH) for the removal of carcinoma or from liver tissue remaining as surgical waste after 
split liver transplantation (TX), as described previously 33. The experimental protocols were 
approved by the Medical Ethical Committee of the University Medical Center Groningen. 
The liver tissue used in this study originated from 32 donors, of which 12 were male and 
20 were female, with age range from 17 to 76 (Table 1). The number of drugs that could be 
tested simultaneously in one liver varied and was limited by the size of the tissue sample 
and thus by the number of PCLS that could be prepared. 
Table 1. Summary of human liver donor characteristics used in this study (n≥5 for each 
endpoint), PH is liver tissue after partial hepatectomy, TX is liver tissue remaining from do-
nor liver after transplantation. The sex and the age range of the donors (with the average 
inside brackets) are identified. The ATP content of human PCLS after 24h of incubation 
(with the average inside brackets) is also indicated. The responder livers do not correlate 
with sex or age or type of liver.
Total     
Liver Used
PH / TX Male / Female Age range 
(years old)
ATP at 24h range 
(nmol/mg protein)
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2.3. Preparation of the hPCLS
hPCLS were made as described previously for human PCLS 41. Pieces of human liver 
obtained after partial hepatectomy were perfused with cold University of Wisconsin (UW) 
organ preservation solution (DuPont Critical Care, Waukegab, IL, USA) immediately after 
removal from the body. Cores with a diameter of 5mm were punched out of the tissue and 
these cores were sliced with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) 
in ice-cold Krebs-Henseleit buffer saturated with carbogen (95% O2 and 5% CO2). PCLS (5 
mm diameter, 200-300 µm thick and ca. 4.5-5.5 mg wet weight) were stored in ice-cold UW 
solution until incubation. 
2.4. Incubation of the hPCLS
Incubation of hPCLS in 12-well plates (Greiner bio-one GmbH, Frickenhausen, Austria) 
was performed as described before 41. In brief, hPCLS were pre-incubated  at 37°C for 1h 
individually in a well containing 1.3 ml Williams’ medium E with glutamax-1 (Gibco, Paisley, 
UK), supplemented with 25 mM D-glucose and 50 µg/ml gentamicin (Gibco, Paisley, UK) 
(WEGG medium) in a 12-well plate with shaking (90 times/min) under saturated carbogen 
atmosphere. Pre-incubation for 1 h allows the hPCLS to restore their ATP levels (data not 
shown) and removes cell debris from the cutting surfaces. After pre-incubation, the hPCLS 
were transferred to fresh WEGG medium in the presence or absence of LPS (24,000 EU/ml) 
and in combination with KC [10 µM] or its analog VC [250 µM], CZ [60 µM] or its analog 
OZ [60 µM], CBZ [400 µM], DF [400 µM], TGZ [15 µM] or the vehicle (final concentration 
of DMSO during incubation ≤0.5%) and incubated further for 24h without any further 
change in medium. The LPS and the drug were administered simultaneously. Pilot studies 
showed no differences in response when the drug was added 4h earlier or later than LPS. 
Preliminary dose-response studies were performed for LPS, with the objective to identify a 
dose of LPS that generated significant inflammatory responses based on the measurements 
of pro-inflammatory cytokines that caused minimal toxicity. The concentrations of drugs 
used in this study were also selected from initial concentration-response relationship 
studies, where we generally selected a concentration that elicits no or minimal drug-only 
hepatotoxicity. The concentrations used were all physiologically relevant as for each drug 
it was lower than 20-fold its plasma maximum concentration (Cmax) value, observed in 
humans upon single- or multi-dose administration with the exception of the concentrations 
chosen for diclofenac (~50-fold Cmax) and olanzapine (~150-fold Cmax). Similar relative 
concentrations were previously employed in in vitro / ex vivo studies 22, 42, 43. Cmax values 
were obtained from a combination of literature searches and available databases, as in Xu 
et al 42. 
Human precision-cut liver slices as an ex vivo model
to study idiosyncratic drug-induced liver injury
95
2.5. Viability of hPCLS
Viability of the hPCLS after 24h incubation with various treatments was determined by 
measuring the ATP content according to the method described earlier 41. In brief, at the end 
of 24h incubation, three replicate hPCLS were collected individually in 1 ml 70% ethanol 
(v/v) containing 2 mM EDTA (pH 10.9) and snap-frozen in liquid nitrogen and stored at 
-80°C until analysis. The samples were homogenized using a Mini-BeadBeater-8 (BioSpec, 
Bartlesville, OK, USA) and centrifuged for 3 minutes at 13000 rpm and 4°C. The supernatant 
was diluted 10 times with 0.1 M Tris HCl containing 2 mM EDTA (pH 7.8) to reduce the 
ethanol concentration. The ATP content of the supernatant was measured using the ATP 
Bioluminescence Assay kit CLS II (Roche, Mannheim, Germany) in a black 96-well plate 
Lucy1 luminometer (Anthos, Durham, NC, USA) using a standard ATP calibration curve.
The remaining pellet was used to determine the protein content of the hPCLS by dissolving 
the pellet in 200 µl of 5 M NaOH for 30 min. After dilution with water to a concentration of 1 M 
NaOH, the protein content of the samples was determined using the Bio-Rad DC Protein Assay 
(Bio-Rad, Munich, Germany) using bovine serum albumin (BSA) for the calibration curve.
Leakage of enzymes (LDH, ALT, and AST) to the media of hPCLS, was measured but the 
data obtained was inconclusive as the results were very variable and differences between 
control and treated hPCLS were not significant. This is in contrast to our mouse studies 
where the leakage of LDH was a sensitive method to measure viability in mouse PCLS 22. 
This may be caused by the larger individual variability in the human liver samples.
2.6. Histomorphology of hPCLS
hPCLS, incubated with the drugs or solvent control for 24h, were subjected to morphological 
evaluation. hPCLS were fixed in 4% formaldehyde in phosphate-buffered saline solution for 
24h at 4°C and stored in 70% ethanol at 4°C. Embedding in paraffin, sectioning (4 µm) and 
staining with hematoxylin and eosin (H&E) was performed as described previously 44.
2.7. Glutathione content of hPCLS
Both reduced glutathione (GSH) and total (reduced plus oxidized (GSSG)) glutathione 
levels were measured in hPCLS following 24h incubation as described previously 22.
2.8. sICAM-1 and cytokine measurement 
The media after 24h hPCLS incubation were analyzed for the release of sICAM-1 and cytokines 
by cytometric bead array (CBA). The levels of nine pro-inflammatory cytokines, namely, 
interferon gamma (IFN-γ), interleukin-1beta (IL-1β), interleukin-10 (IL-10), interleukin-12 (IL-
12), tumor necrosis factor alpha (TNF), CC chemokine ligand 3(CCL3), CC chemokine ligand 
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5(CCL5), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), were measured. sICAM-1 and these nine cytokines were chosen 
because they are known to be involved in inflammatory reactions and the kits to measure 
them are commercially available. The measurement was done using mouse CBA flex sets (BD 
Biosciences, San Jose, CA, USA) according to the manufacturer’s instruction manual. 
2.9. Metabolite measurement of CZ-treated hPCLS
The metabolites of CZ were analyzed in the media following 24h incubation of hPCLS in 
the absence or presence of LPS by reversed-phase liquid chromatography as described 
previously 45. 
2.10. Statistics
Each experiment was performed with a minimum of 5 livers using three hPCLS for 
each experimental condition from each liver. Comparisons of two different groups 
were performed using two-tailed paired Student’s t-test. P-value <0.05 was considered 
statistically significant. Comparisons between multiple groups were performed using 
two-way analysis of variance (ANOVA) using GraphPad Prism 5.0 statistics program 
(GraphPad Software Inc., San Diego, CA, USA). A level of significance of 5% was chosen to 
denote significant difference between means.
3. Results
3.1. Viability of human PCLS
Figure 1. Viability of hPCLS indicated by 
the ATP content after 24h incubation with 
various drugs in the absence (open bars) 
or presence (filled bars) of LPS. ATP con-
tent is expressed as relative values to the 
control hPCLS without LPS-treatment. Data 
represent the average ± SEM of 5-14 ex-
periments, using 3 PCLS per experiment. 
*P<0.05 vs control by t-test and #P<0.05 by 
two-way ANOVA of the four different groups 
together, namely, the control, LPS-only, 
drug-only and LPS+drug groups.
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The viability of hPCLS was determined by comparing the ATP content of the treated 
hPCLS with that of control hPCLS following 24h incubation (Figure 1). The average 
ATP content of hPCLS following 24h incubation was 7.8 ± 0.7 nmol/mg protein (Table 2). 
Although the drug concentrations were selected as a kind of lowest observed adverse effect 
level to cause minimal decrease in ATP content, due to the appreciable variation in the 
human livers, the selected concentration significantly (p<0.05) decreased the ATP content 
in the PCLS of the liver used for the final studies by 15% for VC, 18% for CZ, 19% for OZ, 
and 35% for DF after 24h incubation without LPS, whereas no significant decrease was 
observed for KT, CBZ and TGZ. The lowest observed effect level of VC was much lower in 
hPCLS (250 µM) compared to mouse PCLS where even 1500 µM did not reduce the ATP 
content of mPCLS 22. LPS itself caused slight though significant toxicity in 24h-incubated 
hPCLS (13% loss of ATP content when compared with the control, n=23). LPS did not 
enhance the toxicity of DF, CBZ or TGZ in the hPCLS. However, synergistic toxicity was 
observed when the PCLS were incubated with LPS+KC or LPS+CZ compared to LPS or 
KC or CZ alone. Their ATP levels reduced to approximately half of the value of the control 
PCLS. This synergistic toxicity was substantial considering that treatments with CZ or LPS 
alone only caused slight toxicity and treatment with KC alone did not cause any toxicity at 
all. In contrast, the respective non-IDILI-associated comparator drugs VC and OZ did not 
show this phenomenon. 
Although the overall effects of LPS+KC and LPS+CZ were significant for the group of 
livers tested, there was an appreciable variation in the interaction effects of LPS+drug and 
some human livers did not respond where others responded strongly with synergistic 
toxicity. For instance, synergistic toxicity was observed in 7 out of 10 human livers cotreated 
with LPS+KC and in 9 out of 14 human livers cotreated with LPS+CZ. For the other drugs, 
only 1 out of 5 livers for DF, 3 out of 7 livers for TGZ, and none out of 5 livers for CBZ 
showed synergistic toxicity in the presence of LPS. The parameter used to distinguish 
between the responders (synergistic toxicity observed) and non-responders (synergistic 
toxicity not observed) was based on the ATP data where an individual was considered a 
responder if the reduction of ATP (compared to the control) caused by the co-incubation of 
LPS+drug is greater than the ATP reduction caused by LPS alone plus the ATP reduction 
caused by the drug alone.
The effect of LPS on the toxicity of the drugs was also assessed by histomorphology. 
The histomorphology data (Figure 2) confirmed the findings from the ATP data. hPCLS 
from the responder livers that were incubated with the combination of LPS and KC or CZ 
showed extensive necrotic areas indicated by the loss of nuclei as shown in Figure 2F & 
2G, while incubation with LPS alone or the drug alone showed only comparably minor 
Human precision-cut liver slices as an ex vivo model
to study idiosyncratic drug-induced liver injury
98
toxicity. Moreover, in line with the ATP data, DF treatment resulted in quite substantial 
loss of the viable liver tissue; however there was no difference in the extent of the damage 
in DF-treated hPCLS in the absence or presence of LPS (Figure 2D & 2H). Similarly, 24h 
treatments with VC, OZ, CBZ, and TGZ did not show any appreciable difference in damage 
in the absence or presence of LPS (unpublished results). 
Figure 2. Histomorphology of hPCLS treated respectively with DMSO, KC, CZ, and DF 
in the absence of LPS (A, B, C, D) and in the presence of LPS (E, F, G, H) for 24h. Five 
individual experiments were performed with hPCLS. Representative images from a re-
sponder liver are shown. The sections were stained by hematoxylin-eosine, bar = 100 µm, 
magnification 200x. 
3.2. Glutathione content of human PCLS
Figure 3. Reduced glutathione (GSH) and total glutathione levels in hPCLS following 24h 
incubation with various drugs in the absence (open bars) or presence (filled bars) of LPS. 
The glutathione levels are expressed as relative values to the control hPCLS without LPS-
treatment. Data represent the average ± SEM of 5-6 experiments using 3 hPCLS per ex-
periment. *P<0.05 vs control by t-test and #P<0.05 by two-way ANOVA of four different 
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The reduced and total glutathione levels in hPCLS after 24h incubation are presented 
in Figure 3. The average GSH and total glutathione content of hPCLS following 24h 
incubation were 40.9 and 46.5 nmol/mg protein respectively. In contrast to what was 
found in mouse PCLS where 54% of glutathione was present in the oxidized form, the 
oxidized glutathione (GSSG) level was low (<10%) in all hPCLS and was not changed 
after treatment with the drugs and/or LPS. When compared to the control PCLS, none 
of the drugs alone nor LPS caused any change in GSH or total glutathione levels except 
for DF that reduced these values to approximately half of the values of the control PCLS. 
Coincubation with LPS and DF, CBZ, or TGZ did not reduce these values. However, 
coincubation of either KC or CZ with LPS substantially reduced the levels of both GSH 
(61% and 55% respectively) and total glutathione (69% and 66% respectively) when 
compared to the control, LPS-treated and KC- or CZ-treated PCLS. This reduction was 
observed in 5 out of 6 human livers used in this experiment and was exclusively observed 
for the two drugs (KC and CZ) that caused synergistic toxicity with LPS but not in the 
cases of the other drugs in combination with LPS (compare Figures 1 and 3). Since the 
analysis of the glutathione levels were performed in other livers than the ATP assays due 
to the limitation of the available tissue, we cannot identify the difference in glutathione 
levels between responder and non-responder groups based on the ATP data, but the 
overall effects were significant.  
3.3. Metabolism of CZ-treated human PCLS in the absence and presence of LPS
To investigate whether the effect of LPS on the toxicity and the GSH content was caused by 
increased rate of formation of reactive metabolites, the metabolites of CZ were measured in 
the media of the PCLS treated with CZ with and without LPS (Figure 4). The liver sources of 
the hPCLS were separated into two different groups, the responder livers (n=5) and the non-
responder livers (n=5) based on the presence of synergistic toxicity of LPS+CZ as described 
above. The amounts of the metabolites were determined by measuring the peak area, as the 
absolute amount of each of the metabolite could not be determined due to the unavailability 
of the references of CZ metabolites, Seven different metabolites of CZ were detected in the 
media, clozapine-N-oxide (CZ+O) and its reduced form (CZ+O+2H); N-desmethylclozapine 
(CZ-CH2); glutathione conjugate of CZ (CZ-GSH); cysteine conjugate of CZ (CZ-Cys); cysteine 
conjugate where chlorine was substituted by GSH and further metabolized to Cys of CZ (CZ-
Cys-Cl); and cysteine conjugate of clozapine-N-oxide (CZ-Cys+O). Interestingly, the relative 
amounts of both CZ-Cys and CZ-GSH in the medium were significantly lower among the 
responders in hPCLS incubated with LPS when compared to the ones without LPS. Among 
the non-responders, no difference in the amount of any metabolite was observed in the 
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absence or presence of LPS. However for the other five metabolites, there was no difference 
in the amounts produced by hPCLS incubated with or without LPS or between responders 
and non-responders (unpublished results).
Figure 4. Metabolites produced by hPCLS during 24h incubation with CZ (60 µM) in the ab-
sence and presence of LPS. The graphs show the glutathione conjugate (CZ-GSH) and cor-
responding cysteine conjugate (CZ-Cys) of CZ produced in responders and non-responders 
by addition of GSH to CZ. Exact structures of these metabolites were not determined. Data 
were the average of 10 individual human livers consisting of five responders and 5 non-
responders using 3 slices per experiment. *P<0.05 for CZ vs. LPS+CZ by t-test.
3.4. LPS-induced release of sICAM-1 cytokines in human PCLS
The release of the soluble form of the chemoattractant sICAM-1 and nine inflammatory 
cytokines (IL-1β, IL-10, IL-12, IFN-γ, TNF, CCL-3, CCL-5, G-CSF, and GM-CSF) were 
measured in the media following 24h incubation of the PCLS. LPS treatment of hPCLS 
induced significant release of sICAM-1 and cytokines into the media (Table 2 and Figure 5). 
However, IL-10 and IL-12 release could not be quantified because the concentrations were 
below the detection level and thus no data can be shown for these cytokines. Treatments 
of PCLS with any of the drugs alone did not result in significant changes in cytokine 
release when compared to control PCLS. In contrast, all drugs caused changes in several 
of the LPS-induced release of sICAM-1 and cytokines (Figure 5). sICAM-1 release was 
increased approximately 3 fold compared to the control by the addition of LPS in hPCLS. 
Interestingly, all drugs reduced the LPS-induced sICAM-1 release. The effects of the drugs 
on the release of cytokines varied largely and were drug-specific. DF markedly decreased 
all the LPS-induced cytokine release, while CBZ decreased all cytokines moderately. On the 
other hand, TGZ only substantially reduced LPS-induced IFN-γ but did not influence any 
of the other cytokines. KC, OZ, CBZ and DF significantly decreased the LPS-induced IL-
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1β release. All drugs except TGZ lowered the LPS-induced CCL3 release. CZ was the only 
drug that significantly increased the release of CCL5, while most other drugs decreased 
it. OZ, DF, and CBZ significantly reduced the LPS-induced release of G-CSF and GM-CSF 
and KC reduced G-CSF release only, while CZ was the only drug that elevated the release 
of GM-CSF. Interestingly, KC and CZ, the only two drugs that showed synergistic toxicity 
with LPS, were also the only drugs that significantly increased the LPS-induced release 
of TNF (~1.4 and ~3.0 folds respectively). In contrast, the other drugs did not have any 
influence on its release (OZ and TGZ) or decreased it (VC, CBZ, and DF). Furthermore, 
KC and CZ were also the only two drugs that did not reduce LPS-induced IFN-γ release, 
while the other drugs strikingly decreased it. We failed to identify distinct cytokine profiles 
between responders and non-responders.
Control PCLS LPS-treated PCLS
ATP (nmol/mg protein) 7.8 ± 0.7 6.8 ± 0.7*
Glutathione levels:
• Reduced glutathione         
(nmol/mg protein)





























Table 2. The levels of ATP, glutathione, ICAM-1, and cytokines following 24h incubation of 
hPCLS in the absence (control) and presence of LPS. Data are given as mean ± SEM of at 
least 5 human livers per group. Means of control and LPS-treated groups were compared by 
paired t-test, *p<0.05, **p<0.01 and ***p<0.001 (LPS-treated hPCLS vs. control hPCLS).
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Figure 5.Effect of the various drugs on the LPS-induced release of ICAM-1 and cytokines 
(IFN-γ, IL-1β, TNF, CCL-3, CCL-5, G-CSF, GM-CSF). The levels of cytokine release are 
expressed as relative values to the LPS-treated hPCLS. Treatment with any drug alone 
had no effect in the cytokine release when compared to control hPCLS. Data represent the 
average ± SEM of 5-22 experiments, using 3 hPCLS per experiment. *P < 0.05, **P < 0.01 
and ***P < 0.001 vs. LPS-treated group (t-test).
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4. Discussion
Every new drug possesses a potential IDILI liability 46 but the low and sporadic occurrence 
of IDILI, coupled to the lack of reliable and robust screening methods are two of the reasons 
that it is challenging to predict and prevent IDILI 47. Moreover, the mechanisms of action of 
IDILI in humans have not been fully elucidated. The prediction of IDILI is further severely 
hampered by the appreciable species differences in the hepatotoxicity between human 
and animals 3, 48. Previously, we have used mouse PCLS to study the inflammatory stress 
hypothesis and successfully identified IDILI-associated drugs apart from their non-IDILI-
associated counterparts 22. In this model, we exploited LPS and drug co-administration in 
the PCLS as a model for the inflammatory stress hypothesis, which was developed by Roth 
et al. 15. Although several studies employing human cell cultures (HepG2 cells, THLE cells 
and human primary hepatocytes) were published previously as model for IDILI 43, 49-51, the 
current study is the first attempt to study idiosyncratic drug reactions in human tissue 
culture.
Five reactive metabolite-producing drugs that are known to cause IDILI in humans (along 
with two non-IDILI-related comparator drugs), were tested in the absence or presence of 
LPS in hPCLS system. For a quantitative viability test, we measured ATP levels of hPCLS 
and histomorphology was used to confirm the ATP data. The selected concentration of 
OZ (60 µM) was the same as that of CZ, but as OZ is used at a much lower dose in the 
clinic than CZ, OZ is not associated with DILI in the clinic. The toxicity observed with 
OZ occurred at approximately ~150*Cmax. It should be realized that many non-hepatotoxic 
drugs induce hepatocyte death at concentrations exceeding 100*Cmax
43. The observed VC 
toxicity in hPCLS illustrates a clear species difference as it was not toxic at all in mouse 
PCLS even at a concentration of 1500 µM 22. 
 Synergistic hepatotoxicity was observed when hPCLS were co-incubated for 24h with 
LPS and KC or CZ when compared to the hPCLS treated with LPS or drug alone (Figure 1). 
The histomorphology data confirmed this finding as extensive necrotic areas can be seen in 
hPCLS co-incubated with LPS and KC or CZ (Figures 2F and 2G), which were not detected 
in hPCLS treated with the drugs alone or with LPS alone. This synergistic toxicity related 
to KC and CZ after 24h incubation was also found in our previous study using mouse 
PCLS 22.Our results from PCLS are in line with other in vitro or in vivo results where LPS or 
cytokines enhanced the toxicity of a number of other IDILI-associated drugs (monocrotaline, 
ranitidine, trovafloxacin, nefazodone, nimesulide), but not of their corresponding non-toxic 
comparator drugs, in mice and rats and in cultured cells 19, 20, 43, 50, 52.
The co-exposure of LPS and three other IDILI drugs DF, CBZ, or TGZ did not show 
synergistic hepatotoxicity in hPCLS after 24h incubation (Figure 1), similar to our previous 
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findings in mouse PCLS. We have recently shown that in mouse PCLS, synergistic 
toxicity could be observed in the cases of DF and TGZ after a longer incubation of 48h 
22. Unfortunately, this knowledge was not available at the time these experiments with 
hPCLS were performed. Future experiments need to show whether this is also the case 
in human PCLS. It has been shown that different doses of LPS and different exposure 
times of LPS and drug might be needed to observe the synergistic hepatotoxicity in vivo for 
different drugs 20, 53. An alternative explanation might be that these drugs cause IDILI via 
another mechanism than the one proposed in the inflammatory stress hypothesis, such as 
the danger hypothesis 16, 17 or the pharmacological interaction (p-i) hypothesis 54. Roth and 
Ganey argued that a model based on a single hypothesis might not predict adequately all 
drugs causing IDILI in humans as it is likely that different drugs would exert their toxicity 
via different mechanisms of action 9. 
The development of IDILI involves not only the formation of reactive metabolites but 
may also involve other factors, e.g. the depletion of GSH or a polymorphism in glutathione 
transferases 55. Similar to our previous finding in mouse PCLS 22, significantly lower GSH 
and total glutathione levels were observed after coincubation of LPS and KC or CZ in 
hPCLS when compared to incubation without LPS (Figure 3). LPS itself did not cause any 
reduction in the levels of GSH or total glutathione in control PCLS or PCLS treated with any 
of the other drug tested. As in mouse PCLS, the reduction in glutathione levels correlated 
with the synergistic toxicity observed in the hPCLS coincubated with LPS+KC or LPS+CZ 
(Figures 1, 2, 3). This correlation might signify that less GSH-conjugate was formed due to 
the lower GSH content in the slices, thus more non-detoxified reactive metabolites were 
present causing increased liver injury. A decrease in GSH level could also be associated 
with oxidative stress which is usually accompanied with an increase in GSGSH level 56. 
Since we did not find elevated GSGSH level, the role of oxidative stress in the synergistic 
toxicity of LPS+KC or LPS+CZ is unlikely.  
Since idiosyncrasy is defined as individual differences in responses to stimuli 57 and 
considering the fact that every human is different in terms of genetics, medical history, 
and environmental exposure, there was obviously a variation in the responses related to 
toxicity. The synergistic toxicity phenomenon did not occur in the PCLS from all human 
samples. Our findings were consistent with the fact that IDILI is definitely not observed 
in all patients taking the same drug. Moreover, this variation was also reported in animal 
studies, for instance, despite the fact that Brown Norway is a highly inbred strain, the 
idiosyncratic autoimmunity syndrome only occurred in 50%-80% of the penicillamine-
treated rats 58. Another IDILI model utilizing SOD2+/- mice reported inconsistent liver 
injury where hepatocellular necrosis occurred in only 4 of 6 TGZ-treated mice 59. Based 
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on these observations, we selected five responder and five non-responder livers in the 
CZ-treated group and re-analyzed the data in these groups separately with respect to CZ 
metabolism. Although, it was suggested that the reactive metabolites of CZ play a role in 
agranulocytosis 40, their role in CZ-induced human hepatotoxicity has not been investigated 
10. Formation of glutathione conjugates of CZ (CZ-GSH) have been detected in multiple in 
vitro and in vivo systems 60. Within the responder group, the amounts of the CZ-GSH and 
CZ-Cys (the breakdown product of CZ-GSH 61), were significantly lower in the hPCLS 
incubated in the presence of LPS (Figure 4). In contrast, in the non-responder group, there 
was no difference in the amounts of these metabolites between the PCLS incubated in the 
presence or absence of LPS. The lower amounts of CZ-GSH and CZ-Cys in the responder 
group after coincubation with LPS and CZ can be attributed to the lower GSH level of 
PCLS (Figure 3),  resulting in higher toxicity that might be due to the covalent binding 
of CZ reactive metabolites to proteins. Out of the six livers used for the determination of 
GSH content, five were considered responders that demonstrated reduction of GSH after 
coincubation of LPS+CZ. Further studies are needed to confirm the role of GSH in the 
synergistic toxicity of LPS and CZ.
It has previously been shown that neutrophils and cytokines play very important roles 
in the development of IDILI in the inflammatory stress-related models 7, 15, 19, 52. Although 
the presence of neutrophils could be detected in the slices by immunohistochemistry 
(unpublished results), their numbers were too low to allow quantification. The use of PCLS 
as an ex vivo model by definition lacks the accumulation and infiltration of neutrophils 
after LPS treatment, but as a surrogate marker the release of sICAM-1 to the medium was 
measured instead. sICAM-1 can be secreted by various cells, such as hepatocytes and 
endothelial cells. It has been shown that activated neutrophils are recruited via upregulation 
of ICAM-1 in the endothelial cells 62 and that the increased level of sICAM-1 reflects 
this upregulation 63. While LPS treatment significantly induced the release of sICAM-1 
by hPCLS, all seven drugs, IDILI and non IDILI-associated, decreased this LPS-induced 
release of sICAM-1 (Figure 5). Further studies are needed to identify the importance of 
ICAM-1 and sICAM-1 in relation to the mechanisms of action of IDILI.
LPS has also been shown to elevate the release of inflammatory cytokines in rat 34 mouse 
22 and human 36 PCLS. Correspondingly, LPS substantially induced the cytokine release 
in hPCLS in the current study (Table 2 and Figure 5). To identify possible biomarkers or 
factors involved in the mechanism of IDILI, we compared the effect of the drugs on the 
LPS-induced cytokine release. Only the increased TNF was associated with synergistic 
toxicity of both KC and CZ. None of the measured cytokines could discriminate all 5 IDILI 
drugs from the 2 non-IDILI drugs. Although the synergistic toxicity was observed after 
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coincubation with LPS+KC or LPS+CZ in both mouse and human PCLS after 24h, different 
effects on the LPS-induced cytokine release were observed. In mouse PCLS, the synergistic 
toxicity of KC and CZ was associated with an elevated LPS-induced release of G-CSF and 
GM-CSF, but not with elevated TNF release as in hPCLS 22. In contrast, none of the drugs 
increased G-CSF release and only CZ increased the release of GM-CSF in hPCLS (Figure 
5). In the hPCLS, all drugs except TGZ decreased the LPS-induced CCL3 release and most 
drugs including OZ also decreased LPS-induced CCL5 release in hPCLS. CZ was the only 
drug that increased CCL5 release in hPCLS. In mouse PCLS, on the contrary, none of the 
comparator drugs (VC or OZ) decreased the CCL3 or CCL5 release and none of the drugs 
increased the release of CCL3 and CCL5 in mouse PCLS 22. Additionally, none of the drugs 
increased the LPS-induced release of IL-1β in human PCLS, while in mouse PCLS, three 
drugs (KC, CZ, and CBZ) increased its release. All drugs except KC and CZ substantially 
reduced the release of IFN-γ in hPCLS, whereas in mouse PCLS, this was only the case for 
OZ, DF, and TGZ. 
In line with our current results in hPCLS, a critical role of TNF in inflammatory stress-
related IDILI mechanism was found previously for trovafloxacin and ranitidine in vivo20, 64, 
65, even though it is still controversial whether ranitidine causes IDILI in men 6. Moreover, 
the administration of TNF potentiated the hepatotoxicity of trovafloxacin in rats in vivo66 
and of diclofenac in HepG2 cells 50. TNF is also known to activate endothelial cells and 
to prime neutrophils for activation, leading to the accumulation of neutrophils in tissue 
67-69. These data confirmed the potential role for TNF as a biomarker to identify drugs that 
cause IDILI in the human liver via an inflammatory stress-related mechanism. We cannot 
conclude whether G-CSF, CCL3, or IL-1β play a role in the development of synergistic 
toxicity in hPCLS, but increased GM-CSF and CCL5 appeared to be associated with the 
synergistic toxicity specific for CZ but not for KC in hPCLS. Furthermore, the roles of IFN-γ 
in relation to the synergistic toxicity of KC and CZ with LPS need to be further studied.
In conclusion, we have developed an ex vivo model utilizing hPCLS to detect inflammatory 
stress-related IDILI. Two IDILI-associated drugs (KC and CZ) were identified by this model 
by showing synergistic toxicity with LPS according to the inflammatory stress hypothesis. 
This synergistic toxicity phenomenon after 24h was accompanied by concomitant GSH 
depletion and increased LPS-induced TNF release in hPCLS. Therefore, GSH and TNF 
are potential biomarkers in this hPCLS model to detect IDILI related to inflammatory 
stress. Moreover, the mechanism of IDILI related to CZ might be explained by depletion 
of GSH in the liver, resulting in lower GSH- and cysteine-conjugates of CZ. Further 
research should involve the measurement of these markers in hPCLS after 48h incubation 
and also the inclusion of more IDILI-related drugs together with their non-IDILI-related 
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comparator drugs to be tested in hPCLS. Another important conclusion is that there are 
marked species differences in how the same drug affects LPS-induced cytokine release 
in mouse and human. This underlines the importance of using human tissue to elucidate 
the mechanisms of IDILI in humans. Additionally, the use of hPCLS contributes to the 
reduction and replacement of animals in drug research. Therefore, the hPCLS system may 
be a prospective ex vivo translational screening tool that can be utilized in the preclinical 
and clinical settings to characterize IDILI at various stages of drug development. 
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1. Summary and Discussion
Adverse drug reactions (ADRs) are a serious problem for public health and an obstruction 
to drug development and clinical use after marketing. ADRs affect millions of people and 
can result in hospitalization and even death. Among all ADR cases, the liver is the most 
frequently affected organ due to its high exposure and capacity to metabolize drugs. Drug-
induced liver injury (DILI) is the number one cause of acute liver failure cases in the U.S. 
and has also been the top reason of drug withdrawal from the market 1-4.
As introduced in chapter 1, DILI can be categorized into intrinsic (type A) vs. 
idiosyncratic (type B) DILI. Intrinsic DILI usually exhibits dose and time dependency and 
can be detected during pre-clinical or clinical trials. Overdose of the intrinsic hepatotoxin 
paracetamol or acetaminophen (APAP), is responsible for most of the cases of liver failure 
among any other drugs 3. A reactive metabolite of APAP, N-acetyl-p-benzo-quinone imine 
(NAPQI), is thought to be responsible for APAP-related hepatotoxicity. On the other hand, 
idiosyncratic DILI occurs unpredictably in a small minority of the people taking the same 
drug (less than 1 in 1000 people), is not related to the pharmacological effects of the drug 
and does not have an obvious dependence to dose or time. While intrinsic DILI normally 
occurs during drug overdose, idiosyncratic DILI can occur when patients taking normal 
therapeutical doses of a drug and is responsible for approximately 13% of acute liver failure 
cases in the US 3. Several hypotheses have been described to explain the mechanisms of 
action of idiosyncratic DILI and many of these hypotheses involve the metabolism of drugs 
into reactive metabolites 5, 6. One hypothesis is called the ‘inflammatory stress’ hypothesis 
because it states that the presence of a concurrent inflammatory reaction can interact with 
drug therapy to precipitate idiosyncratic DILI. This modest inflammatory stress can lower 
the threshold for drug hepatotoxicity, thereby shrinking the therapeutic window resulting 
in a toxic response at an otherwise safe dose of the drug. Alternatively, a drug might also 
augment a mild inflammatory reaction rendering it injurious 7, 8. Several in vivo and in 
vitro models based on this inflammatory stress hypothesis have been developed involving 
coexposure with drugs associated with human idiosyncratic DILI and an inflammagen, 
such as lipopolysaccharide (LPS), to produce synergistic (or idiosyncratic) hepatotoxicity. 
The current thesis focused on the development of a potential ex vivo model utilizing 
precision-cut liver slices (PCLS), in which all liver cell types are present possessing normal 
liver tissue architecture, to study the species differences in intrinsic (chapters 2 & 3) and 
idiosyncratic (chapters 4 & 5) DILI. There are several advantages of utilizing PCLS over 
other in vitro systems. PCLS are superior to primary hepatocytes and HepG2 cells as 
these systems are lacking the other liver cell types and at least in the case of HepG2 cells, 
they also possess inadequate biotransformation capacity 9, 10. Co-culturing hepatocytes 
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and other cells was used as a model but this is a quite complex method as it is difficult 
to assess the correct ratio of the different cell types and to establish correct cell to cell 
contacts. Additionally, in the idiosyncratic DILI model involving inflammatory reactions, 
cytokines are suggested to play a role. Even though it is possible to add cytokines to the 
hepatocyte cultures, PCLS supposedly give more representative levels and mixtures of 
cytokines produced by inflammatory reactions (such as ones induced by LPS) similar to 
the situations in the real liver.
Species difference in the hepatotoxicity of APAP has been previously investigated 
in primary hepatocytes 11. In chapter 2, similar findings were confirmed in PCLS, in 
which mouse was the most sensitive species to APAP toxicity, followed by rat, and then 
human. In studies on the mechanism of toxicity of a xenobiotic, a non-toxic analog with 
a pharmacological activity similar to that of the toxic compound is frequently taken as 
control to distinguish pharmacological from toxicological effects. Therefore, the toxicity of 
N-acetyl-meta-aminophenol (AMAP), a regioisomer of APAP with similar analgesic and 
antipyretic properties, was also tested in PCLS from these species. AMAP has been widely 
considered as a non-toxic isomer of APAP, even though AMAP had only been studied in 
mice and hamsters. Although AMAP indeed did not cause hepatotoxicity at concentrations 
where APAP was toxic in mouse PCLS, surprisingly, AMAP was equally toxic as or even 
more toxic than APAP at all concentrations tested in both rat and human PCLS based on 
the ATP level and histomorphology of the slices. Thus, AMAP is potentially toxic in men. 
Interestingly, no glutathione conjugate or S-containing metabolites of the GSH conjugate 
of AMAP were detected in all three species. Moreover, PCLS from mouse, the least 
sensitive species to AMAP toxicity, produced ten times more hydroquinone metabolites 
(the assumed proximate reactive metabolites) of AMAP compared to rat or human PCLS. 
This suggested that the toxicity of AMAP in rat and human is not caused by the alleged 
proximate reactive hydroquinone metabolites. Conclusively, there were marked species 
differences in the toxicity and metabolism of APAP and AMAP. 
These findings indicate the importance of using a human test system when selecting 
non-toxic analogs of drugs. We also showed that human and animal PCLS can be a suitable 
and straightforward method to test species differences in hepatotoxicity.
To investigate the potency to use excreted proteins as biomarker for DILI, the profiles 
of proteins excreted into the medium of PCLS as a result of drug-induced injury were 
analyzed in chapter 3 and compared to urine profiles in mice treated with APAP. The 
toxicity of AMAP in rat and human PCLS was confirmed as the profiles of the proteins 
in the medium of AMAP-treated PCLS were very similar to the profiles of APAP-treated 
PCLS and differed from the controls. However, in mouse PCLS, the protein profiles of 
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APAP-treated and AMAP-treated PCLS medium were substantially different, which is in 
line with the observation that the applied concentration of AMAP was not toxic in mouse 
PCLS. Furthermore, protein profiles of mouse PCLS medium were shown to resemble in 
vivo mouse urinary profiles in the case of APAP-induced liver injury. Protein identification 
revealed the same key proteins in the medium of APAP-treated mouse PCLS as in the urine 
of APAP treated mice. Treatments of both APAP and AMAP in rat and human PCLS as 
well as treatment of APAP only in mouse PCLS resulted in a marked decrease in hepcidin 
concentration in the PCLS medium. PCLS from these three species treated with another 
hepatotoxin, diclofenac (DF), also exhibited a decreased hepcidin concentration in the 
medium, while treatment with lipopolysaccharide (LPS) significantly increased it. These 
findings correlated well with previous in vivo data where APAP treatment decreased the 
hepcidin level in the plasma and livers of mice with APAP-induced liver injury, as a result 
of oxidative stress (van Swelm et al., 2012) and that LPS was known to be a strong inducer 
of hepcidin 12. 
In conclusion, the use of PCLS may be useful to identify urinary proteins as liver-
derived proteins. Moreover, protein profiling can be a promising and non-invasive method 
for biomarker identification in vitro/ex vivo (in medium) or in vivo (in urine) and hepcidin 
might serve as a potential novel in vitro/ex vivo biomarker for DILI.
It was hypothesized that APAP-induced liver injury occurs by two phases, a metabolic 
phase (involving GSH depletion and protein adducts) and an oxidative phase (involving 
oxidative stress and mitochondrial permeability transition (MPT)) 13, 14. MPT is an abrupt 
increase in the permeability of the inner mitochondrial membrane to ions and small 
molecular weight solutes. MPT is associated with increased oxidative stress as well as 
decreased ATP synthesis and it causes superoxide anion release from the mitochondria, 
which is lethal for the cell 13, 15. Cyclosporine A (CsA) binds to cyclophilin D in the MPT 
pore and has been shown to be a specific and potent inhibitor of MPT 15, 16. Cyclosporine A 
was also used to decrease oxidative stress and attenuate APAP-induced hepatotoxicity in 
mice in vivo and in vitro14, 17. To investigate whether the unexpected AMAP toxicity in rat 
and human PCLS is associated with MPT, we coincubated PCLS with AMAP (5 mM) and 
CsA for 24h. While 2.5 µM CsA already slightly reduced the viability of rat PCLS by ~20%, 
in human PCLS, CsA was not toxic up to 5 µM. Therefore, the effects of CsA were studied at 
concentrations of 5 and 2.5 µM in rat and human PCLS respectively. Surprisingly, instead 
of reducing the toxicity of AMAP, CsA significantly enhanced the toxicity of AMAP in 
both rat and human PCLS, as coincubation with AMAP and CsA decreased the ATP levels 
of the PCLS to approximately half of the values of the AMAP-treated rat or human PCLS. 
It was previously reported that the addition of CsA as a chemosensitizer could enhance 
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the toxic adverse reactions of doxorubicin, such as nephrotoxicity, in rats. However, 
under circumstances where doxorubicin caused only a low level of toxicity in the liver of 
these rats, the combined treatment of doxorubicin and CsA did not actually enhance this 
hepatotoxicity 18. More recently, chronic administration of CsA by itself was shown to be 
capable of inducing hepatotoxicity in rats and guinea pigs by generating reactive oxygen 
species (ROS) 19-22. 
In conclusion, our results do not provide evidence for an involvement of the MPT in 
AMAP-induced liver injury and AMAP may interact with CsA producing synergistic 
hepatotoxicity as observed in Figure 1. However, further research is needed to elucidate 
the mechanisms of hepatotoxicity involving this interaction between AMAP and CsA. 
Figure 1. Viability of PCLS indicated by the ATP content after 24h incubation with AMAP 
(5 mM) in the absence (open bars) or presence (black bars) of CsA (5 µM in rat or 2.5 µM 
in human). ATP content is expressed as relative values to the respective control PCLS 
without CsA-treatment. Data represent the average ± SEM of 4 (rat) or 6 (human) experi-
ments using 3 PCLS per experiment. *P<0.05 or ***P<0.001 vs. control PCLS, #P<0.05 vs. 
AMAP-treated PCLS by paired t-test.
Based on these results and other previously-performed experiments 23, 24, PCLS appear 
to be a promising tool to identify drugs that potentially cause intrinsic DILI and to study 
the mechanisms behind the toxicity.
Chapter 4 and chapter 5 focused on the development of an ex vivo model using PCLS 
to detect idiosyncratic DILI in mouse and human PCLS. We developed our model based 
on the inflammatory stress hypothesis proposed by Roth et al. involving the simultaneous 
exposure to idiosyncratic DILI-inducing drug and LPS as an inflammagen 7. We 
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investigated both the effects of LPS on the toxicity of the drugs and the effects of the drugs 
on the LPS-induced inflammatory reactions. Five drugs that produce reactive metabolites 
and are known to cause idiosyncratic DILI in humans were selected to be tested in our 
model. These drugs were ketoconazole (KC), clozapine (CZ), diclofenac (DF), troglitazone 
(TGZ), and carbamazepine (CBZ). Following 24h incubation, both mouse and human 
PCLS coincubated with LPS and KC or CZ exhibited synergistic toxicity based on ATP 
levels, histomorphology, and (only in mouse) leakage of lactate dehydrogenase (LDH). 
Voriconazole (VC), the comparator drug for KC that is not known to show idiosyncratic 
DILI, was not toxic in mouse PCLS or in rats in vivo 25, but it causes dose-dependent non-
idiosyncratic hepatotoxicity that occurs in approximately 51% of patients 26, 27. Despite 
VC-induced toxicity, coincubation with LPS and VC, did not cause synergistic toxicity. 
Likewise, incubation of olanzapine (OZ), the comparator drug of CZ, and LPS also did 
not cause synergistic toxicity. This synergistic toxicity phenomenon was accompanied by 
a concomitant depletion of glutathione (GSH). The other 3 drugs that cause idiosyncratic 
DILI in humans, DF, TGZ, and CBZ, did not show synergistic toxicity with LPS after 24h 
incubation in both mouse and human PCLS and no depletion of GSH. We also studied 
the effect on the LPS-induced cytokine production as cytokines have been suggested to 
be involved in the mechanisms of idiosyncratic toxicity 28 and moreover, we wanted to 
investigate whether they could be used as potential biomarkers for idiosyncratic DILI. 
None of the drugs alone significantly induced changes in the release of any cytokine, while 
LPS significantly elevated the release of the following cytokines: interferon gamma (IFN-γ), 
interleukin-1beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor (TNF), CC chemokine 
ligand 3(CCL3), CC chemokine ligand 5(CCL5), granulocyte colony-stimulating factor 
(G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Our strategy 
was to search for common phenomena in the LPS induced synergistic toxicity of KC and 
CZ. In mouse PCLS, KC and CZ were the only two drugs that increased the LPS-induced 
release of G-CSF and GM-CSF. On the other hand, this was not the case in human PCLS 
where TNF was the only cytokine that was further elevated by KC and CZ and not by 
the other drugs after 24h incubation. Our finding on TNF in the human PCLS was in line 
with others who reported that TNF also plays a critical role in inflammatory stress-related 
idiosyncratic DILI mechanism of aflatoxin B1, trovafloxacin, and ranitidine in rats and 
mice in vivo29-32. 
These data suggest that TNF as well as GSH can be used as predictive biomarkers of 
inflammatory stress-related idiosyncratic DILI in human PCLS, and potentially in other 
in vitro/ex vivo systems. Furthermore, GSH can also serve as a translational biomarker in 
mice in vitro, ex vivo, and maybe even in vivo. Despite similar findings in the synergistic 
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toxicity phenomenon related to LPS+KC and LPS+CZ in both mouse and human PCLS, 
there were marked species differences in how these drugs affect LPS-induced release of 
cytokines, suggesting different mechanisms of idiosyncratic hepatotoxicity might be 
involved between mouse and human. 
Initially, we observed that there was a concomitant increase in IL-1β in the cases of 
synergistic hepatotoxicity related to LPS+KC and LPS+CZ in mouse PCLS. Therefore we 
investigated whether IL-1β could be the cause of this synergistic toxicity. However, the use 
of the pro-inflammatory cytokine interleukin IL-1β instead of LPS did not potentiate the 
hepatotoxicity of KC or CZ in mouse PCLS. In addition, the use of neutralizing antibody 
anti-IL1β also did not attenuate the synergistic toxicity caused by coincubation of mouse 
PCLS with LPS and KC or CZ (unpublished results). These observations suggest that more 
cytokines and other inflammatory mediators are probably involved in the synergistic 
toxicity mechanisms here. This is in line with the findings of Cosgrove et al. who showed 
that the incubation of HepG2 cells and primary hepatocytes with a mix of several pro-
inflammatory cytokines when compared to one individual cytokine produced the most 
significant synergistic toxicity of several idiosyncratic drugs tested 28.
It was quite unexpected to find synergistic toxicity only in 2 out of 5 idiosyncratic drugs 
as they are all known to cause IDILI in man. Hence, in chapter 4, we investigated if there 
is any correlation between incubation time and of the observation of synergistic toxicity in 
mouse PCLS. We found that two of the idiosyncratic DILI-related drugs that did not cause 
synergistic toxicity with LPS after 24h incubation, namely DF and TGZ, demonstrated 
synergistic toxicity with LPS following 48h incubation of mouse PCLS based on the ATP 
contents. However, even after 48h, LPS still did not enhance the toxicity of CBZ in mouse 
PCLS. It cannot be excluded that different concentrations of LPS or CBZ and different 
exposure times between them are needed to observe the synergistic hepatotoxicity 
for CBZ. An alternative explanation might be that CBZ causes idiosyncratic DILI via 
another mechanism than the one proposed in the inflammatory stress hypothesis, such 
as the danger hypothesis 33, 34 or the pharmacological interaction (PI) hypothesis 35. Future 
investigations should focus on the measurement of the LPS-induced release of cytokines 
after 48h incubation and compare it with data from the 24h incubation. 
In chapter 5, we introduced the terms ‘responders’ (synergistic toxicity observed) and 
‘non-responders’ (synergistic toxicity not observed) among human individuals. Although 
the overall effects of LPS+KC and LPS+CZ were significant for the total group of livers 
tested, there was an appreciable variation in the interaction effects of LPS+drug implying 
that some human livers did not respond where others responded strongly with synergistic 
toxicity. For instance, synergistic toxicity was observed in 7 out of 10 human livers (70% 
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responders) cotreated with LPS+KC and in 9 out of 14 human livers (64% responders) 
cotreated with LPS+CZ. On the other hand, only 1 out of 8 mice was considered as a 
non responder. Interestingly, we found that the relative amounts of both the glutathione 
conjugate (CZ-GSH) and the cysteine conjugate (CZ-Cys) of CZ were significantly lower 
among the responders in hPCLS incubated with LPS when compared to the ones without 
LPS. Among the non-responders, no difference in the amount of any metabolite was 
observed in the absence or presence of LPS. The lower amounts of CZ-SG and CZ-Cys in 
the responder group after coincubation with LPS and CZ can be attributed to the lower 
GSH level of this group of PCLS, resulting in the higher amount of non-detoxified reactive 
metabolites of CZ leading to higher toxicity that might be due to the covalent binding of 
these metabolites to proteins. This variance in the metabolic profiles of different people 
could be attributed to genetic polymorphisms in enzymes responsible for the production 
of reactive metabolites. Also polymorphisms in glutathione S-transferase were suggested 
to have the potential to increase the susceptibility to idiosyncratic DILI 36. It would be 
interesting to further investigate these factors.
Neutrophils were found to be a mediator of injury in LPS-potentiated hepatotoxicity 
in rats in vivo, induced by aflatoxin B1, monocrotaline, and trovafloxacin 37-39 and are 
involved in induction of liver injury by hepatotoxic doses of LPS 40. During activation, 
neutrophils release various cytotoxic factors, including ROS and proteases 41. It was 
shown that neutrophil proteases might contribute to hepatocellular injury by mechanisms 
independent of direct hepatocyte killing 42. One disadvantage related to the use of PCLS 
to predict idiosyncratic DILI related to inflammatory stress hypothesis is the absence 
of neutrophil accumulation and infiltration from the circulation into the liver after LPS 
treatment. However, it cannot be excluded that the neutrophils present in the liver tissue 
during harvesting may play a role in the synergistic toxicity in PCLS. 
In an attempt to find more sensitive biomarkers that can be used to predict idiosyncratic 
DILI, we investigated the roles of keratin-18 (K18) and high mobility group box-1 (HMGB1) 
proteins in our LPS-potentiated hepatotoxicity model in PCLS. K18 and HMGB1 are two 
recently-developed biomarkers for liver injury that have been previously reported as 
circulating mechanistic indicators of cell death mode in animal models 43-45 and in clinical 
studies 46. There are two forms of K18, namely, full length K18 (FL-K18) and caspase-
cleaved K18 (C-K18). FL-K18 and HMGB1 are released passively during necrotic cell 
death, while C-K18 is generated during apoptosis 47, 48. The levels of both HMGB1 and the 
two forms of K18 were significantly elevated during APAP-induced liver injury in mice, 
in which the elevation of HMGB1 in mouse serum was detected earlier than of alanine 
aminotransferase (ALT) 43-45, which is one of the most commonly used biomarkers for 
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liver injury. Subsequently, we measured the release of these three proteins in the medium 
samples of mouse and human PCLS, which were coincubated with idiosyncratic DILI-
associated drugs and LPS for 24h in collaboration with the group of Prof. Kevin Park at 
University of Liverpool (unpublished results). The leakage of ALT of the same medium 
samples was also measured for comparison between ALT and HMGB1 or FL-K18. We did 
not see an extra release of one of these markers due to LPS coincubation. Unexpectedly, we 
found a perfect correlation between the obtained values of ALT and either K18 or HMGB1, 
irrespective of the drug treatment and the presence or absence of LPS in mouse PCLS 
(Figure 2). This finding suggests that these two new biomarkers are not superior in PCLS 
when compared to ALT leakage. 
Figure 2. The absolute values of ALT plotted against the absolute values of (a) full-length 
K18 or (b) HMGB1 in mouse PCLS. These values were measured under various conditions 
in the absence or presence of different drug and/or LPS.
Furthermore, transcriptomics can be a powerful tool to improve the ability to predict, 
detect, and characterize idiosyncratic DILI. Toxicogenomics is widely used in drug 
discovery and development to screen candidate drugs and study their adverse effects and 
toxic risks. Toxicogenomics allows for the elucidation of molecular mechanisms of toxicity 
and the detection of biomarkers for toxicity 24. We performed DNA microarray studies 
in human PCLS incubated with DF, KC, CZ, and OZ in the absence and presence of LPS 
for 24h. With the aim to find new biomarkers that can detect and predict idiosyncratic 
DILI, we applied Affymetrix DNA array expression data analysis to find specific genes 
that are significantly upregulated or downregulated only in the combination treatment 
(LPS+idiosyncratic drug) sample and not in the controls, nor in samples treated with drug 
alone or LPS alone, nor in samples treated with the non-toxic comparator drug in the 
presence of LPS. The genes that are only specifically regulated in the PCLS coincubated 
with LPS and idiosyncratic drugs and not regulated in negative comparator drugs can 
potentially be new biomarkers for idiosyncratic DILI and shed light on its mechanism. 
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These analyses are currently ongoing. However, a preliminary analysis indicated that most 
changes in gene expression were in the PCLS cotreated with LPS+KC and LPS+CZ (Figure 
3). These two treatment groups also showed the highest numbers of overlapping genes that 
are significantly changed. There were few overlapping genes between LPS+CZ and LPS+OZ 
groups and LPS+DF cotreatment appeared to show a very distinct gene expression profile 
when compared to the other drugs. These findings may suggest some common idiosyncratic 
hepatotoxicity pathways between KC and CZ and the 49 upregulated common genes as 
well as 25 downregulated common genes may serve as biomarkers for idiosyncratic DILI 
in PCLS. Further analyses of these microarray data need to be performed to elucidate more 
in-depth mechanisms and to find biomarkers related to idiosyncratic DILI.   
Figure 3. The number of genes regulated only in the ‘LPS+drug’ groups (FC>2 against con-
trol, FDR<0.01) and not regulated in ‘LPS only’ or ‘drug only’ groups (FC ‘LPS+drug’ > 1.5 * 
FC ‘LPS only’ or ‘drug only’).
2. Concluding Remarks
We have developed an ex vivo model utilizing rat, mouse, and human PCLS that is capable 
to detect intrinsic DILI (APAP-induced) and idiosyncratic DILI related to inflammatory 
stress hypothesis. This ex vivo PCLS model is considered a higher throughput model when 
compared to in vivo models and at the same time it is also a more representative model than 
other in vitro models as all liver cell types are present in their natural environment in PCLS, 
which is important because of the possibility to identify the cytokines and the metabolites 
produced by the PCLS. Moreover, the possible interindividual differences observed in 
PCLS are also important to identify sensitive individuals.  Another significant advantage 
is that PCLS can be a robust translational model with the possibility of using liver tissue 
from animals and humans and compare their findings. Our studies have identified not 
only significant differences between rat, mouse and human PCLS in their sensitivity for 
the toxicity of drugs like APAP, AMAP and VC to mention a few, but we also detected 
prominent species differences in the cytokine release upon LPS challenge and LPS+drug 
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treatment. We identified hepcidin as a translational biomarker for intrinsic DILI in PCLS 
and it can also be further investigated as an in vivo DILI biomarker in humans. GSH can 
be another prospective translational biomarker that can be measured in in vitro and ex vivo 
systems as well as in animals in vivo. In addition, TNF is considered as a budding in vitro/
ex vivo biomarker for inflammatory stress-related idiosyncratic DILI in humans but not 
in mice. The species differences in toxicity, metabolism, and the effects on LPS-induced 
cytokine release underline the importance of human experiments in addition to animal 
experiments to elucidate the mechanisms of intrinsic and idiosyncratic DILI in humans. 
Moreover, the use of PCLS contributes to the reduction of the number of animals used in 
research as a liver from an individual animal can generate many PCLS (~40 from a mouse 
liver and ~200 from a rat liver) than can be used to test multiple treatment conditions. 
Similarly, the use of human PCLS may also contribute to the reduction and eventually 
replacement of animal experiments in toxicology.  
3. Future Directions and Perspectives
To follow up and advance the studies initiated in this thesis, there are several possibilities 
for future research. Generally speaking, larger numbers of idiosyncratic DILI-related drugs 
together with their negative comparator drugs may be included and tested in PCLS because 
it is very likely that different drugs would exert their toxicity via different mechanisms 
of action 49. As described in chapter 4, prolonging the incubation time from 24h to 48h 
may identify more drugs as idiosyncratic DILI inducing drugs. The 48h experiments 
were only performed in mouse PCLS, thus future experiments should elucidate if longer 
incubation of human PCLS will also show synergistic toxicity of LPS with either DF, TGZ, 
CBZ, or any other drugs that are associated with idiosyncratic DILI with concomitant 
decrease in GSH and changes in LPS-induced cytokine release. Additionally, metabolite 
profiling, with particular interest in the GSH conjugation, of KC and other idiosyncratic 
drugs that show synergistic toxicity should be performed to identify any differences in the 
metabolism profiles between responders and non-responders in the absence or presence of 
LPS, combined with analyzing the polymorphisms in GST or phase 1 enzymes involved in 
bioactivation of the drugs. The new information, combined with the current metabolism 
data of CZ, will give us more information on the role of reactive metabolites in idiosyncratic 
DILI in PCLS. 
The gene microarray analysis is a promising powerful tool to study the mechanisms 
of intrinsic and idiosyncratic DILI. Pathway analysis can elucidate the specific biological 
or toxicological pathways involved in the mechanisms of idiosyncratic DILI in PCLS. All 
these combined data can contribute to establishing PCLS as a powerful ex vivo screening 
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tool for idiosyncratic DILI.
Ultimately, thorough screening of drug candidates is necessary to correctly choose the 
relatively safest drug candidates and avoid those with high potential of causing intrinsic 
and idiosyncratic DILI. The analyses of the production of reactive metabolites, levels of 
hepcidin, and the levels of GSH, TNF or other cytokines after cotreatment with LPS was 
demonstrated to be promising here. 
In conclusion, the PCLS system may be a robust and promising ex vivo translational 
screening tool that can be utilized in the preclinical settings to identify and characterize 
human-specific intrinsic and idiosyncratic DILI at various stages of drug discovery and 
development. 
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Schadelijke bijwerkingen van medicijnen (in het engels aangeduid als Adverse Drug 
Reactions, ADR’s) vormen een ernstig probleem voor de volksgezondheid en een 
belemmering voor de ontwikkeling van geneesmiddelen en het klinische gebruik na 
marketing. ADR’s treffen miljoenen mensen en kunnen leiden tot ziekenhuisopname en 
zelfs de dood. De lever is het orgaan dat het meest te lijden heeft van ADRs vanwege 
de hoge blootstelling aan geneesmiddelen en het vermogen om ze te metaboliseren tot 
schadelijke verbindingen. Geneesmiddel-geïnduceerde leverbeschadiging (drug-induced 
liver injury, DILI) is de belangrijkste oorzaak van acuut leverfalen en het is ook een van de 
belangrijkste redenen waarom geneesmiddelen uit de handel genomen worden.
Zoals beschreven in hoofdstuk 1 kan DILI worden onderverdeeld in intrinsieke (type 
A) en idiosyncratische (type B) DILI. Intrinsieke DILI vertoont meestal een dosis- en 
tijdsafhankelijkheid en het wordt vaak al gedetecteerd tijdens de pre-klinische of vroege 
klinische testen. De meeste gevallen van geneesmiddel-geïnduceerde leverfalen worden 
veroorzaakt door overdosering van het intrinsiek levertoxische paracetamol (APAP). De 
verantwoordelijkheid voor de levertoxiciteit van paracetamol wordt toegeschreven aan een 
reactieve metaboliet van APAP, N-acetyl-p-benzo-quinone imine (NAPQI). Idiosyncratische 
DILI daarentegen komt voor in een zeer kleine minderheid (minder dan 1 op de 1000) van 
de mensen die een normale therapeutische dosering van het geneesmiddel  nemen. Het 
toxische effect is niet of nauwelijks voorspelbaar tijdens preklinische en klinische studies, 
en is niet gerelateerd aan de farmacologische effecten van het geneesmiddel. Terwijl 
intrinsieke DILI meestal optreedt na een overdosis van het medicijn, kan idiosyncratische 
DILI optreden bij patiënten die een normale therapeutische dosis van een geneesmiddel 
krijgen. Verscheidene hypothesen zijn beschreven om de werkingsmechanismen van 
idiosyncratische DILI te verklaren en veel van deze hypothesen gaan uit van het ontstaan 
van reactieve metabolieten van geneesmiddelen. Eén van die hypotheses wordt de 
‘inflammatoire stress’ hypothese genoemd, omdat die is gebaseerd op de veronderstelling 
dat een gelijktijdig optreden van een ontstekingsreactie tijdens medicijngebruik kan leiden 
tot idiosyncratische DILI. Deze inflammatoire stress kan de drempel voor levertoxiciteit 
door een geneesmiddel verlagen, waardoor het therapeutische venster kleiner wordt, wat 
uiteindelijk resulteert in een toxische respons op een normaal gesproken veilige dosis van 
het medicijn. Ook kan een geneesmiddel een milde ontstekingsreactie versterken waardoor 
er weefselschade ontstaat. Verscheidene in vivo en in vitro modellen zijn op basis van 
deze inflammatoire stress hypothese ontwikkeld, waaronder gelijktijdige blootstelling aan 
geneesmiddelen met een ontstekingsbevorderende stof, zoals lipopolysaccharide (LPS), 





gericht op de ontwikkeling van een mogelijk ex vivo model dat gebruik maakt van precies 
gesneden leverplakjes (PCLS). Dit weefselpreparaat bezit nog de normale leverarchitectuur, 
waarbij alle levercellen aanwezig zijn in hun fysiologische verhouding en in hun normale 
matrix. PCLS gemaakt van lever van verschillende proefdierspecies en van de mens zijn 
gebruikt om verschillen tussen mens en proefdier in intrinsieke (hoofdstukken 2 en 3) en 
idiosyncratische (hoofdstukken 4 en 5) DILI te bestuderen.
De levertoxiciteit van APAP is eerder onderzocht in verschillende diersoorten met 
behulp van primaire hepatocyten. In hoofdstuk 2 werden soortgelijke bevindingen 
bevestigd in PCLS, waarin de muis de meest gevoelige soort bleek te zijn voor APAP 
toxiciteit, gevolgd door de rat en daarna de mens. In onderzoek naar het mechanisme 
van de toxiciteit van een xenobioticum (lichaamsvreemde stof) wordt vaak een niet-
toxisch analogon met een vergelijkbare farmacologische activiteit gebruikt als controle om 
farmacologische van toxicologische effecten te onderscheiden. Daarom werd de toxiciteit 
van N-acetyl-meta-aminofenol (AMAP), een regioisomeer van APAP met vergelijkbare 
analgetische en antipyretische eigenschappen, ook getest in PCLS van deze soorten. AMAP 
wordt algemeen beschouwd als een niet-toxische isomeer van APAP, ofschoon AMAP 
alleen is onderzocht in muizen en hamsters. Hoewel AMAP inderdaad geen levertoxiciteit 
veroorzaakte bij concentraties waar APAP toxisch was in PCLS van de muis, was AMAP 
verrassend genoeg even toxisch of zelfs toxischer dan APAP bij alle concentraties die 
getest werden in zowel PCLS van de rat als de mens op basis van het ATP-niveau en 
de histomorfologie van de leverplakjes. Hieruit kan worden geconcludeerd dat AMAP 
potentieel toxisch is in de mens, en dus niet als niet-toxisch analogon gebruikt kan worden 
in het onderzoek. Interessant daarbij is dat in geen van de drie onderzochte species het 
glutathionconjugaat of S-bevattende metabolieten van het glutathionconjugaat van AMAP 
werden gedetecteerd. Bovendien produceerden PCLS van de muis, de minst gevoelige soort 
voor AMAP toxiciteit, tien keer meer hydroquinon metabolieten (de metaboliet waaruit de 
veronderstelde reactieve metaboliet wordt gevormd) van AMAP dan ratten of humane 
PCLS. Dit suggereerde dat de toxiciteit van AMAP in ratten en mensen niet veroorzaakt 
wordt door de veronderstelde reactieve hydroquinon metabolieten. Concluderend, 
er werd een duidelijk verschil in de toxiciteit en het metabolisme van APAP en AMAP 
tussen soorten gevonden. Deze bevindingen wijzen op het belang van een testsysteem met 
menselijk weefsel bij het selecteren van niet-toxische analogen van medicijnen. We toonden 
ook aan dat het gebruik van PCLS van zowel mens als dier een geschikte en eenvoudige 
methode kan zijn om soortverschillen in levertoxiciteit te testen.
Om te onderzoeken of uitgescheiden eiwitten als biomarker voor DILI gebruikt kunnen 
worden, werden de profielen van eiwitten die uitgescheiden waren in het medium van de 
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PCLS als gevolg van geneesmiddel-geïnduceerde schade in hoofdstuk 3 onderzocht en 
vergeleken met eiwitprofielen in de urine van muizen behandeld met APAP. De toxiciteit 
van AMAP in PCLS van rat en mens werd bevestigd doordat de profielen van de eiwitten in 
het medium van AMAP behandelde PCLS vergelijkbaar waren met de profielen van APAP 
behandelde PCLS en verschilden van de controles. Zoals verwacht waren de eiwitprofielen 
van het medium van APAP-behandelde muizen PCLS wezenlijk verschillend van die 
van AMAP-behandelde PCLS, dit is in overeenstemming met de waarneming dat de 
toegepaste concentratie van AMAP niet toxisch was in PCLS van muizen. Bovendien leken 
de eiwitprofielen van het medium van muizen PCLS blootgesteld aan APAP op de urine 
profielen van muizen in vivo met APAP geïnduceerde leverbeschadiging. Eiwitidentificatie 
onthulde dat in het medium van APAP behandelde muizen PCLS in belangrijke mate 
dezelfde eiwitten zaten als in de urine van APAP behandelde muizen. Behandelingen van 
ratten en humane PCLS  met zowel APAP en AMAP en behandeling van muizen PCLS 
met alleen APAP in resulteerde in een sterke afname in de hepcidine concentratie in het 
PCLS medium. PCLS van deze drie soorten behandeld met een ander hepatotoxische 
stof, diclofenac (DF), vertoonde eveneens een verminderde hepcidine concentratie in het 
medium, terwijl behandeling met lipopolysaccharide (LPS) de concentratie significant 
deed toenemen. Deze bevindingen correleerden goed met eerdere in vivo data waar APAP 
het hepcidine niveau in het plasma en de levers van muizen verlaagde, als gevolg van 
oxidatieve stress en waar LPS de hepcidine concentratie sterk deed verhogen. Concluderend 
kan het gebruik van PCLS nuttig zijn om eiwitten in de urine te identificeren als eiwitten 
die van de lever afkomstig zijn. Bovendien kan het analyseren van het eiwitprofiel een 
veelbelovende en niet-invasieve methode zijn voor de identificatie van biomarkers in vitro 
/ ex vivo (bv in medium van PCLS) of in vivo (in urine) en hepcidine zou kunnen dienen als 
een potentiële nieuwe in vitro / ex vivo biomarker voor DILI.
Hoofdstuk 4 en hoofdstuk 5 richten zich op de ontwikkeling van een ex vivo model 
met het gebruik van PCLS om idiosyncratische DILI in PCLS van muis en mens te 
detecteren. We ontwikkelden ons model gebaseerd op de inflammatoire stress hypothese, 
geϊntroduceerd door Roth et al., waarbij gebruik gemaakt wordt van gelijktijdige 
toediening van het geneesmiddel met LPS. We onderzochten de effecten van zowel LPS 
op de toxiciteit van de geneesmiddelen als de effecten van de geneesmiddelen op de LPS-
geïnduceerde ontstekingsreacties. Vijf middelen die reactieve metabolieten produceren 
en bekend zijn om het feit dat ze idiosyncratische DILI veroorzaken bij mensen werden 
geselecteerd om getest te worden in ons model. Deze medicijnen waren ketoconazol (KC), 
clozapine (CZ), diclofenac (DF), troglitazon (TGZ) en carbamazepine (CBZ). Na 24 uur 
incubatie vertoonden zowel muizen als humane PCLS geïncubeerd met LPS plus KC 
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of LPS plus CZ, synergistische toxiciteit gebaseerd op ATP niveau, histomorfologie en 
(alleen in muis) lekkage van lactaat dehydrogenase (LDH). Als controle onderzochten we 
voriconazol (VC), een geneesmiddel dat dezelfde farmacologische werking heeft als KC, 
maar dat geen idiosyncratische DILI veroorzaakt in patiënten. Dit middel bleek niet toxisch 
in muizen PCLS of in ratten in vivo, maar het is bekend dat het een dosisafhankelijke, 
niet idiosyncratische levertoxiciteit veroorzaakt in mensen die optreedt in ongeveer 51% 
van de patiënten. Ondanks VC-geïnduceerde toxiciteit, leidde co-incubatie met LPS en 
VC niet tot synergistische toxiciteit. Ook veroorzaakte incubatie van olanzapine (OZ), het 
niet-toxische analogon van CZ, tegelijk met LPS ook geen synergistische toxiciteit. Dit 
verschijnsel van synergistische toxiciteit ging gepaard met een gelijktijdige afname van 
glutathion (GSH). De andere drie geneesmiddelen die idiosyncratische DILI veroorzaken 
in mensen, DF, TGZ en CBZ, lieten geen synergistische toxiciteit zien met LPS na 24 uur 
incubatie in zowel PCLS van muis als mens en geen vermindering van GSH. We hebben 
ook het effect op de LPS-geïnduceerde cytokineproductie bestudeerd, omdat cytokines een 
rol zouden kunnen spelen in de mechanismen van idiosyncratische toxiciteit en bovendien 
wilden we onderzoeken of ze kunnen worden gebruikt als potentiële biomarkers 
voor idiosyncratische DILI. Geen van de geneesmiddelen ïnduceerde significante 
veranderingen in de uitscheiding van een van de gemeten cytokines, terwijl LPS de afgifte 
van de volgende cytokines significant verhoogde: interferon gamma (IFN-γ), interleukine-
1beta (IL-1β), interleukine-6  (IL-6 ), tumor necrose factor (TNF), CC chemokine ligand 3 
(CCL3), CC chemokine ligand 5 (CCL5), granulocyt kolonie-stimulerende factor (G-CSF) 
en granulocyt-macrofaag kolonie-stimulerende factor (GM-CSF). Onze strategie was om 
naar gemeenschappelijke verschijnselen te zoeken in de LPS geïnduceerde synergistische 
toxiciteit van KC en CZ. In PCLS van de muis, waren KC en CZ de enige twee middelen 
die de LPS-geïnduceerde afgifte van G-CSF en GM-CSF verhoogden. Maar dit was niet het 
geval in humane PCLS waar TNF de enige cytokine was die verder verhoogd werd door 
KC en CZ en niet door de andere geneesmiddelen na 24 uur incubatie. Onze bevinding 
over TNF in humane PCLS kwam overeen met die van anderen die meldden dat TNF een 
cruciale rol speelt in inflammatoire stress-gerelateerde idiosyncratische DILI mechanismen 
van aflatoxine B1, trovafloxacine, en ranitidine in ratten en muizen in vivo. Deze gegevens 
suggereren dat zowel TNF als GSH gebruikt kunnen worden als voorspellende biomarkers 
van inflammatoire stressgerelateerde idiosyncratische DILI in humane PCLS en mogelijk 
ook in andere in vitro / ex vivo systemen. Bovendien kan GSH ook als translationele 
biomarker dienen in muizen in vitro, ex vivo en misschien zelfs in vivo. Ondanks vergelijkbare 
bevindingen in het synergistische toxiciteit fenomeen gerelateerd aan LPS + KC en LPS + 
CZ in zowel muizen als humane PCLS, waren er belangrijke verschillen tussen muis en 
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mens in hoe deze geneesmiddelen de LPS-geïnduceerde afgifte van cytokines beïnvloeden. 
Dit suggereert dat de mechanismen van idiosyncratische levertoxiciteit die betrokken zijn 
bij de muis en mogelijk verschillend zijn van die van de mens.
Het was redelijk onverwacht om alleen synergistische toxiciteit te vinden in 2 van de 
5 idiosyncratische geneesmiddelen, omdat ze allemaal bekend zijn als veroorzakers van 
IDILI in de mens. Vandaar dat we in hoofdstuk 4 onderzocht hebben of er een correlatie 
bestaat tussen de incubatietijd en de observatie van synergistische toxiciteit in PCLS van 
muizen. We vonden dat twee van de idiosyncratische DILI-gerelateerde medicijnen die geen 
synergistische toxiciteit met LPS veroorzaakten na 24 uur incubatie, namelijk DF en TGZ, 
wel synergistische toxiciteit vertoonden (gebaseerd op ATP) met LPS na 48 uur incubatie 
van muizen PCLS. Maar zelfs na 48 uur verhoogde LPS nog steeds niet de toxiciteit van 
CBZ in muizen PCLS. Toekomstig onderzoek zal erop gericht zijn om deze synergistische 
toxiciteit na 48 uur verder te karakteriseren.
In hoofdstuk 5 hebben we de termen ‘responders’ (synergistische toxiciteit waargenomen 
in een individueel weefselmonster) en ‘niet-responders’ (geen synergistische toxiciteit 
waargenomen in een individueel weefselmonster) geïntroduceerd. Hoewel de totale 
effecten van LPS + KC en LPS + CZ significant waren voor de gehele groep van geteste 
humane levers, was er een aanzienlijke variatie in de effecten van de interactie van LPS 
+ medicijn, wat er op duidt dat sommige humane levers niet reageerden waar andere 
levers wel sterk reageerden met synergistische toxiciteit. Zo werd synergistische toxiciteit 
waargenomen bij 7 van de 10 humane levers (70% responders) behandeld met LPS + KC 
en in 9 van de 14 humane levers (64% responders) behandeld met LPS + CZ. Anderzijds 
werd slechts 1 van de 8 muizen als een niet-responder beschouwd. Interessant is dat we 
vonden dat de relatieve hoeveelheden van zowel het glutathionconjugaat (CZ-GSH) en 
cysteïneconjugaat (CZ-Cys) van CZ significant lager waren onder de responders in hPCLS 
geïncubeerd met LPS in vergelijking met die zonder LPS. Onder de niet-responders werden 
er geen verschillen in de hoeveelheid van deze metabolieten waargenomen in de aan- of 
afwezigheid van LPS. De lagere hoeveelheden van CZ-SG en CZ-Cys in de responder groep 
na co-incubatie met LPS en CZ kan worden toegeschreven aan het lagere GSH niveau 
van deze groep PCLS, wat zou kunnen resulteren in een grotere hoeveelheid reactieve 
metabolieten van CZ wat weer leidt tot hogere toxiciteit die veroorzaakt zou kunnen 
worden door de covalente binding van deze reactieve metabolieten met eiwitten.
Samenvattend, hebben wij een ex vivo model ontwikkeld met gebruik van ratten, 
muizen en humane PCLS dat in staat is de intrinsieke (APAP geïnduceerde) DILI en 
idiosyncratische DILI gerelateerd aan de inflammatoire stress hypothese te detecteren. Dit 
ex vivo PCLS model wordt als een meer efficiënt model beschouwd in vergelijking met 
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in vivo modellen. Tegelijkertijd lijkt het ook een beter representatief model dan andere in 
vitro modellen, omdat in PCLS alle celtypes van de lever in hun natuurlijke omgeving 
aanwezig zijn, wat belangrijk is vanwege de mogelijkheid om de effecten van cytokines 
uitscheidingen de metabolieten geproduceerd door de PCLS te identificeren. Bovendien 
is de mogelijkheid om interindividuele verschillen waar te nemen met PCLS belangrijk 
om gevoelige individuen te identificeren. Een ander belangrijk voordeel is dat PCLS een 
robuust translationeel model kan zijn met de mogelijkheid om leverweefsel van dieren 
en mensen te gebruiken en hun bevindingen te vergelijken. Onze studies hebben niet 
alleen significante verschillen tussen ratten, muizen en humane PCLS in hun gevoeligheid 
voor de toxiciteit van geneesmiddelen aangetoond, maar ook prominent soortverschillen 
gedetecteerd in cytokine afgifte na LPS stimulatie en LPS + geneesmiddel behandeling. 
We identificeerden hepcidine als translationele biomarker voor intrinsieke DILI in PCLS 
en hepcidine kan ook verder worden onderzocht als in vivo DILI biomarker bij de mens. 
GSH kan een andere potentiële translationele biomarker zijn dat gemeten kan worden 
in in vitro en ex vivo systemen bij gelijktijdige blootstelling aan LPS en geneesmiddel en 
ook in dieren in vivo. Bovendien kan TNF verder worden onderzocht als een in vitro / 
ex vivo biomarker voor inflammatoire stress-gerelateerde idiosyncratische DILI in mensen 
maar niet in muizen. De soortverschillen in toxiciteit, metabolisme, en de effecten op LPS-
geïnduceerde cytokine afgifte onderstrepen het belang van experimenten met humaan 
weefsel of humane cellen in aanvulling op dierexperimenten om de mechanismen van 
intrinsieke en idiosyncratische DILI in de mens te ontrafelen. Bovendien draagt het gebruik 
van PCLS bij tot de vermindering van het aantal dieren dat gebruikt wordt in onderzoek, 
omdat uit een lever van een individueel dier vele PCLS kunnen worden gemaakt (~ 40 uit 
een muizenlever en ~ 200 uit een rattenlever) die gebruikt kunnen worden om meerdere 
behandelcondities te testen. Evenzo zal het gebruik van humane PCLS ook kunnen 
bijdragen aan de vermindering en uiteindelijke vervanging van dierexperimenten in de 
toxicologie.
Concluderend kan het PCLS systeem een  robuust en veelbelovend ex vivo translationeel 
screenings instrument zijn, dat kan worden gebruikt in preklinische experimenten om 
humaan-specifieke intrinsieke en idiosyncratische DILI in een vroeg stadium van de 
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willingness to come and support me for my defense here. I regret that my sister, Ci Neng, 
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P.S. For all the people reading this sentence, from now on it’s Dr. Hadi to you  :-p   

